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Abstract 
                                                                                                                                             
Abstract  
It is well established that mucosal dryness is the most common symptom in primary 
Sjögren’s Syndrome (pSS) patients, affecting the nasal, oral and genital mucosa. A 
systematic review was conducted and a study with the following aims was established: 1) 
To assess the functions of the smell, taste and sexuality in patients with pSS. 2) To determine 
whether the mucosal dryness has an impact on the functions of the smell, taste and 
sexuality in pSS patients. 3) To investigate the impact of the impairment of the functions of 
smell, taste and sexuality on the quality of life (QoL) and mental health well-being in women 
with pSS. 
Methodology: Sixty-five pSS patients and 62 sex-matched healthy volunteers were 
recruited for this study. The smell function was assessed by the University of Pennsylvania 
Smell Identification Test (UPSIT). The taste function was comprehensively evaluated by 
assessing the gustatory function using the Taste Strips Test (TST), and the neurosensory 
threshold by an electrogustometer (EGM). The sexual function was assessed by the Female 
Sexual Function Index (FSFI). The oral dryness was assessed by means of stimulated and 
unstimulated salivary flow rate (SFR), clinical assessment of oral dryness scale (CODS) and 
Xerostomia Inventory (XI). The World Health Organisation Quality of Life-BRÉF (WHOQoL- 
BRÉF) and Oral Health Impact Profile-14 (OHIP-14) were used for the general and oral health 
related QoL respectively. The Hospital Anxiety and Depression Scale (HADS) was used to 
assess the mental health status.  
Results: Data analysis showed that the smell dysfunction was twice as prevalent in the 
patients group (41.5%, n=27/65) compared with healthy volunteers (24.1%, n=15/62). This 
difference was even more pronounced when assessing the gustatory function impairment, 
which was six times more prevalent in pSS patients (54%, n=34/63) than in healthy 
participants (8.3%, n=5/60). The neurosensory threshold of taste was three times higher in 
the patients’ group (31.7%, n=20/64) compared with the healthy volunteers (9.8%, n=6/61), 
and was associated with gustatory deterioration in pSS group (β=-0.4, 95% CI=-0.2 – 0), 
indicating possible neurological impairment in this group. As expected, the salivary flow rate 
and the clinical oral dryness score were significantly lower in the patient group compared 
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with healthy volunteers. No evidence was found to support that the oral dryness was 
associated with deterioration of smell, taste or sexual functions in pSS patients. The number 
of sexually active pSS patients (n=28) was half of that in the healthy volunteers group (n=42), 
and the FSFI showed that the sexual function was significantly impaired in pSS patients 
(p=<0.05). The self-administered questionnaires showed that the life quality was 
significantly compromised in patients, who were more anxious (58.5%, n=38/65) and four 
times more depressed (32.3%, n=21/65) compared with healthy volunteers (Anxiety=21%, 
n=13/61; depression=8.2%, n=5/61). However, neither smell nor taste dysfunction were 
contributory factors to the reduced QoL, but the sexual dysfunction was the main factor 
contributed to the compromised general QoL in pSS patients.  
Conclusion: The smell, taste and sexual impairment are manifestations seen in pSS, but only 
the sexual dysfunction appear to have a diminishing effect on the QoL and mental health 
well-being of patients. The taste deterioration in pSS does not seem to be associated with 
mucosal dryness but maybe precipitated by a Sjӧgren’s syndrome-associated neuropathy.   
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Introduction 
Sjögren’s Syndrome (SS) is an inflammatory autoimmune rheumatic disorder that affects 
exocrine glands, especially salivary and lacrimal glands, causing reduction of the glandular 
secretions (Fox, 2005). The glandular dysfunction can result into dryness of the related 
mucosal surfaces, typically ocular and oral mucosa, but nasal and genital mucosa can also 
be affected (Rasmussen et al., 1986, Jacobsson et al., 1992, Marchesoni et al., 1995). It is 
well established that mucosal dryness is the main characteristic feature of the syndrome 
(Henkin et al., 1972, Isik et al., 2016), which can be severe enough to affect the functions of 
the related organs, namely the smell, taste and sexuality. However, the extent to which the 
mucosal dryness alters these functions is not well known.  
Deterioration of the smell and taste is a frequently reported symptom by pSS patients. 
Henkin et al. (1972) and Kamel et al. (2009) found that smell and taste are impaired and 
compromising each other in pSS patients, and influenced by the dryness of the mucosal 
surfaces. Negoro et al. (2004) showed that taste dysfunction was less frequently found in 
SS patients than previously reported, and that it was affected by the oral dryness, in a way 
that impedes substances from reaching the taste buds. Weifenbach et al. (1995) and Gomez 
et al. (2004) reported different results of the lack of association between taste deficit and 
mucosal dryness in SS patients. Therefore, the evidence in the literature regarding the smell 
and taste dysfunction in SS patients is conflicting. 
Women with SS often suffer from vaginal dryness and dyspareunia, and the possible 
explanation for these symptoms is the local inflammation of vaginal mucosa (Skopouli et 
al., 1994, Marchesoni et al., 1995, Mulherin et al., 1997, Cirpan et al., 2007). Mulherin et al. 
(1997) presented evidence of the association between oral symptoms and vaginal dryness 
in SS patients. Other studies suggested that dryness and dyspareunia could adversely 
influence the sexual well-being of SS women (van Nimwegen et al., 2015, Priori et al., 2015). 
Sexual well-being is an important aspect of the life quality, and addressing this is an 
essential component of delivering holistic patient-centred care.   
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There have been several studies showing that the quality of life is compromised in SS 
patients (Kamel et al., 2009, van Nimweden et al., 2014), however, there is none that looked 
at the collective effect of the smell, taste and sexual impairment on patients’ well-being.  
In this study, we hypothesised that the functions of the smell, taste and sexuality are 
impaired due to dryness of the mucosal linings in pSS patients (Primary hypothesis), and 
that this impairment compromises the QoL and the mental health status of these patients 
(Secondary hypothesis).  
This is the first study that presents the collective effect of the senses dysfunction, and 
provides clinical evidence for the need to establish management pathways to address these 
problems. 
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2.1 History of Sjӧgren’s Syndrome 
A Swedish ophthalmologist, Henrik Sjӧgren, was the first to give a comprehensive 
description of the syndrome that later took his name (Manthorpe et al., 1981, Jonsson 
and Brun, 2010). In his doctoral thesis in 1933, Sjӧgren detailed his findings, clinical and 
histological, in a study of 19 women suffering from xerostomia and keratoconjunctivitis 
sicca, 13 of whom had arthritis (Sjögren, 1933, Jonsson and Brun, 2010). Sjӧgren’s 
findings shed light on the relationship between oral and eyes dryness, with rheumatic 
disorders.  
Before it was well defined by Sjӧgren, the syndrome was imprecisely described by 
Johann Mikulicz in 1892 (Mikulicz, 1937). Mikulicz presented evidence of bilateral 
painless swelling in the parotid, minor salivary and lacrimal glands of a Prussian man, 
associated with profuse round cells infiltration, but no symptoms of xerostomia or 
kerato-conjunctivitis sicca. Mikulicz was not sure of the disease’s nature, which led him 
to describe the case as a “mystery”, and to diagnose the condition as a category of 
lymphoma. In 1925, the term “Gougerot Syndrome’’, named after a French 
dermatologist, was used in France. Gougerot described three cases with severe oral, 
lacrimal and vaginal dryness, (Gougerot, 1946). This was the first understanding of the 
sicca nature of the syndrome prior to Sjӧgren’s description.  
In 1949, Holm reported a link between salivary and lacrimal glands malfunction with 
rheumatologic conditions, which facilitated the diagnosis of the syndrome (Holm, 1949). 
Since the 1960s, the understanding of the nature and aetiology of the syndrome and the 
correlated clinical and serological measures has been improved. For instance, a link was 
made between lymphoma and Sjӧgren’s Syndrome by Talal and Bunim (1964), which 
helped explain Mikulicz findings of relating the syndrome to lymphoma. Thereafter, the 
first differentiation into primary and secondary was presented by Bloch et al. (1965).  
The first histologic assessment of the lymphocyte infiltration that occur in the labial 
glands was suggested by Chisholm and Mason (1968), and the presence of 
autoantibodies (Ro/SSA) found in blood serum was first described in 1969 by Clark et al. 
(1969), which has now become a clinical objective measure for the diagnosis of the 
syndrome.  
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2.2 Classification and diagnostic criteria 
Sjӧgren's syndrome (SS) is categorised into two types, primary (pSS) and secondary (sSS) 
(Kassan and Moutsopoulos, 2004, Mitsias et al., 2006, Jonsson and Brun, 2010). The 
latter occurs in conjunction with other autoimmune diseases, such as Rheumatoid 
Arthritis (RA) or Systemic Lupus Erythematosus (SLE), whilst pSS presents on its own 
(Jonsson and Brun, 2010). The first illustration for this classification was suggested by 
Bloch et al. (1965). 
Since then, the need to establish unique criteria to serve as a clinical diagnostic 
standardization for SS patients was raised. This was deemed necessary, to provide 
comparable data, which is an essential requirement for research purposes. This concern 
led to the presentation of the Preliminary European Classification criteria by a 
multicentre project between 1988 and 1996 (Vitali et al., 2002). Ever since it was 
released, the European criteria has largely been employed in observational and 
interventional studies, as well as in clinical practice. These criteria set were based on six 
items; any four out of the six items meet the diagnosis of pSS. These items included (a) 
ocular symptoms (subjective), (b) oral symptoms (subjective), (c) ocular signs (objective, 
defined by positive Schirmer-1 test and/or Rose Bengal score), (d) salivary glands 
involvement assessed by parotid sialography, scintigraphy and unstimulated salivary 
flow rate, (e) focus score assessed by salivary gland biopsy, (f) the presence of 
autoantibodies represented by antinuclear antibodies (ANA), rheumatoid factor and/or 
anti-Ro and anti-La/SSB. 
However, a number of criticisms was raised after releasing these criteria set. The main 
one being the possibility of fulfilling the criteria in the absence of either positive salivary 
glands biopsy or positive autoantibodies. This means that patients with sicca symptoms 
(dry eyes and mouth syndrome without evidence of autoimmune disease present) who 
are not showing autoimmune antibody might also be classified as pSS with these criteria. 
Hence, between 1998 and 2002, the European criteria were revised by experts from 
America and Europe after conducting another study on a different study group to 
improve accuracy, whilst maintaining the previous scheme of the original criteria. The 
revised criteria is known as the American-European Consensus Group criteria (AECG) 
(Appendix 1) (Vitali et al., 2002). Its strength lies in the obligatory inclusion of one of the 
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two objective measures; positive histology and/or presence of autoantibodies. This 
resulted in an accurate diagnosis clinically and a better-defined pSS group of patients. 
This made the research results of investigations using these criteria more reliable and 
consistent.  In fact, since its publication, the AECG criteria have been used in more than 
1300 studies around the world (Vitali et al., 2013), which supports its credibility and 
global acceptability. 
Subsequent to the publication of the AECG criteria, the Sjögren’s International 
Collaborative Clinical Alliance (SICCA), was established in the USA to oversee an 
international SS depository of clinical data to serve as supporting information for future 
SS studies (Daniels et al., 2009, Whitcher et al., 2010, Daniels et al., 2011, Malladi et al., 
2012, Shiboski et al., 2012). The project was multicentre, conducted as a collaboration 
between the USA and several other sites across the world including the UK. A large 
number of patients (n=2090) were recruited for this observational study. The 
investigators used the AECG criteria to recruit their study group to come up with a new 
set of diagnostic criteria,  which dictated that for the diagnosis of pSS patients must have 
at least two of the following three items: (a) positive anti-Ro and/or anti-La antibodies, 
or positive rheumatoid factor and antinuclear antibody; (b) positive keratoconjunctivitis 
sicca, with an ocular staining score of more than three; (c) positive results of labial glands 
biopsy defined by a lymphocytic focus score of more than one focus/4mm2 (Shiboski et 
al., 2012). In addition to the built in bias of study group selection in this study, the 
resulted diagnostic criteria was not supported by evidence, but rather depended on 
observation in a large number of patients. Although the authors of the SICCA study 
presented their results as superior to the previously published criteria, others have 
shown that a misclassification can occur especially when patients meet only one of the 
SICCA criteria, and presenting with oral and ocular complaints of dryness, which both 
have not been included in these criteria (Vitali et al., 2013). Interestingly, the SICCA team 
ignored including two important symptoms of SS, these were the mouth dryness and/or 
the increase in the DMF score. Although the SICCA team acknowledged the importance 
of these two symptoms and that they were considered for years as manifestations of 
the hallmark of SS diagnosis.  
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Additionally, unlike the AECG criteria, the SICCA criteria does not discriminate between 
the subdivisions of SS (primary and secondary SS). A number of studies have shown that 
there is a distinction between the two subdivisions in terms of the degree of associated 
arthritis, presence of certain autoantibodies, severity of oral manifestations, levels of 
certain proinflammatory cytokines, B lymphocyte titre and even in the proteomic 
constituents of saliva (Tsampoulas et al., 1986, Gal et al., 2000, Shiari et al., 2006, 
Hernandez-Molina et al., 2010, Baldini et al., 2011, Furuzawa-Carballeda et al., 2014, 
Hwang et al., 2014). Therefore, differentiation between the two subtypes of the 
syndrome is important. The question remains whether there was a need to come up 
with a new criteria altogether taking into account that the AECG criteria has been used 
successfully for a number of years including in the SICCA study. 
Rasmussen et al. (2014) have conducted a comparison between the, the AECG and SICCA 
criteria, on 837 participants in Minnesota, USA. The comparison showed that there was 
no significant difference (p=0.19) in classifying SS patients using both systems. Similarly, 
a literature review by Bowman and Rao (2014) concluded that the SICCA criteria cannot 
be considered as a novel scheme.  
A newly published set of criteria that combined features of the SICCA and AECG criteria, 
were recently validated and called the American College of Rheumatology (ACR)-
European League Against Rheumatism (EULAR) (Tsuboi et al., 2017). The methodology 
of these criteria was based on data and clinical judgement of experts, and a final 
definition of pSS was based on five objective items. These were the presence of focus 
score of ≥1 (based on number of foci/4 mm2), positive anti-SS-A/Ro, ocular staining of 
≥5 (or Van Bijsterveld Score of ≥4), Schirmer’s test of ≤5 mm/5 min on at least one eye 
and unstimulated salivary flow rate of ≤0.1 mL/min. The performance of these criteria 
showed higher sensitivity but lower specificity than the most widely accepted diagnostic 
criteria of the revised Japanese criteria (Fujibayashi et al., 2004), AECG and ACR criteria. 
A high specificity, which the new criteria lacks, is an important aspect of diagnostic 
criteria, because it prevents subjects without pSS to fulfil the diagnosis and to enter 
clinical studies or trials. Consequently, there is a strong argument in favour of using the 
AECG criteria in diagnosing pSS patients. 
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2.3 Epidemiology 
2.3.1 Incidence 
Studies of the incidence of primary Sjӧgren's Syndrome (pSS) from around the world are 
summarised in table 2-1. The reported incidence of SS was found to be ranging from 3.9 
in the period 1976-1992, to 11.8 in the period 2005-2009. 
A study from Olmstead County, Minnesota, USA, reviewed the data retrospectively 
between the years 1976 and 1992 with a total reached population of 108,145 in 1992, 
found that the annual incidence of pSS was 3.9 per 100,000 (95% CI=2.8-4.9). The study 
reported that when age was adjusted, the female to male ratio was 13:1 (Pillemer et al., 
2001). It is worth noting that this study was based in one state in the USA and therefore 
not necessarily representative of the whole of the USA. 
Interestingly, another study conducted in Slovenia by Plesivcnik Novljan et al. (2004), 
concluded annual incidence of pSS as 3.9 per 100,000 (95% CI=1.1-10.2), exactly the 
same as the above USA study, despite the difference in the study setting and population. 
The researchers examined the clinical records prospectively from 2000 to 2002, with a 
total population of 599,895 and a female to male ratio of 11:1. The study sample was 
representative of the whole country’s population.  
A further prospective study, conducted in the northwest of Greece with a total 
population of 488,435 for the period from 1982 to 2003. The study reported an 
incidence of 5.3 per 100,000 annually (95% CI=4.6-6.3), with a female to male ratio of 
20:1 (Alamanos et al., 2006). The study was conducted in one particular region of Greece 
that was not representative of the whole country. 
Three more studies were conducted in Taiwan (Weng et al., 2011, Yu et al., 2013b, Yu et 
al., 2013a), and their pooled incidence rate that was reported in a systematic review by 
Qin et al. (2014), was equal to 6.57 per 100,000 person yearly. It appears that Asians 
have higher incidence rate than other populations. This could be attributed to the 
impact of environmental factors that might trigger inflammatory response in susceptible 
individuals. The sample size and different study designs might also contribute to the 
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discrepancy in the incidence rate worldwide. In the UK, the frequently quoted incidence 
rate of SS is 0.6% of adults (BSSA). 
All studies agreed that females are by far the most affected gender by SS.  The F:M ratio 
ranges from 9:1 (Talal, 1992) to 13:1 (Ramirez Sepulveda et al., 2017). Despite the 
difference in the observed female to male ratios, the most quoted and accepted ratio is 
9:1 (Bayetto and Logan, 2010, Manthorpe et al., 1981, Jonsson and Brun, 2010, Yee. and 
Paget., 2005, Jonsson et al., 2002). 
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2.3.2 Prevalence 
The prevalence of pSS varies between studies, depending on the diagnostic criteria applied 
and the study design conducted. It is known that the prevalence of any disease depends on 
its duration and incidence rate (Hennekens C and Buring J, 1987). Therefore, with incurable 
diseases the rate of incidence should be lower than that of the prevalence. This is confirmed 
in table 2-2 (Also see table 2-1), which enlists the available studies about the prevalence of 
pSS in different countries chronologically. 
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    1: American European Consensus Group Criteria   
    2: ages 40-44 years; 
    3: 71-74 years;  
    4: International Classification of Diseases-10th version; 
    5: International Classification of Diseases-9th version 
    NS: Not specified 
    
 
  
Table 2-2: The prevalence of primary Sjӧgren’s Syndrome worldwide. 
Country 
Author, date of 
 publication 
           Study 
           Design 
pSS 
cases 
Total 
population 
Criteria 
applied 
                 Prevalence rate  
                (95% CI)/ 100,000 
UK Whaley et al, 1972 Hospital based 4 122 NS 3300 
USA 
Washingt
on 
Strickland et al, 1987 
Retirement home 
based 
2 103 NS 1900 
Greece Drosos et al, (1988) Cross-sectional 3 62 European 4838 
China Zhang et al, 1995 
Community 
Population Survey 
16 
7 
2066 
Copenhage
n 
San Diego 
770 
330 
Japan Miyasaka et al., 1995 Population based 17000 
~120,000,00
0 
Japanese 
1.9  males 
25.6  females 
Denmark Bjerrum (1997) 
Prospective 
population study 
1 
3 
504 
Copenhag
en 
European 
200 - 800 
600 - 2.100 
Greece Dafni  et al, 1997 Population Survey 5 837 European 600 (95% CI 190 - 1.390) 
Slovenia Tomsic et al. (1999) Population Survey 2 332 European 600 (95% CI 70 – 2.160) 
UK Bowman et al, 2004 Population Survey 2 846 AECG1 100 - 400 
Greece 
Trontzas and Andrianakos 
(2005) 
Population Survey 13 8740 AECG 150  (95% CI 90 - 210) 
Mexico Sanchez et al., 2005 Hospital based 40 300 AECG 2,700 (95% CI 900 – 4500) 
Greece Alamanos et al. (2006) Population Based 422 488,435 AECG 92.8 (95% CI 83.7–101.9) 
Turkey Kabasakal et al, 2006 
Cross-sectional 
population survey 
6 
13 
831 
AECG 
European 
720 (95% CI 330 – 1.570) 
1560 (95% CI 920 – 2.660) 
Norway Haugen  et al, 2008 Population survey 
155 
69 
2864 
 
AECG 
 
European 
 
220 (95% CI 150 - 320)2 
1400 (95% CI 1.020 – 1.920)3 
 
440 (95% CI 340 - 570)2 
3390 (95% CI 2.770 – 4.140)3 
Turkey Birlik et al, 2009 Population Survey 
6 
10 
2835 
AECG 
European 
210 (95% CI 30 - 290) 
350 (95% CI 100 - 450) 
Greece Anagnostopoulos et al. (2010) 
Cross-sectional 
population survey 
4 1705 AECG 230 (95% CI 220 - 750) 
Norway Goransson e t al, 2011 Population Based 424 852,342 AECG 50 (95% CI 48 - 52) 
Denmark Eaton  et al, 2011 Population Based 2615 5,472,032 ICD-10 4 48 (95% CI 45-49) 
Italy Sardu et al. (2012) Population Based 10 2887 European 31 (95% CI 13-61) 
China 
(Taiwan) 
See et al. (2013) Population Based 583 1,000,000 ICD-95 58.3 (95% CI 53.6 - 63.0) 
France Maldini C et al, 2013 Cross-sectional 133 1,172,482 AECG 10.2 (95% CI 8.5 – 12.2) 
China 
(Taiwan) 
Yu et al, 2013  
Population based 
longitudinal study 
154 963,355 ICD-9 16 (95% CI 4.3–18.7) 
Brazil Valim et al. (2013) 
Cross-sectional 
population survey 
2 1205 AECG 170  (95% CI 20 – 598.3) 
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2.4 The relationship of the clinical variables and QoL 
SS has been shown to negatively affect the general and oral health related quality of life of 
patients (Strombeck et al., 2003, Lopez-Jornet and Camacho-Alonso, 2008). The mental 
health well-being was found to be markedly affected in SS patients that can be 
characterised by a combination of anxiety and/or depression (Bongi et al., 2013, van 
Nimwegen et al., 2015). Mucosa-associated dryness is the main clinical feature of SS that 
can affect the function of the related organs and interfere with the quality of life. In order 
to facilitate understanding the relationship between the clinical variables and the health-
related quality of life, Wilson and Cleary (1995) proposed a conceptual model of patients’ 
outcome that was revised and simplified later on by Ferrans et al. (2005) (Figure 2-1). The 
revised Wilson and Cleary model encompasses the following: 
- Biological and physiological variables 
- Symptom status 
- Functional status 
- General health perception 
- Overall quality of life 
- Oral health related quality of life 
This was applied to the current literature review as below: 
 
Figure 2-1 The revised conceptual model 
  
Literature Review 
 
44 
 
2.5 BIOLOGICAL AND PHYSIOLOGICAL VARIABLES IN SJӦGREN’S SYNDROME 
2.5.1 Smell 
1. Physiology of smell 
The sense of smell was described as the sentinel of the brain by Critchley (1986). It plays an 
important role in the safety, quality of life and nutrition, as it determines foods and 
beverages smelling, and provides a warning bell for hazards detection as in rotted food 
(Christopher Hawkes and Doty, 2009). The same authors viewed this sense as an indicator 
of brain function. 
The olfactory area is lined with special kind of epithelium, in which its mucous is secreted 
from specialized mucous secreting glands called ‘’Bowman’s glands’’. Whilst the rest of the 
nasal cavity structures (bony, cartilaginous and turbinates) are covered by ‘’mucous-
secreting respiratory epithelium’’ (Menco, 2003). 
The mucous membrane in the olfactory area plays significant role in the smell perception 
of odorant molecules. This is achieved by transferring signals through specialised receptors 
on the cilia of the lining epithelium to the brain centres (Imamura and Hasegawa-Ishii, 
2016). The process includes two actions: first, the transfer events of odours to the nasal 
neuroepithelium, and second, the processing of these information into the brain, especially 
the olfactory bulb and the higher brain centres (Breer, 2008). 
The general somatic innervation of the nose, especially the lining mucosa is derived from 
the trigeminal cranial nerve (CN V), while the involuntary autonomic nerve supply comes 
from the sphenopalatine ganglion. Additionally, the upper part of the nasal cavity is 
supplied by branches of the nasociliary nerve, whereas the posterior part is nourished by 
branch of the maxillary nerve (nasopalatine nerve) (Sinnatamby, 2006). 
2. Odour coding mechanism   
Odorant molecules are usually classified into hydrophobic and lipophilic particles with 
different binding affinities that lock onto the smell receptors (Amoore, 1967). The main 
function of these molecules, is to pass the aqueous barrier of the nasal mucosa, an activity 
which in some cases assisted by soluble protein molecules called ‘’odorant binding 
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proteins’’ (Briand et al., 2002). Therefore, this mechanism is highly influenced by the 
amount of mucosa wetness in the nasal cavity.  
Some odours are similar in their chemical structures but exert different smell. Moreover, 
odorants can be recognized by more than one receptor, while on other occasions, a single 
receptor is able to differentiate a variety of other odours (Christopher Hawkes and Doty, 
2009). Thus, it is still unclear to explain the olfactory system works. But generally, it can be 
pointed out to important structure named amygdala, which is responsible to process the 
olfactory signals (Hudry et al., 2001). The amygdala is located in the anterior temporal lobe 
of the brain (ibid), which can be activated by pleasant and intense odours (Zald and Pardo, 
1997, Anderson et al., 2003). The amygdala has a considerable input from the olfactory 
bulb, and it is connected to a number of brain parts (basal ganglia, orbitofrontal cortex, 
thalamus and hypothalamus). The piriform cortex, which is located in the anteromedial 
temporal lobe in the brain, together with the amygdala react in accord to the valence, 
intensity and memory of an odour, to be processed later by another centre, mainly the 
orbitofrontal cortex; in which finally represented by specific smell sensation to an odour 
(Christopher Hawkes and Doty, 2009).  
3. Types of smell dysfunction 
Smell dysfunction was described and classified into different terminologies in accord to 
their severity and the way of perception. Table 2-3 highlights each term with a brief 
definition. 
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                  Table 2-3: Definitions of smell disorder terms by Hawkes (2002), p:50 
Term Definition 
Anosmia Loss of the sense of smell 
Hyposmia or microsmia Decline of smell sensation 
Dysosmia Impairment of the sense of smell 
Parosmia or troposmia Dysfunction due to specific stimulus 
Phantosmia Impairment when there is no external stimulus 
Cacosmia Unpleasant smell 
Torquosmia Burning type of distortion 
Hyperosmia Increased sensitivity of smell sensation 
Osmophobia Certain smells dislike 
Heterosmia Same smell for all odors applied 
Presbyosmia Deterioration of the sense of with age 
 
4. Factors influencing the acuity of Smell 
 Diseases 
A number of common diseases can have a negative impact on smell function. These diseases 
vary from simple cold to neurodegenerative disorders. Christopher Hawkes and Doty (2009) 
categorized in a list the main types of diseases that affect the quality of smell including SS 
(Table 2-4). There are only a few studies providing evidence of the effect of SS on smell 
(Henkin et al., 1972, Weiffenbach and Fox, 1993, Porter, 2010). These studies provided 
valuable assessments and results but did not attempt to relate the change in smell function 
to the degree of dryness.  
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Table 2-4: List of the main types of diseases that have an impact on olfaction by Christopher Hawkes 
and Doty (2009), p:117  
Disease Type 
Local nasal infection 
Polyps, allergic rhinitis, sinusitis, common cold, influenza, AIDS, prion 
disease, fungal infection. 
Head injury Usually in the posterior or lateral part of the head. 
Epilepsy Olfactory aura, complex partial seizure 
Migraine Before, during or after attack 
Multiple sclerosis (MS) During relapse or in advanced stages. 
Tumors and 
inflammatory diseases 
Nasopharyngeal carcinoma, Wgener’s granulomatosis, olfactory groove 
meningioma or neuroblastoma, facial Paget disease, Sjögren’s Syndrome 
Endocrine 
Diabetes, Addison’s disease, Cushing and Klinefelter syndromes, 
pseudohypoparathyroidism, Kallman syndrome, septo-otic dysplasia 
Neurodegenerative Parkinson’s disease, Alzheimer’s disease, dementia 
 
 Age  
The effect of ageing on the quality of olfaction after the sixth decade of life is generally 
agreed, but this is not clear in relation with gender. Kamel et al. (2009) found a negative 
correlation between smell and age in pSS patients compared with controls. Although the 
authors attributed the smell dysfunction to dryness in pSS group, there was no attempt to 
measure the severity of mucosal dryness, neither subjectively nor objectively. 
Bhattacharyya and Kepnes (2015) conducted a self-assessment cross-sectional survey for 
smell disorders on 142 million of American adults, and observed that 10.6% of the 
participants reported increasing prevalence of smell dysfunction with increasing age. The 
cause of anosmia was also attributed to the environmental factors, which has an 
accumulative damaging effect on the nasal epithelium throughout life (Christopher Hawkes 
and Doty, 2009, Doty and Kamath, 2014). The same authors as well as Doty et al. (1984), 
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Doty et al. (1996) and Hummel et al. (2007), have referred the impairment of the smell 
function to the ageing effect on the reduction rate of protein synthesis, reduced 
intramucosal blood flow and high mucus viscosity in the olfactory epithelium. 
 Gender 
Women score slightly higher on identification tasks at all ages (Doty et al., 1984, Hummel 
et al., 2007). However, unlike age, the evidence in the literature suggests that gender does 
not have a direct impact on smell dysfunction. These observations were also supported by 
Kern et al. (2014) findings, where a lack of association was shown between gender and smell 
dysfunction. Hayes and Jinks (2012) presented evidence, which showed that both age and 
sex do not seem to have influence on olfaction, despite the more accurate guessing of 
women to the correct odour than men (p=0.001).  
 Smoking 
Studies on animals showed that the exposure to volatiles that come from burning tobacco, 
could damage the olfactory neuroepithelium. Vanscheeuwijck et al. (2002) have described 
the pathology of the upper respiratory tract epithelium in a study that used rats to expose 
‘’nose-only’’ to either fresh air or mainstream cigarette smoke. There was noticeable basal 
cell hyperplasia, squamous metaplasia and goblet cell hyperplasia in the study group of rats. 
Perhaps due to the fact that hyper activity of the respiratory epithelium is a protective 
response, there is hardly ever anosmia seen with smoking persons.  
Although Hayes and Jinks (2012) found that smoking affect odorants threshold levels of 
olfaction, recent observations on patients with Parkinson’s disease (PD) by Lucassen et al. 
(2014), refuted that assumption. Hayes and Jinks (2012) suggested that the quality of smell 
identification sense is associated with the duration of smoking history. Doty et al. (1984), 
Frye et al. (1990) and Sharer et al. (2015) believe that there is a considerable difference in 
the smell identification test scores, between smokers and non-smokers when age is 
adjusted. 
  
Literature Review 
 
49 
 
 Pollution 
Attention has been recently focused on the impact of environmental pollution on olfaction, 
between rural and city residents. For example, a study by Hudson et al. (2006) compared 
the olfactory function between residents of Mexico city, which has high ambient air 
pollution, and residents of the state of Tlaxcala; a region that is geographically similar to 
Mexico city, but with low air pollution. It was concluded that the city “long-term’’ residents 
have impaired sensation of olfaction compared with the “long-term’’ residents of Tlaxcala 
state. The state’s subjects were able to detect the smells of orange and coffee at lower 
concentrations, more than those of the city participants. Although the study did not provide 
a strong evidence of the olfactory epithelium damage by pollution, this research succeeded 
in demonstrating a significant difference in the olfactory function between subjects live in 
rural dwellings, and those live in polluted conurbations. Especially, after adjusting for the 
influential variables, such as age, altitude, socioeconomic levels of participants, climate and 
having the same administrator to carry out the study. Findings by Hudson et al. (2006) were 
the first to show the effect of air pollution on olfaction. More studies, later on, were able to 
support the previous findings, and showed that the accumulative effect of environmental 
factors have a negative impact on olfaction (Christopher Hawkes and Doty, 2009, 
Sorokowska et al., 2013, Guarneros et al., 2013, Doty and Kamath, 2014).  
 Medications 
In comparison with taste, most medications have little effects on smell. Long-term 
consumption of certain drugs might have an impact on olfactory quality function. Little 
evidence is available to support this. Most of the available evidence are based on personal 
reports, and thus no quantitative comparisons have been carried out. Hawkes and Doty 
(2009) suggested that the disease itself could cause smell dysfunction, instead of the 
medication used for treating it. Whereas two studies reported that some kinds of 
antihypertensive therapeutics, especially calcium channel blockers, have high percentage 
of side effects on both smell and taste function (Deems et al., 1991, Doty et al., 2003). 
Deems et al. (1991) who conducted a study on 750 patients in Pennsylvania University in 
the US, attributed the reason to the impairment of “electro-olfactogram’’ impulse 
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transmission, which is a calcium-mediated mechanism to the olfactory bulb (Restrepo et al., 
1990). Hawkes (2002) mentioned that lipid lowering agents, antibiotic, antifungal, 
antithyroid, antidepressant, antiepileptic and nasal decongestant, can also have an adverse 
impact on olfaction. 
Welge-Lussen et al. (2004) and her team have successfully proved that the intranasal local 
anaesthesia, is capable of reducing olfaction acuity temporarily, but unable to abolish its 
activity (Welge-Lussen, 2004). Despite the fact that this study was conducted on 20 
participants only, it presents evidence of the effect of local anaesthetization on the 
neurology of olfaction. Hence, subjects complaining from smell disorder after surgical 
operations, should consider the impact of the general anaesthesia used in the operation, 
and may allow its effect to resolve spontaneously.  
 Head trauma  
Head injury is one of the commonest causes for olfactory dysfunction. In a recent systematic 
review by Schofield et al. (2014), the negative impact of head injury was reported. The 
review highlights the finding of 25 studies on the effect of head injury on olfaction; although 
the review considered language and publication restriction, the scientific value of the study 
cannot be hidden. According to Jafek et al. (1989) explained the reason of the traumatic 
brain injury impact on olfaction from neurological point of view. The authors believed that 
the problem is due to the damage of the olfactory nerve fibres that emerge from the 
cribriform plate, in their pathway to enter their destination in the olfactory bulb. The skull 
does not necessarily need to fracture in order to inversely affect olfaction. A blow or even 
a whiplash could be sufficient to cause smell dysfunction (Delank and Fechner, 1996).   
 Congenital abnormalities 
Congenital anosmia is a very rare condition, where individuals experience complete loss of 
smell sensation since birth. It was believed that the condition is solely due to olfactory bulb 
agenesis (Qu et al., 2010), but recent studies indicated the presence of gene mutations, that 
have a significant role in the transduction of olfactory signals to the brain (Moya-Plana et 
al., 2013, Karstensen et al., 2015). This gene mutation is X-linked chromosome, which is 
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dominantly found in males and mainly transmitted by male to male; but has also been 
occasionally observed in females by Chen et al. (2013b). 
5. Measurement of smell 
There are numerous tests described in the literature for the assessment of patients’ ability 
to smell. Identification tests that are used in clinics rely on the patients’ ability to identify 
odours, whilst threshold tests rely on the ability to detect low concentrations of odours. 
Identification tests are the most widely used and can be self-administered sometimes as in 
the University of Pennsylvania Smell Identification Test-40 (UPSIT-40) (Doty et al., 1984). 
The test consists of scratch and sniff of 40 odorants, and a shorter version of 12-item is also 
available for quick clinical screening purposes (Doty et al., 1996). If smell dysfunction is 
detected by the shorter version, further assessment is usually recommended.  
Other commonly used smell identification test is the Sniffin’ Sticks Test (SST) which has been 
developed by Kobal et al. (1996). The test comprises of multiple pen-like devices, each of 
which has a particular odorant. The patient will recognize smells through 16 sticks and 
should choose the relevant option from the four choices provided (forced choice test) in a 
separate sheet. The reliability of this test is less than that of the full UPSIT but it is 
comparable to the shorter version of it. Later on, an extended version of SST called TDI index 
has been developed by Ahne et al. (2000) to be more reliable, which was tailored to assess 
the three main elements of the chemosensory smell function, these are threshold, 
identification and discrimination (where patients have to determine which of the sticks 
smells differently) via 48 sticks which requires long time to be conducted and professional 
trained supervision compared to the ordinary identification version of SST and UPSIT.  
6. Review of the research showing smell dysfunction in patients with Sjӧgren’s Syndrome 
PSS patients frequently report olfactory disorders and only a few studies looked at the 
problem in these patients. In a pioneering study by Henkin et al. (1972), a high percentage 
(90%) of smell dysfunction was found in SS patients. The authors attributed the results to 
the dryness of the nasal mucosa that was reported by 92% of the patients. Although this 
Literature Review 
 
52 
 
study provided evidence of the smell dysfunction in these patients, they recruited a rather 
limited number of mixed syndromes: 11 secondary SS, 14 sicca syndrome, two SLE and two 
pSS patients only who were diagnosed based on clinical judgement. Similarly, a study by 
Kamel et al. (2009) reported significant deterioration of smell function (43%) and suggested 
that the deficit in olfaction was because of the nasal mucosa dryness in pSS patients and 
suggested that the reported impaired quality of life was influenced by the smell dysfunction. 
They also reported that the smell was adversely associated with age in pSS patients. 
Although the study used the reliable AECG criteria in diagnosing pSS patients, the main 
weakness in this study being the small sample size of the patients recruited (n=28).  
Four more studies in the literature have compared the smell function in SS patients but no 
attempt was made to investigate whether the smell was associated with the severity of the 
mucosal dryness. In a clinical trial by Rasmussen et al. (1986) who evaluated the sensitivity 
to the odour of coffee in 36 SS patients, has failed to demonstrate a deficit of the smell 
function in pSS patients. Another small Chinese study by Su et al. (2015b) that assessed the 
smell identification by the sniffin sticks in 15 SS subjects and 32 patients with burning mouth 
syndrome (BMS). The study reported no significant difference between the two groups 
(SS=10.7, ±3.5, BMS=11.8 ±2.6, p=0.21), although reporting lower smell scores in SS patients 
compared with BMS subjects. A recent small study by Rusthen et al. (2017) reported 
significant olfactory disorder in 31 pSS patients compared with 33 healthy controls. The 
authors argued that the reason for the smell dysfunction in pSS patients was the systemic 
inflammatory process associated with the syndrome, which contradicts findings of a 
previous study where no significant association was found between the impairment of 
olfactory performance and the inflammatory markers of the syndrome activity 
(Weiffenbach and Fox, 1993).   
There is contradiction in the literature not only on the association of the smell dysfunction 
in SS, but also on its aetiology.  
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2.5.2 Taste  
1. Physiology of taste 
Taste buds are distributed mainly over the tongue, and to a lesser extent on the pharynx 
and the oesophagus. Each taste bud consists of cluster of receptors in which they aggregate 
to form swellings or tiny prominences called papillae, which are divided into four types 
named after their grouping pattern: circumvallate, foliate, filiform and fungiform. A central 
pore is located at the apex of each bud to permit the entry of fluids, hence, moisture plays 
an important role in its function. The large fungiform together with circumvallate papillae 
are found on the root of the tongue. The foliate papillae are found on the posterolateral 
margins of the tongue, and the filiform papillae are spread on the dorsal surface of the 
tongue.  
Multiple pathways serve the nerve supply of the tongue; therefore, it is unlikely to have a 
complete taste loss. The four cranial nerves that supply the tongue are V, VII, IX and X. The 
common touch, temperature and pain sensation through the anterior two thirds of the 
tongue is fed by trigeminal nerve (V) by its lingual branch. The posterior third, along with 
the surrounding soft palate, are supplied by glossopharyngeal nerve (IX), and the taste 
sensation of the anterior two thirds, is perceived by the chorda tympani, a branch from the 
facial nerve, which also contains secretomotor fibers that supply the sublingual and 
submandibular salivary glands (Sinnatamby, 2006). The chorda tympani conveys taste 
stimuli from the taste buds to the brain centres. Experts are of the opinion that if a lesion 
or neuropathy damages the nerves that are responsible on taste can cause hypogeusia, and 
where a damage affects the salivary glands, mouth dryness and in turn compromised taste 
function may occur (Malaviya and Ramu, 1981, Spector and Stark, 1983, Okuda et al., 1994, 
Hashimoto et al., 2012). These findings need to be supported by further studies, and a study 
with SS would help. 
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2. Types of taste dysfunction  
Taste dysfunction is reflected in various terms, which explain the severity of each 
abnormality according to the individual perception. Table 2-5 illustrates each term with 
brief definitions.  
                  Table 2-5 Taste abnormalities definitions by Hawkes (2002), p: 125. 
 
Term 
 
Definition 
Ageusia Loss of the sense of taste 
Hypogeusia or microgeusia Decline of taste sensation 
Dysgeusia Distortion of the sense of taste 
Parageusia Taste distortion due to specific stimulus 
Phantogeusia Taste distortion with no stimulus 
Cacogeusia Unpleasant taste 
Torquegeusia Burning taste 
Hypergeusia Increased taste sensitivity 
Gustatophobia Certain taste dislike 
Heterogeusia Same taste for all tastants applied 
Presbygeusia Reduction of taste sensation with age 
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3. Factors that Influence taste sensation 
Several factors are known to affect the quality of taste perception. The following review will 
consider the main factors that are thought to mostly affect the taste function. 
 Diseases 
There is a number of diseases and conditions known to have adverse effect on the taste 
sensation (Table 2-6). These diseases varied from simple infections to neurodegenerative 
dysfunction. Hawkes (2002) enlisted the commonest diseases associated with taste 
disorders where SS was included. In Yamamoto et al. (2009), it was found that taste buds 
atrophy is noticeable in SS patients due to decreased salivary flow rate. The study relied on 
a digital microscope only in its investigations, with no attempt to test the function of the 
sense of taste in this study group. Another study by Enger et al. (2011) pointed to the effect 
of pSS on taste alteration in 49% of pSS patients with high oral distress (p<0.001) out of 177 
patients. Although the response rate of this study was good (72%), the results were not 
confirmed objectively. However, in this area of research, there is no publication examined 
the change in taste perception to the degree of oral dryness in pSS patients, which is known 
to be part of the syndrome. 
Moreover, it has been recently reported by Nagai et al. (2015), that depression is inversely 
correlated with the sweet taste threshold (r=-0.472, p=0.031). This supports the relation 
between mental health status and taste perception. Similar findings were reported by Karita 
et al. (2012) and Naudin et al. (2015), who all agreed that taste acuity perception depends, 
to some degree, on the mental health status of patients.  
There is evidence showing that Parkinson’s disease, chronic hepatitis C, and HIV have an 
adverse impact on taste sensation (Shah et al., 2009, Musialik et al., 2012, Raja et al., 2013). 
Deems et al. (1991) found that dysgeusia was reported in higher percentage of patients 
suffering from upper respiratory tract infection and nasal sinus diseases compared with 
other conditions. Therefore, in the current project we excluded participants with any 
disease other than SS, with possible impact on taste. The following table, which is quoted 
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from Hawkes (2002), highlights the commonest diseases that have an impact on the taste 
perception. 
           Table 2-6 The commonest diseases that have negative impact on taste perception, by 
Hawkes (2002). 
Diseases Type 
Tumors Middle ear tumor, jugular foramen tumor 
Trauma Petrous bone fracture, neck injury damaging glossopharyngeal 
 nerve, cortical trauma, orbitofrontal cortex injury  
Surgical procedure Bilateral thalamotomy, laryngectomy, neck radiation, 
 middle ear surgery, tracheal intubation 
Vascular disorder Lateral medullary syndrome, pontine hemorrhage, 
 internal carotid artery dissection 
Systemic disease 
 
Type I & II diabetes, cystic fibrosis, renal failure, familial dysautomia, 
primary amyloid, Cushing’s disease, cretinism,  
cranial arteritis, Sjӧgren’s syndrome 
Infection Bell’s palsy, viral encephalitis, influenza, leprosy, periodontitis,  
glossitis, Guillan-Barre syndrome, AIDS 
Deficiency states B3 and B12, vitamin A, zinc 
Psychiatric Depression, schizophrenia 
Developmental Congenital facial hypoplasia 
 
 Age and gender  
The influence of age and gender on the sense of taste has been explored in a number of 
studies. Mojet et al. (2001) reported significant loss of taste threshold in older people 
(p<0.003), but the gender did not contribute to the taste loss. Similar findings by Ng et al. 
(2004) who reported that taste threshold of older subjects (0.414, ±0.366, p=0.001) was 
significantly higher than that of young (0.084 ±0.057, p=0.001) and middle aged participants 
(0.082, ±0.076, p=0.001). Findings by Suchecka et al. (2012) also concluded that the 
intensity of the salt taste response decreases with ageing process, especially over the age 
of 50. The study pointed to a gender discrepancy, in that women were more able to 
recognize salt taste compared with men (p=0.05). However, others did not support the 
above assumption, but found that age does not have an adverse effect on taste acuity 
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(Mojet et al., 2003, Mojet et al., 2005, Kamel et al., 2009). Further investigations are needed 
to resolve the above contradictions.  
 Medications 
Many drugs are excreted in saliva, and hence, it is envisaged that drugs can impair taste 
function either by adversely affecting the neural transduction mechanism of the taste buds 
or by presenting the drug’s taste itself (Henkin, 1994). However, Henkin, 1994 believed that 
taste dysfunction could be restored after therapy termination, while effects that continue 
to persist might necessitate treatment to alleviate the symptoms. Nevertheless, and 
according to Hawkes (2002), who deemed that the disease itself could cause the adverse 
effect on the taste perception, rather than the drugs used in its alleviation. It has been 
shown that the drugs used to treat diseases such as asthma, muscular spasm, depression, 
sleeping problems and cardiovascular diseases, can cause mouth dryness and affect taste 
perception (Casaburi et al., 2002, Godara et al., 2011, Suliburska et al., 2012). Notably, it is 
thought that zinc deficiency which is caused by prolonged injection of β-lactam antibiotics 
for the treatment of some diseases, has also a negative impact on taste sensitivity (Jones et 
al., 1987). However, Negoro et al. (2004), presented different observation, in which serum 
zinc that is measured in SS patients, in comparison with sicca sufferers does not significantly 
correlate with their taste sensitivity. This finding partially agrees with that of the systematic 
review by Nagraj et al. (2014), who found very low quality evidence of the impact of the 
zinc supplement on taste function.  
 Smoking 
The effect of smoking on taste perception has been studied and conflicting findings were 
obtained. A study was conducted in 1961 by scientists from South Africa, who recruited 156 
medical students, half of whom were smokers Krut et al. (1961). The study concluded that 
the taste acuity of smokers did not significantly differ from that of non-smokers for sweet, 
sour and salt, while the perception of tasting bitter was the worst among smokers. This can 
be attributed to the prolonged practice of the habit. This finding was confirmed by others 
who believed that taste perception was not affected neither in smokers nor non-smokers 
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in their study groups (Shah et al., 2009, Konstantinidis et al., 2010). Asim Mustafa Khan et 
al. (2016 ) reached to a different conclusion and found that smoking has a negative impact 
on taste perception in a group of 30 smokers compared to 30 non-smokers.  
It was anecdotally believed that taste returns to normal after smoking cessation. This could 
be due to the recovered function of the taste buds that were damaged by smoking; 
however, detailed studies are needed to confirm this belief.  
 Head trauma 
Head trauma has an impact on taste perception since it could damage the brain lobules that 
expresses taste sensation. Paul J. Schechter and Henkin. (1974) together with Daniel A. 
Deems et al. (1991), reported altered and decreased taste acuity after head trauma. 
Participants in their studies performed poorer than normal subjects.  
 Irradiation 
Irradiation could significantly worsen taste function and decreases the subjective taste 
sensation of patients (Saito et al., 2002, Caputo et al., 2012, McLaughlin and Mahon, 2014). 
This could be due to the fact that cancer patients who are subjected to radiotherapy and/or 
chemotherapy, are prone to having poor oral health, psychological status and hence 
negatively impact the nutritional status, where all of which impact the perception of 
different senses. In addition, this group of patients are known to have xerostomia caused 
by radiotherapy (Paterson et al., 2015), that can compromise taste perception. 
 4. Measurement of taste 
The gustatory function of the taste buds was often examined by presenting a variety of 
aqueous solutions with different concentrations to test subjects (Henkin et al., 1963). 
However, this approach has several limitations, the main one being the water content that 
may create environment different from the natural oral circumstances for patients with dry 
mouth syndrome. In addition, aqueous solutions possess sensitive response to shelf life and 
room temperature. Therefore, a number of tests that do not rely on aqueous solutions for 
taste stimulation was developed. These tests comprised of either chewable dried taste 
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tablets of the four basic taste stimuli (sweet, sour, salt and bitter) (Ahne et al., 2000), or 
cellulose-based filter papers which impregnated with different concentrations of each 
tastant (Mueller et al., 2003). Although these approaches have met the requirement of long 
shelf life, some limitations were found and should be mentioned. The main of which being 
that the tablets have to be chewed therefore the possibility of regional taste assessment of 
the tongue is not applicable. For the impregnated filter paper strips, there are reservations 
about the celluloid texture of the strips, which may not be helpful in testing patients with 
dry mouth syndrome, but regional taste testing of the tongue is applicable with this test. 
The Electrogustometer (EGM) is the only quantitative method available to date for the 
assessment of the neural function of the taste sensation performed by chorda tympani 
nerve. The device was first introduced by Krarup (1958), and is widely used in neurological 
departments for the regional mapping of the neuronal taste sensation thresholds which is 
expressed in decibels (dB) (Miller et al., 2002, Berling et al., 2011). Ellegard et al. (2007) 
advised to use the machine as a complementary procedure to the gustatory tests rather 
than been used as a replacement for them. Using gustatory and neuro-electrogustometry 
tests provides full picture for the taste function process. One limitation of the EGM worth 
to be mentioned that the patient may respond to the common sensation, which is supplied 
by the trigeminal nerve rather than responding to the sensory stimulation by the chorda 
tympani. However, the sensory threshold of the trigeminal receptors is higher than that for 
chorda tympani (Miller et al., 2002, Stillman et al., 2003). 
5. Review of the research showing taste dysfunction in patients with Sjӧgren’s 
Syndrome 
There is only a few evidence in the literature of the taste function in SS patients. A 
hypothesis was proposed by Henkin et al., 1972 which stated that the scarcity of saliva lead 
to a deficit in the ability of transferring signals to the taste buds. The authors also concluded 
that the dryness of oral mucosa raised the chance of promoting oral microbial infections 
that usually disturbs taste sensation and recognition. The study was the first that 
demonstrated taste disorder in 90% of 29 tested patients with SS. Although they provided 
evidence of the taste impairment in this group of patients, authors of the study assessed 
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oral dryness by clinical inspection rather than by objective assessment. Additionally, 
patients were not diagnosed using reliable criteria as the study was conducted before any 
diagnostic criteria were developed. Moreover, authors of the study reported insufficient 
objective evidence to establish the diagnosis of SS, therefore, the result of the study may 
not be applied on SS patients. Henkin and colleagues findings were refuted later by a study 
performed by Weifenbach et al. (1995), who reported no significant difference of the taste 
function between SS patients compared with healthy controls, and no impact of saliva 
scarcity was found on taste. The study appeared to be more reliable than that of Henkin et 
al., 1972 in its design and number of patients recruited, although they did not apply valid 
diagnostic criteria.  
A decade later, a Japanese study by Negoro et al. (2004) reported 18% taste dysfunction 
among SS patients, which is lower than that reported previously (Henkin et al., 1972). The 
study emphasized the impact of oral dryness on the quality of the sense of taste but 
reported no effect on the neurosensory threshold of taste. Another research by Gomez et 
al. (2004), showed that all SS patients and matched healthy controls, were able to detect 
and recognize the four basic tastes (sweet, salty, sour, and bitter) at suprathreshold 
concentrations. However, SS patients exhibited varied degrees of dysgeusia compared with 
controls. Mild dysgeusia was observed only for the sweet and salt tasting ability in the SS 
group, but severe dysgeusia in sour and bitter was recorded compared with controls. The 
study, however, found no correlation between the scarcity of saliva and the deficit in tasting 
ability in pSS patients, in agreement with Weiffenbach et al. (1995).   
Kamel et al. (2009) concurred Henkin et al. (1972) and Negoro et al. (2004) in suggesting a 
correlation between oral dryness and taste dysfunction in SS patients, and was the first to 
assess the impact of taste dysfunction on the QoL of patients. Kamal’s study further 
reported that taste is a robust function throughout the life and that it is not influenced by 
age, a finding that strongly contradicts others who found that taste was deteriorated with 
aging process (Gomez et al., 2004, Suchecka et al., 2012). The study found a significant 
reduction in the QoL of pSS patients (n=28) compared with the healthy controls (n=37), and 
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referred this reduction to the chemosensory impairment of the smell and taste functions 
together. About 70% of pSS patients of the same study were suffering from hypogeusia. 
However, salivary flow rate measurement was not employed equally for all participants. 
Therefore, reporting a correlation between oral dryness and taste impairment may not be 
applicable in pSS patients. Kamel and colleagues have also studied the relation between the 
functions of the smell and taste in pSS patients, and reported a strong correlation between 
both functions. Kamal’s findings supported previous study by Dzaman et al. (2005) who 
concluded that individuals with smell impairment had problems in correctly identifying the 
basic tastes. However, other studies believed that the sense of smell is not correlated with 
that of taste (Stinton et al., 2010, Fasunla et al., 2012, Ros et al., 2012, Chen et al., 2013a). 
Although the study used the reliable criteria of AECG in diagnosing patients, the low number 
of population employed did not allow for formal hypothesis testing, which is a general 
weakness of all of the above-mentioned studies. Therefore, the evidence in the literature 
regarding the correlation between both senses is unclear. 
A recent small study on 31 pSS patients who were diagnosed by AECG criteria, reported 
poor olfactory and gustatory function that are not correlated with the depletion of salivary 
secretion (Rusthen et al., 2017). The study also reported impaired oral health quality and 
referred the reason of the oral health problems to the taste impairment, burning sensation 
of tongue and halitosis. The same study reported weak association between gustatory 
function with age, medications or disease duration, but a strong correlation with olfactory 
function in pSS patients However, with the limited number of patients recruited for the 
study, this argument may not be reliable.   
Over all, the studies agreed that taste dysfunction is prominent in SS patients but the 
association with the oral dryness or smell impairment remains disputed. 
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2.6 SYMPTOMS STATUS 
2.6.1 Dryness of the mucosa and xerostomia 
Since it was firstly described by Henrik Sjӧgren, the most overwhelming symptoms 
described by patients is the oral dryness, which is also known by xerostomia. Hyposalivation 
in Sjӧgren’s Syndrome occurs due to the lymphatic infiltration of the salivary glands that 
leads to functional destruction (Gerli et al., 1997). With the hypofunction in the salivary 
glands, a depletion of saliva and its natural lubricative and protective constituents are prone 
to unfavourable consequences. The change in saliva quantity and quality may affect the 
hard tissues as well as the soft tissues and their related functions. By moistening chewed-
up food, saliva helps in conveying food particles to be analysed by taste buds, in a manner 
that facilitates transduction by ion channels and/or specific protein receptors, to transmit 
taste signals to the thalamus, insula and orbitofrontal cortex in the brain. Taste quality 
coding, relies upon the response of neurons, and the way they are evoked with certain 
tastes (Kaplan and Baum, 1993). Without saliva, none of the aforementioned activities 
would take place. Additionally, the lack of saliva precipitates Candida infection, which in 
turn has a negative impact on the taste perception (Sakashita et al., 2004). 
2.6.2 Definition of xerostomia 
Xerostomia is the subjective feeling of oral dryness where salivary glands impairment may 
or may not be associated with the problem. Xerostomia is more common in middle-aged 
people and has been shown to affect the oral health quality of sufferers (Locker, 2003, Ikebe 
et al., 2005). 
2.6.3 Measurement of xerostomia 
 Xerostomia inventory  
This is an 11-item scale to measure the severity of xerostomia, which is the subjective 
sensation of chronic mouth dryness that has a great impact on QoL (Hahnel et al., 2014). 
The Xerostomia Inventory (XI), was firstly developed and validated by Thomson et al., in 
1999 and was subjected to further validation in the following year (Thomson WM et al., 
2000). The XI provides five numerical options of responses that range from “never” to “very 
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often” giving a scale to the oral dryness, rather than classifying sufferers into either 
xerostomic or non-xerostomic as proposed by previous tools (Fox et al., 1987, Narhi, 1994). 
In 2011, Thomson et al proposed a modification of the scale to a shorter version (Summated 
Xerostomia Inventory (SXI) consisting of five items validated in a multicentre study 
(Thomson et al., 2011). Hahnel et al. (2014) validate this tool for clinical and research 
purposes successfully. The study was a single-centre but involved subjects from different 
ethnic origins who had consistent results. The convergent validity of SXI with the global oral 
health question used in the study, demonstrated very good to excellent correlation (r=0.6-
0.8) with Chronbach’s alpha value of 0.7. Although the shortened version of the inventory 
was validated and shown to be a reliable tool, it was deemed to be lacking in questions 
relevant to our project objectives, and therefore the full list of the original XI questions was 
used in the current study. 
2.6.4 Review of the research showing xerostomia in patients with Sjӧgren’s Syndrome 
The dysfunction of salivary glands could precede autoimmunity process in SS (Nikolov and 
Illei, 2009). However, xerostomia is not an exclusive symptom of SS and other conditions 
such as smoking and medicines intake can cause hyposalivation (Porter and Scully, 2000, 
Rad et al., 2010). Additionally xerostomia is subjective to the individual’s tolerance and 
adaptation for oral dryness (Scully and Felix, 2005, Ramos-Casals et al., 2012).  
Studies on the salivary constituent in patients with SS showed that with the reduced rate of 
salivation, the protein concentrations and some bacterial species such as Streptococcus and 
Veillonella were significantly increased in saliva of SS patients compared with matched-
controls (Eliasson et al., 2005, Siddiqui et al., 2016).  
Investigating the oral manifestations in 55 patients with dry mouth syndrome including SS, 
revealed increased symptoms of angular cheillitis, lip dryness, ulcerations and aphthae 
appearing on the patients’ oral mucosa (Blochowiak et al., 2016).  
Hyposalivation can be assessed via measuring salivary flow rate; however, patient-reported 
xerostomia was considered as a significant indicator for SS in a large cohort of 2046 SS 
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patients. The study also suggested to consider patient-reported xerostomia in SS 
classification as it represents patients’ own perspective about the severity of the syndrome 
(Billings et al., 2016).  
Xerostomia is the subjective sensation of oral dryness, while hyposalivation is the objective 
assessment for oral dryness when the unstimulated salivary flow rate (UWSR) is less than 
0.1 mL/min (Jorkjend et al., 2004, Villa et al., 2015). van der Putten et al. (2011) found that 
item two and four of XI were significantly correlated with hyposalivation in a group of 
residents at nursing home in Netherlands. Although the sample size was selective and 
limited, this association added extra importance to the validity of XI. The opposite was the 
case with findings by Minicucci et al. (2013), who concluded that XI was not (p>0.1) 
correlated with the salivary flow rate in menopausal women, presuming that there was no 
evidence in the literature of a correlation between xerostomia and hyposalivation. 
Nevertheless, the unique sensation of mouth dryness felt by xerostomic patients or people 
suffering from low salivary flow rate has one outcome, which reflects a negative impact on 
individual’s QoL (Cho et al., 2013). The latter is a Korean study to investigate the 
determinants of the European League against Rheumatism SS Patient Report Index 
(ESSPRI)*, in comparison with other clinical parameters. Cho et al. (2013) used XI to 
compare the impact of xerostomia on QoL in two groups, pSS patients and non-SS sicca 
participants. The researchers found that XI scores correlated significantly with several 
components of the SF-36 in the non-SS group, and no correlation was found between both 
scales in the pSS group. Nevertheless, the ESSPRI and XI were significantly correlated with 
each other in both tested groups. The latter correlation added further support to XI, since 
that ESSPRI was deemed by Cho et al. (2013) to be a disease specific for pSS patients. Other 
studies presented more evidence of a correlation between XI and the OHRQoL when 
assessed by OHIP-14 (Willumsen et al., 2010). 
 
_________________________________________ 
*ESSPRI: is a specific index to measure the severity of pSS symptoms 
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2.7 FUNCTIONAL STATUS 
2.7.1 Sexual functioning 
1. Definition of sexual functioning 
Sexuality is a complex process of physical and emotional reaction during the sexual 
response cycle. According to definition by the National Health Service (NHS), any problems 
occur during any phase of the sexual response cycle, is known by the sexual dysfunction 
(SD). SD can include loss of desire, loss of arousal, problems with orgasm, and pain during 
sex. Women are more likely to suffer from SD (32%) than men (23%) (Nicolosi et al., 2006), 
which is an aspect that affects the QoL of individuals. It was recognised that SD in patients 
with rheumatic diseases including SS can be referred to a number of factors (multifactorial) 
including mucosal dryness, rather than being attributed to a particular reason (Tristano, 
2012). However, little was published about the subject, which could be due to the sensitivity 
of the problem. 
2. Measurement of sexual functioning 
 Female Sexual Function Index  
This study explores variety of clinical aspects of the impact of pSS on patients. However, it 
was not feasible to cover each aspect with its assessing tool holistically in the literature 
review and hence it was decided to choose the most reliable and widely used assessing tool. 
The Female Sexual Function Index is a self-reporting scale known by FSFI, which was 
developed by Rosen et al. (2000) to measure the female sexual function through six 
domains via 19 items. These domains are desire, arousal, lubrication, orgasm, satisfaction 
and pain; where higher scores indicate better sexual functioning from a total of 36 points 
(ibid). Its psychometric properties were tested by different studies and with different 
language versions. It was agreed by number of studies, that the scale has a good validity 
and reliability, excellent internal consistency, adequate test-retest reliability and good 
discriminant validity (Rosen et al., 2000, Meston, 2003, Sidi et al., 2007, Chang et al., 2009, 
Sun et al., 2011, Takahashi et al., 2011, Ghassamia et al., 2013, Filocamo et al., 2014, Lee et 
al., 2014, Ryding and Blom, 2015, Crisp et al., 2015, Kalmbach et al., 2015). The scale was 
also used as a gold standard to validate newly developed or translated questionnaires (Corty 
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et al., 2011, Herbenick et al., 2011, Momenimovahe et al., 2015), which added more weigh 
to its usefulness. 
There have been several studies that used FSFI in the assessment of the sexual activity in 
patients with rheumatic diseases (Tseng et al., 2011, El Miedany et al., 2012, Shahar et al., 
2012, Ferreira Cde et al., 2013, Anyfanti et al., 2013, Anyfanti et al., 2014, Frikha et al., 2014, 
Coskun et al., 2014); where converged conclusions were drawn from these studies, which 
suggested that SD was strongly present in patients with rheumatic diseases. However, 
findings by Tseng et al. (2011) contrasted the aforementioned studies, and reported similar 
rates of SD in females with Systemic Lupus Erythematosus (SLE) and healthy controls. In the 
same study, particular number of SLE patients who developed SS, were not significantly 
different from those without it. These conflicts need to be resolved.  
Females’ SD is commonly associated with anxiety and depression in rheumatic patients; this 
was described in a group of pSS patients by van Nimwegen et al. (2015). The authors of the 
study believed that pSS patients recorded significant lower scores than healthy controls in 
FSFI (p<0.001) in domains of arousal, desire, lubrication, orgasm and pain. Therefore, the 
reduced scores of FSFI could be a good indicator for depression and anxiety in rheumatic 
patients. 
Another study by Priori et al. (2015) which has also used FSFI in assessing the quality of 
sexual life in pSS patients. The study found that the scale was a useful tool in evaluating 
vaginal dryness status after treatment prescription, such as oral pilocarpine and cemiveline, 
which are both potent in alleviating oral dryness (Vivino et al., 1999, Petrone et al., 2002). 
Priori and colleagues further concluded that the affected mental health status, represented 
by high scores of the mental health assessment tool, was inversely correlated with lower 
scores of FSFI. This finding was in line with others (van Nimwegen et al., 2015), and shed 
light on the negative impact of SD on the mental health well-being.  
An attempt to shorten and modify the original scale was carried out in 2010, to be more 
practical for clinical settings. Isidori et al. (2010) abridged the scale from its full version of 
19 items to six items only that was called FSFI-LL, to indicate women’s lifelong sexual 
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function. The shortened version demonstrated accurate results with high sensitivity (0.93%) 
and specificity (0.94%). The new version was also tested by Burri et al. (2010) and was 
shown to have good reliability and validity. However, the authors recommend the abridged 
scale for clinical use as well as for studies with limited time coverage, as it provides brief 
information.  
3. Review of the research showing sexual dysfunction in patients with Sjӧgren’s Syndrome 
The fact that the female to male ratio in pSS patients is 9:1, supports the theory that female 
hormones may play a key role in the pathogenesis of this syndrome. Skopouli et al. (1994) 
reported a significant difference in the presence of dyspareunia in 40% of premenauposal 
SS patients (n=51) in comparison with 3% of premenauposal healthy controls. However, the 
authors believed that half of SS patients in the study had potential dyspareunia, which 
originated from trauma or inflammatory process that might occur in other organs as a 
consequence of the syndrome. Marchesoni et al. (1995) found that vaginal dryness and 
dyspareunia occurred in 61% and 55% of SS patients (n=36) versus 39% and 33% of healthy 
controls respectively, with significant difference between the two groups. Nevertheless, 
authors did not find a correlation between lacrimal or oral dryness with the sexual activity 
in SS patients. Likewise, Mulherin et al. (1997) suggested that dyspareunia was present in 
SS patients (n=11) several years prior to the appearance of oral or ocular symptoms. 
However, the classification criteria used to diagnose SS patients was not rigorous enough, 
and this can be referred to the fact that the AECG criteria was not yet released at that time. 
The results of the aforementioned studies were refuted by Valtysdottir et al. (2003) who 
argued that there was no correlation between sexual activity and decreased vaginal 
lubrication in SS patients (n=21). The authors found that the psychological factors had 
stronger influence on sexuality than physical determinants. Additionally, the study reported 
that the decrease in the serum DHEA-S, which is noticed to reduce in SS patients, associated 
with the decrease in mental well-being and that the latter affects the sexual activity. 
Hartkamp et al. (2008) contradicted the above findings, and reported that DHEA does not 
have a role in the course of SS female patients compared with placebo group. 
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Goodwin (1997) and Frikha et al. (2011) assumed that any disease associated with chronic 
fatigue syndrome, might have a negative influence on the marital relationships represented 
by sexual and shared events. The study was conducted with sample size of 131 partners, in 
which the females reported higher scores of fatigue compared to their spouses. Another 
study by (Blazquez et al., 2015b) on females with chronic fatigue syndromes including SS, 
reported more avoidance in the sexual activities, less satisfaction and less communications 
in the SS patients, and referred the reason to the fear of pain due to the decrease in 
lubrication. However, the study relied on subjective measures and no objective tests were 
carried out. Furthermore, although recruiting a large sample size of 615, the sample was 
not representative of the Spanish population, as the authors recruited patients from one 
hospital in one city in Spain. Additionally, assessment of medications and mental status was 
not taken into account. Moreover, they recruited women only, despite of their attempt to 
investigate SD in conditions that are seen in men. However, the study contributed in 
supporting number of the very few studies that correlated between SD in fatigued patients.  
There are only few studies looking at the SD in a well-defined pSS study group identified in 
accordance to the American-European diagnostic criteria. A case-control study by van 
Nimwegen et al. (2015) investigated the impact of pSS on the sexual function in relation to 
the mood status of female patients. Authors of the study reported that women with pSS 
had lower FSFI scores (Median FSFI=20.6) with worse mood status than controls (Median 
FSFI=30.3). Although the study has a limitation of selection bias for sexually active patients 
only, it represents a recent evidence in this field. Findings of another study by Priori et al. 
(2015), supported the latter in which pSS female patients showed impaired sexual function. 
The study demonstrated an inverse correlation between FSFI with age and HADS separately. 
The authors made efforts to examine the impact of the symptoms and activity of the disease 
subjectively and objectively on the sexual function, and found that SD was influenced by 
vaginal dryness and interfered with QoL. The latest study in this field was from Turkey by 
Isik et al. (2016), who investigated pSS women’s satisfaction with their sexual life. The 
authors found that pSS patients (n=46) had significantly impaired sexual function and low 
satisfaction of their sexual activity compared to age and sex-matched controls (n=47). The 
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authors referred the SD to the age, vaginal dryness and impaired physical and emotional 
function due to the disease. Despite the relatively small sample size, authors put efforts in 
matching the groups by excluding patients with severe systemic diseases or complications, 
and patients who were using antidepressants or diuretics, to eliminate the unfavourable 
impact on patients’ sexual life.  
Looking at the studies that assessed SD in other rheumatic diseases in an attempt to assess 
the problem in similar debilitating conditions, El Miedany et al. (2012) proved that SD is a 
common problem in patients suffering from RA. However, the main weakness in this study 
was the lack of controls for comparison. Ferreira Cde et al. (2013) looked at the same 
problem in a number of RA, where authors of the study attributed the reason for SD to the 
autoimmune effect of the syndrome and the medications used for its remedy. Nevertheless, 
no clinical evidence was provided to support these findings. In the same research field, 
Abdel-Nasser and Ali (2006) and Josefsson and Gard (2012), referred the reason of SD in RA 
patients, to the physical disability and fatigue. Another study on RA group by Shahar et al. 
(2012) concluded that the disease activity has a direct impact on the severity of SD, which 
supports the latter findings. 
In the same context, a relatively old study by Bhadauria et al. (1995) referred the reason for 
SD in patients with Systemic Sclerosis to the chronic inflammatory process of the disease. 
The study used comprehensive questionnaire, which was especially designed to assess the 
gynaecologic manifestations. This questionnaire was not validated, and there was no 
reference to its contents in the publication. Additionally, no control group was used for 
comparison. However, the performed clinical vaginal evaluation for part of the recruited 
subjects, added some importance to the study.  
In a case control study to assess SD in SLE female patients by Tseng et al. (2011), it was 
concluded that patients had similar rates of sexual activity with that of controls. However, 
although the response rate of participants was high (92% patients, 73% controls), authors 
used Chinese translation of FSFI, which has not been validated. The study found that 30% 
of SLE patients had SS and this did not alter or aggravate FSFI scores, compared with SLE 
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group without SS. Authors attributed these results to the activity of SLE that was not 
affected by secondary SS. However, it cannot be confirmed that secondary SS does not have 
an effect on sexual life. Therefore, in order to develop a proper conclusion concerning the 
impact of secondary SS on SD, a study that compares SD in patients with different 
autoimmune diseases complicated by SS would help. 
4. Neurological manifestations  
Peripheral neuropathy (PN) is one of the common symptoms of the syndrome, occurring in 
20% of pSS patients (Svein I. Mellgren et al., 1989 , Govoni et al., 1999, Ramos-Casals et al., 
2008, Pavlakis et al., 2011, Jamilloux et al., 2014). The neurological manifestations (NM) 
may present in a variety of forms such as trigeminal neuropathy, sensory neuropathy with 
ataxia and radiculoneuropathy (Mori et al., 2005). It is thought that the peripheral nervous 
system (PNS) is the most predominantly involved in pSS compared with the central nervous 
system (CNS) (Chai and Logigian, 2010, Gono et al., 2011), whereas Teixeira et al. (2013)  
believed that both PNS and CNS have similar frequency of involvement in the course of pSS. 
Although the exact cause for this aspect in SS is still not completely understood, there are 
studies have shown that neurological symptoms are associated to anti-Ro and anti-La 
antigens, and is not related to vitamin B12 deficiency (Scofield et al., 2012). This finding 
challenges the general belief that low vitamin B12 has an effect on the integrity of the 
nervous system. 
Another study by Agmon-Levin et al. (2012) concluded that vitamin-D low levels is 
correlated with PN in pSS patients. It has been reported that vitamin-D supplement has a 
noticeable role in the alleviation of neuropathic symptoms in diabetic patients (Valensi et 
al., 2005, Lee and Chen, 2008). It was anticipated to get similar outcome when this 
supplementation is given to pSS patients. However, a randomized control trial is needed to 
provide evidence for this. 
Different suggestions have been considered for the relief of NM. Rist et al. (2011) 
recommended the use of intravenous immunoglobulin therapy, to reduce the severity of 
the symptoms; although this treatment has the benefit of avoiding the prolonged use of 
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immunosuppressive agents, its high cost should be considered. Rituximab and 
corticosteroids have also been proved useful (Seve et al., 2007, Rist et al., 2011, Jamilloux 
et al., 2014). It was observed by Jamilloux et al., (2014) that the increase in corticosteroids 
administration in pSS patients, is associated with the severity of the NM symptoms. This 
study has also observed that the increase in B-cell proliferation correlates with the severity 
of NM. There are no studies to date of the association between NM and the acuity of smell 
and/or taste perception in pSS patients.  
2.8 GENERAL HEALTH PERCEPTION 
2.8.1 Fatigue and depression 
1. Definition of fatigue and depression 
Fatigue is one of the most common symptoms in SS and can interfere with QoL. It was 
described as a combination of the impairment of both somatic (voluntary) and mental 
efficacies, so that the deterioration of both components is a consequence of its 
manifestation (Meijer et al., 2009). Fatigue is one of the symptoms of depression that is 
defined by the loss of energy and is listed in the Diagnostic and Statistical Manual of Mental 
Disorders criteria (The manual was published by the American Psychiatric Association that 
covers all categories of mental health disorders). Therefore, fatigue and depression occur 
together in the majority of patients (Targum and Fava, 2011). 
 
Depression is the state of low mood that is used in many senses such as state of grief, 
demoralization, low self-esteem and pessimism (Snaith, 1987). This state has been shown 
to be most likely to respond to a tailored psychotherapy as well as pharmacotherapy (Jobst 
et al., 2016).  
 
2.8.2 Measurement of depression 
 Hospital anxiety and depression scale 
A number of questionnaires developed for the assessment of individuals’ mental health 
status. This included questionnaires tailored to assess depression only such as Beck 
Depression Inventory and Patient Health Questionnaire (PHQ-9) (Beck et al., 1961). Other 
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instruments have the bonus of assessing anxiety and depression as the two emotional 
components of an individual, such as the Hospital Anxiety and Depression Scale (HADS). This 
self-administered scale was designed in 1983 by Zigmond and Snaith to assess the level of 
anxiety and depression that patients might experience due to physical sickness (Zigmond, 
1983). This questionnaire comprised of 14 items, which are easy to read and answer. Half 
of the items refers to anxiety assessment (HADS-A) and the rest to depression assessment 
(HADS-D), so that the two dimensions of anxiety and depression are constructed. In this 
tool, there are four scoring levels for each question, which are ranged from zero to three 
depending on the severity of the condition. This means that each question has a total of 
four choices, so that subjects do not have a middle option to choose. A final score of 0-7 for 
each subscale represents non-cases, scores range of 8-10 indicate doubtful cases, whereas 
a score of 11 or more represent certain clinical anxiety and/or depression (Zigmond, 1983). 
Bjelland et al. (2002) believed that HADS has comprehensive screening properties for each 
of its domains. This was also supported by a French study, which confirmed HADS ability to 
detect symptoms of anxiety and depression in group of working people Bocerean and 
Dupret (2014). However, the sample size recruited in this study was not representative, as 
only workers in the major companies were considered in this survey; but the high response 
rate of 95% from a total of 20992 participants who fully completed HADS, is noteworthy.  
Differently, a meta-analysis by Norton et al. (2013), contradicted findings of the latter two 
studies, by showing that the scale does not serve as a good detector between symptoms of 
anxiety and depression. Data of the study were drawn from studies selected for inclusion in 
a systematic review by Cosco et al. (2012). Both studies argued that the scale provides only 
a general distress assessment. However, results by both studies are questionable, due to 
the language restriction considered and the low response rate (39%).  
Both anxiety and depression were sought to be investigated in the current project.  HADS, 
as a measure of depression showed validity, reliability, sensitivity, specificity simplicity, 
speed, ease of use that assesses both symptoms together in one questionnaire and good 
psychometric properties with different language versions (Fatt et al., 2007, Honarmand and 
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Feinstein, 2009, Annunziata et al., 2011, Reda, 2011, Wang et al., 2011, Muller et al., 2012, 
Roberge et al., 2013, Haugan and Drageset, 2014).  
HADS was used as a gold standard to validate other similar instruments in a number of 
studies. The most recent being the validation of the German version of Mother-Generated 
Index (MGI) where HADS was used as a validity indicator (Grylka-Baeschlin et al., 2015). 
Another study by Helvik et al. (2011) confirmed that HADS performs well discrimination 
between its two subscales with proper internal consistency of 0.78 and 0.71 for anxiety and 
depression respectively. This has also been supported in study by Watson et al. (2014), 
where a validation of three mood assessing tools [Beck Anxiety Inventory (BAI), Beck 
Depression Inventory-II (BDI-II) and HADS] was conducted on a group of multiple sclerosis 
(MS) patients. The study concluded that HADS demonstrated high sensitivity and specificity 
for both of its domains: Anxiety (90%, 77%) and Depression (92%, 81%) respectively, with 
an optimum cutoff score of 11. While for BDI-II and BAI a sensitivity of 85% and 80%, and a 
specificity of 76% and 46% were demonstrated for both scales respectively; at an optimum 
cutoff score of 23 (for BDI-II) and 10 (for BAI). These figures disclose the slightly better trend 
of HADS, in comparison with the rest of the scales in the same study.   
HADS was also used with patients suffer from autoimmune diseases such as rheumatoid 
arthritis (RA) (Chatzitheodorou et al., 2008, Aras et al., 2013) and pSS (Valtysdottir et al., 
2003, Bowman et al., 2004a, Stevenson et al., 2004, Inal et al., 2010, Gandia et al., 2014). 
Moreover, it was also used in studies that focused on assessing the mental health well-being 
in patients with oral problems, olfactory and sexual dysfunction (Ni Riordain et al., 2010, 
Irani et al., 2010, Silva et al., 2012, Watrowski and Rohde, 2014, Azevedo et al., 2014). The 
studies’ findings support HADS effectiveness in evaluating the mental health status in these 
study groups. More specifically, this scale was used in measuring the mood status of pSS 
female patients, in relation with the quality of sexual life (van Nimwegen et al., 2015, Priori 
et al., 2015). The latter two studies found that HADS had inverse correlation with the 
impaired sexual activity in pSS patients. This indicates that the scale was measuring what it 
was meant to measure.  
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2.8.3 Measurement of fatigue 
 Visual analogue scale  
This scale is a psychometric rating tool, arranged in a continuous linear manner to measure 
the intensity or the subjective outcome of a condition, which is frequently used in clinical 
and epidemiologic research. The scale is abbreviated to VAS that usually consists of a 
horizontal line of a fixed length of 100 mm, with ends oriented from the worst on the left 
to the best on the right. It has been used in a number of studies and under different topics, 
the most widely known is pain VAS (Huskisson, 1974, Price et al., 1983) and xerostomia VAS 
(Dry mouth VAS) (Pai et al., 2001), which were both validated successfully. Furthermore, 
VAS was effectively used to assess the level of fatigue in pSS patients (Harboe et al., 2009, 
Norheim et al., 2012), however, a limitation of having a unidimentional nature was pointed 
out. The authors recommend using a multidimensional scale instead, so that more 
information could be obtained. However, another three trials by Mariette et al. (2004), 
Mariette et al. (2015) and Salom et al. (2015) valued the scale in reflecting the success of 
the treatment targeted towards pSS patients. Similarly, there are very supporting findings 
for the strong correlation between VAS and other validated instruments, such as EULAR 
Disease Activity Index (ESDAI), ESSPRI, SF-36, the Multidimensional Assessment of Fatigue 
(MAF) (p<0.001) (Ibn Yacoub et al., 2012, Lendrem et al., 2014, Pertovaara and Korpela, 
2014).  
 
2.8.4 Review of the research showing fatigue and depression in patients with Sjӧgren’s 
Syndrome 
Patients suffering from almost all rheumatic disorders normally experience fatigue, hence, 
with the consequential depression a direct impact on quality of life was observed 
(Barendregt PJ1 et al., 1998, Segal et al., 2008, Ng and Bowman, 2010). Fatigue is also 
thought to be one of the most important reasons to seek medical treatment by SS sufferers 
(Barendregt, 1998).  It is an important and simple indicator for pSS activity, compared with 
other laboratory tests such as antinuclear antibody (ANA), extractable nuclear antigen panel 
(ENA) and erythrocyte sedimentation rate (ESR) (ibid).  
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A study by Meijer et al. (2009) showed that patients with secondary SS (n=50) had worse 
physical functioning and health related QoL (HRQoL), when compared with pSS (n=185) 
sufferers. This finding is questionable, as the sample size recruited for secondary SS was not 
comparable to that of pSS patients. Given that, the associated rheumatic disease with 
secondary SS patients was most frequently RA and/or SLE, and that each disease has its own 
impact on the associated SS. These complications might exert different effect and burden 
on the physical activity of the patient that cannot be generalized for secondary SS sufferers. 
Consequently, this finding contrasts with Sutcliffe et al. (1998) who found no difference 
between groups of pSS and secondary SS associated with SLE in terms of functional status.  
Another study proposed a significant positive correlation between fatigue and depression 
in a comparison between pSS and RA female patients (Barendregt PJ1 et al., 1998). The 
study reported no significant difference between the two groups in terms of depression, 
but only for the dimensions of general and mental fatigue. It was asserted that pSS subjects 
recorded higher scores on those dimensions than RA patients, indicating a worse status, but 
no meaningful differences. Indicating that when depression was adjusted in this study, no 
significant difference was found between the two study groups.  
It is easy to understand that chronic fatigue has a direct impact on the patients’ 
psychological status and hence their QoL (Ng and Bowman, 2010). However, in a cohort 
study conducted in the USA, Segal et al. (2008) proposed a higher percentage of fatigue 
experienced in 67% of pSS patients, while depression was found in only 32% of subjects 
suffering from fatigue. In the same context, another study argued that depression and 
fatigue are in the forefront among other symptoms of pSS that force women to visit 
physicians more frequently than controls, and to retire early as well (Westhoff et al., 2012). 
While in a case-control study, it was reported that women with pSS recorded a low to mild, 
but significant decrease in their physical capacity compared to the healthy controls, who 
were age and sex matched (Strombeck et al., 2003). However, Bowman et al. (2004a) had 
comparable results with that of Strombeck et al., although the study did not assume an 
association between fatigue and depression in pSS patients. 
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In reviewing the literature, it became apparent that the correlation between fatigue and 
depression has been studied extensively.  
2.9 QUALITY OF LIFE 
Despite of being dated back since 1964, when the expression ’’quality of life’’ was firstly 
used by President Lyndon B. Johnson in his speech in the Square Garden in New York 
(Johnson, 1964). It remains difficult to explain what “Quality of Life” exactly means. The 
term is commonly used to describe the health status (physically, psychosocially, well-being, 
life satisfaction and happiness) based on the importance of these elements to the individual 
him/herself (Barofsky, 2012). Later on, the WHO has defined the term as individuals’ 
perceptions of positions in their life, in terms of the culture and value systems in which they 
live and in relation to their goals, expectations, standards and concerns. 
Therefore, it can be inferred that the term is used to describe individual’s perspective of life 
subjectively. It is an outcome that is known as debilitating but not life threatening for 
patients (Iacopino, 2010). As if there is a group of people diagnosed with different diseases, 
treated with variety of medications and came from miscellaneous cultural backgrounds, 
their definition to QoL might be different, depends on their ability to cope with the 
problems they encountered. Thus, the term “Quality of Life” is considered as ‘’multi-
criteria’’ as well as ‘’type-dependent’’ expression (McCall, 1975).  
2.9.1 Measurement of quality of life 
In the new global health concept, measuring QoL became important for some systemic 
disease experiences. In this context, there has been increasing number of studies that 
assess the QoL of patients with different diseases, including SS. A number of authors 
measured QoL in variety of ways in accordance with the research requirements. Hence, 
different instruments were developed and used for this purpose, such as the Short Form 
(SF-36) of the Medical Outcome and the brief form of the World Health Organization Quality 
of Life (WHOQOL-BRÉF) (Barendregt PJ1 et al., 1998, Bowman et al., 2004a, Champey et al., 
2006, Bowman et al., 2007, Goodchild et al., 2008). The following review sheds light on the 
questionnaire that has been chosen to achieve the current projects’ targets.                                                                                                         
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2.9.2 Review of the research showing quality of life in patients with Sjӧgren’s Syndrome 
measured by WHOQOL-BRÉF  
The questionnaire is self-administered to measure the level of general QoL in the previous 
two weeks. It is a comprehensive instrument that measures four facets of life domains 
(physical health, psychological, social relationship and environment) by a total of 26 items, 
where higher scores indicate better QoL (Bowman et al., 2004a, WHO, 1998). The scale was 
originally designed as a 100-item measure by the World Health Organization (The World 
Health Organisation, 1995), which later was shortened to be WHOQOL-BRÉF (Skevington et 
al., 2013). The former is ideal to be used in clinical trials or larger studies, as it allows global 
and detailed assessment of the QoL for individuals, but in some instances, it was thought 
impractical to be answered by participants. For this reason, the shortened form of 
WHOQOL-BRÉF was developed to provide full-scale, yet, brief assessing instrument for the 
QoL. The WHOQOL instruments in general, are very useful in epidemiological studies, which 
allow assessment of the nature of the disease. The instruments can also provide evaluation 
of the impact of the health problem subjectively, to help assess how this problem impairs 
different aspects of the person’s life (WHO). 
The psychometric properties of the WHOQOL-BRÉF was assessed by Skevington et al. 
(2013), who found that the instrument performs well with good validity and reliability. The 
authors believe that the instrument’s performance, being cross-culturally sensitive and a 
multilingual scale put the instrument at the forefront of the tools that measure QoL. 
Another study by Taylor et al. (2004) examine the psychometric properties of this scale on 
a randomly selected group with rheumatoid arthritis (RA), in comparison with healthy 
controls. It was found that the instrument has adequate psychometric properties and 
internal consistency (α>0.80) in each domain, except the social, where poor internal 
consistency was recorded. The test-retest reliability was adequate, which indicates 
acceptable stability (interclass correlation coefficient >0.70). However, the relatively low 
response rate (59%) was observed as a weakness in the study. As individuals who failed to 
return the questionnaires, might have worse QoL than respondents. 
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In a study by Castro et al. (2014), where a comparison between two instruments was 
conducted, it was found that WHOQOL-BRÉF was more suitable than the Short Form, 36 
(SF-36), in assessing QoL in a group of Brazilian old women. This was reported after 
comparing the validity and reliability of the two instruments in this study group. Although 
both tools were reliable and valid in assessing QoL for research and clinical uses, WHOQOL-
BRÉF possesses special properties in evaluating QoL changes of the group studied. 
Researchers observed that WHOQoL-BRÉF prioritises assessment of ageing process and 
peoples’ perspectives on QoL from their points of view; in addition, it does not focus on the 
physical impairments as the SF-36 does.  
The instrument was used in assessing and comparing QoL in a number of autoimmune 
diseases including SS by Bowman et al. (2004a), Goulia et al. (2010) and Hyphantis et al. 
(2011). The results of these studies were in line with the previous findings in which patients 
with RA, pSS and SLE had reduced QoL when compared with healthy controls (Sutcliffe et 
al., 1998, Strombeck et al., 2003, Tensing et al., 2001, Rostron et al., 2002, Bowman et al., 
2004a, Belenguer et al., 2005, Stewart et al., 2008, Baturone et al., 2009, Segal et al., 2009). 
However, the cross-sectional design used in the three aforementioned studies has the 
disadvantage of providing a snapshot of a selected population at a certain time, regardless 
of the individuals’ status assessment before and after the time of data collection. Hence, 
this design provides information of association only, rather than a hypothesis testing 
(Hennekens C and Buring J, 1987). Therefore, a longitudinal study and surveillance of the 
QoL, could provide a comprehensive evaluation of the patients’ life quality. 
The questionnaire was also used with a well-defined group of pSS patients, alongside other 
instruments to examine the relation between QoL and the mental health status (Inal et al., 
2010). The results of this study presented comprehensive assessment of QoL by using two 
measures: WHOQOL-BRÉF and SF-36; which supports findings by Bowman et al. (2004b). 
The SF-36 measures HRQoL from the medical point of view, while the WHOQOL-BRÉF 
assesses the QoL from individuals’ perception which helps in epidemiological surveys. 
Several limitations were identified in this study, including that the exact component that 
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contributes to the impairment of HRQoL in pSS patients was beyond the scope of the study. 
Moreover, the deficit of the impact of therapeutic agents on QoL in these patients was not 
considered. Additionally, the study assessed the degree of mood disorders on cases only, 
which does not help in providing a reliable conclusion.  
2.10 ORAL HEALTH RELATED QUALITY OF LIFE 
2.10.1 Definition of oral health related quality of life 
The oral health related QoL (OHRQoL) is a multidimensional construct that represents 
subjective evaluation of individual’s oral health perception. This perception reflects self-
comfort when eating, sleeping, and pursuing social interaction. It also shows individual’s 
self-esteem and satisfaction with respect to personal oral health (Rockville, 2000, Sischo 
and Broder, 2011). 
2.10.2 Measurement of OHRQoL 
A number of questionnaires are available to assess the oral health status including the 
General Oral Health Assessment Index (GOHAI) (Atchison and Dolan, 1990), and Oral Health 
Literacy Assessment (OHLA) for adults (Naghibi Sistani et al., 2014). However, the most 
popular, widely used questionnaire for the assessment of oral health quality is Oral Health 
Impact Profile-14 (OHIP-14).  
2.10.3 Review of the research showing OHRQoL in patients with Sjӧgren’s Syndrome 
The OHIP-14 is a self-reporting instrument that measures the oral health outcomes from 
patient’s perception that may affect their well-being. It also provides a theoretic framework 
of the social impact of oral disorders (Slade, 1997). Originally, it was developed as a 49-item 
questionnaire (full OHIP) after a number of approaches to measure the impact of the oral 
health problems on patients’ perception. It was adapted from the WHO classification of 
impairments by Locker in 1988 (Gilson et al., 1975, Slade, 1997, Locker, 1988). The full OHIP 
comprised of seven dimensions, these are physical pain, functional limitation, physical 
disability, psychological discomfort, psychological disability, social disability and handicap. 
Later on, a shortened version of OHIP-14 was developed with respect to a subset of two 
questions for each one of the seven dimensions of the full OHIP (Slade, 1997a). The 
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shortened form has a good validity, reliability and precision compared to the full OHIP when 
both were used in a cross-sectional study in South Australia (Slade, 1997a). This was also 
supported by Fernandes et al. (2006), Baker et al. (2006), Stenman et al. (2012), Khalifa et 
al. (2013) and Nikbin et al. (2014), who all approved its good validity, reliability, appropriate 
internal consistency and discriminant validity.  
The shortened version was used in a number of studies, in which the impact of dryness and 
salivary hypofunction on OHRQoL was tested subjectively. Additionally, it was also shown 
that the index was sensitive in measuring the level of OHRQoL in xerostomic patients (Ikebe 
et al., 2007, Busato et al., 2009, Cho et al., 2012, Nikbin et al., 2014, Benn et al., 2015). 
More specifically, the questionnaire was used in assessing OHRQoL of pSS patients (Enger 
et al., 2011, Mumcu et al., 2013). Enger and colleagues confirmed that the instrument has 
a high internal reliability (0.94) in assessing the OHRQoL for all its items. The scale was 
validated in a general dental practice in the UK by Fernandes et al. (2006), whom found that 
the scale had a good level of validity and reliability. It was also validated in several languages 
and was shown that the scale has acceptable reliability and validity (Navabi et al., 2010, 
Roumani et al., 2010, Stenman et al., 2012, Papagiannopoulou et al., 2012, Leon et al., 
2014). Being used with pSS patients, in a UK cohort, has encouraged applying the scale in 
the current project. 
It could be debated that the General (formerly Geriatric) Oral Health Assessment Index 
(GOHAI) is a better instrument for assessing OHRQoL for the current project, as it has good 
psychometric properties, better response rate and ability to differentiate between the less 
damaged parts compared with OHIP-14 (Hassel et al., 2008). Nonetheless, a study 
conducted by Locker D (2001), which compared between both instruments, reported that 
none of the scales was superior to the other in assessing OHRQoL. The study has also found 
that they were equal at predicting life satisfaction and psychological well-being in this study 
group. Moreover, Cronbach’s alpha was found to be higher in OHIP-14 than GOHAI, which 
means better internal consistency and reliability. In the same context, Rodakowska et al. 
(2014) found that both instruments were correlated strongly with each other when applied 
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on a group of old Polishes aged 55 and over, who were recruited by means of convenience 
sampling. Although the sampling process was set at 90% type two error, it does not 
represent rigorous findings as the convenience sampling method was based on collecting 
data from people who were easily reached, hence, this had the benefit of serving the views 
of specific group and not the entire population. Provided that the use of the first translated 
version of the Polish OHIP-14 that had not been validated might have biased the results. 
Nevertheless, a study by Nikbin et al. (2014) on a group of Iranian diabetic patients, had 
settled the matter, by asserting that OHIP-14 was better than GOHAI in diagnosing oral 
disorders.  
OHIP-14 has been, as yet, used in a number of papers since the time of its development, 
with variety of study groups under different disorders, and with different languages, which 
supports its validity and reliability.  
In conclusion, the literature review revealed that there is insufficient information on the 
effect of dryness on smell, taste and sexual function and whether the impairment of these 
senses has an effect on QoL of patients.   
 
2.11 Hypothesis development 
From the above review, it was concluded that: 
 PSS is prevalent worldwide and a remarkable increase in its incidence has been observed 
recently.  
 SS Patients are affected by fatigue, joint pain and neuropathy, however, the most 
common, and overwhelming symptom is the dryness of the mucosal linings.  
 The literature is scanty in studies that relate the severity of mucosal dryness with the 
function of the related organs, in particular, smell, taste and sexuality and whether an 
existing dysfunction can compromise patients’ life quality.  
 The literature is conflicted on whether the smell and taste functions are correlated with 
each other.  
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 There is lack in studies that investigate the aetiology of the taste function in pSS patients 
and whether it is related to the mucosal dryness or to neurosensory impairments.  
In conclusion, the literature review revealed that there is insufficient information on the 
effect of dryness on smell, taste and sexual function and whether the impairment of these 
senses has an effect on QoL of patients. A systematic review was conducted to test the 
hypothesis that the mucosal dryness has an impact on the functions of the smell, taste and 
sexuality in pSS patients, as described in more details in the following chapter.  
The aims of this project were as follows: 
1. To assess the functions of the smell, taste and sexuality in women with pSS,  
2. The consequences of the impairment of these functions may have on the QoL and 
mental health well-being. 
3. To investigate whether the severity of the mucosal dryness in pSS patients, is 
associated with the deterioration of the functions of the smell, taste and sexuality. 
 
 83 
 
 
 
CHAPTER 3: SYSTEMATIC REVIEW AND 
META-ANALYSIS 
 
Systemic Review and Meta-Analysis 
84 
 
We reviewed the literature systematically for evidence on whether mucosal dryness affects 
the function of smell, taste, sexuality or quality of life in primary Sjӧgren’s women. The 
methodology for the systematic review was registered with PROSPERO in 2015 (Al-Ezzi M. 
et al., 2015) and the date submitted to the Journal of Modern Rheumatology was on 07th 
Aug 2016 revised on 29th Sep 2016 and accepted on 13th Oct 2016 (Al-Ezzi et al., 2016) 
(Appendix 26).  
3.1 Introduction 
Primary Sjögren’s Syndrome (pSS) is a systemic autoimmune rheumatic disorder of 
unknown origin, affecting women nine times more commonly than men (Fox, 2005). 
Inflammation of exocrine glands occurs as a result of excessive infiltration of autoantibodies 
leading to functional destruction. The burden of pSS is substantial and is compounded by 
the lack of effective treatment. Dryness of mucosal surfaces is the main characteristic 
feature of this syndrome, typically dry eyes and mouth. Yet, other mucosal surfaces can also 
be involved such as nasal and vaginal mucosa and can affect associated function and 
interfere with quality of life (Rasmussen et al., 1986, Jacobsson et al., 1992, Marchesoni et 
al., 1995).  
Smell and taste alteration are frequently reported symptoms by pSS patients. Studies have 
found that smell and taste are impaired and correlated with each other in pSS patients, and 
influenced by mucosal surfaces dryness (Henkin et al., 1972, Porter, 2010). One study 
showed that taste disorders in Sjӧgren’s patients are less frequently found than previously 
reported, and is linked to the reduction in salivary flow rate, in a way that impedes 
substances from reaching the taste buds (Negoro et al., 2004). Others, however, reported 
little association between taste deficit and mucosa dryness in Sjӧgren’s patients [8, 9]. 
Women with pSS often suffer from vaginal dryness and dyspareunia with the possible 
explanation for these symptoms being local inflammation of the vaginal mucosa (Skopouli 
et al., 1994, Marchesoni et al., 1995, Mulherin et al., 1997, Cirpan et al., 2007). An evidence 
was presented of the association between oral symptoms and vaginal dryness in Sjӧgren’s 
patients (Mulherin et al., 1997). Other studies suggested that dryness and dyspareunia 
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could adversely impact the sexual well-being of women with pSS (van Nimwegen et al., 
2015, Priori et al., 2015). Sexual wellbeing is an important aspect of quality of life and 
addressing this is an essential component of delivering holistic patient-centred care.  In this 
study, we aimed to determine the impact of mucosal dryness on smell, taste, sexual 
function and quality of life in women with pSS.  
3.2 Methods 
A prospective protocol was registered (PROSPERO number CRD42015024354) (Al-Ezzi M. et 
al., 2015). This review was performed using recommended methods and reported in 
accordance with the preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) statement. 
3.3 Search strategy and eligibility criteria 
Several electronic sources for published studies from inception to June 2015 were searched. 
The databases included Ovid-Medline, Web of Science, Scopus, Embase and Cochrane 
Library. MeSH and Boolean logic of the following search terms were used: Sjogren 
Syndrome, Sjogren Disease, hyposmia, anosmia, smell, smell*, olfact*, odour, nasal, nasal*, 
taste, taste*, gust, gust*, tastant, falvour, flavour, gustation, ageusia, hypogeusia, sex, sex*, 
obstet*, gyne*, gynae*, vagina, vagina*, dyspareunia. Recent issues of relevant publications 
and the reference lists of included texts and relevant review articles were searched. Experts 
were contacted for additional studies and data to clarify ambiguity. No search software has 
been used, EndNote was employed to merge retrieved citations and eliminate duplications. 
We placed no restriction on language or study population. 
Studies were selected for analysis if they satisfied the following criteria: i) Studies of pSS 
female patients vs. healthy controls; ii) Smell, taste and sexual dysfunction were a primary 
or secondary outcome; iii) Quality of life and mental health well-being were a secondary 
outcome iiii) Studies that used the American European Consensus Group (AECG) criteria to 
diagnose for pSS patients. Studies were eliminated if pSS diagnosis was based on clinical 
experience or other diagnostic criteria. Unpublished studies of the association has not been 
found. A flow chart of the study selection was generated.  
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3.4 Data extraction and quality assessment 
All titles and abstracts for relevant studies were screened, and a final selection for full text 
papers was conducted. Reasons for exclusion were documented (Appendix 20). Full texts of 
eligible studies were independently read and data were extracted by two reviewers (MA) 
and (NP). The two authors discussed the outcome, any disagreements were resolved by 
consensus. The following data was extracted: study characteristics (authors, year of 
publication, title, country of the study, study design); population characteristics (patients’ 
inclusion and exclusion criteria, sample size, mean age, disease duration, response rate and 
drop out); intervention (type of intervention, mean score of questionnaires and/or clinical 
tests used, purpose of testing, outcome and summary of study). We modified the validated 
Newcastle-Ottawa Scale (NOS) instrument for quality assessment of the final selected 
studies. This modification was applied by including relevant items from NOS case-control, 
NOS cohort and the modified NOS of cross-sectional design by Herzog et al. (2013) to meet 
the study’s criteria (Appendix 21). Quality assessment was independently performed by MA 
and NP; any discrepancies were discussed and a third independent reviewer (KK) was 
involved if it could not be resolved. A star system was applied to evaluate studies’ quality in 
terms of three criteria: Participant’ selection, comparability, exposure and outcome 
assessment.  
3.5 Meta-analysis 
Standardised mean differences (SMD) and a confidence interval (CI) of 95% were calculated 
for continuous data. A random–effect model was applied to reduce heterogeneity in 
combining studies’ data in order to get an overall SMD. Heterogeneity was evaluated via 
Tau2, Chi2, df and I2 at a p-value of ≤ 0.05. Overall effect was assessed using Z score with 
significance set at p<0.05. Funnel plot for the detection of publication bias and subgroup 
analysis to investigate heterogeneity will be applied when the number of trials is at least 
ten (Higgins JPT, 2011). We contacted the authors by email to obtain additional data for the 
meta-analysis. The correlation of smell, taste, sexual function, quality of life and mental 
health well-being with pSS was evaluated using Review Manager meta-analysis software 
(version 5.3; Cochrane Collaboration, Copenhagen, Denmark). 
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3.6 Results 
3.6.1 Study selection 
Final searches were undertaken in April 2016 and a total of 2767 articles were initially 
identified using the search strategy in five search engines. An overall agreement between 
reviewers achieved 99%. After reviewing titles and/ or abstracts, it was noticed that there 
is no article studied the effect of dryness on the three elements together (smell, taste and 
sexuality) in Sjӧgren’s patients. Therefore, our search strategy has been focused on studying 
the effect of pSS on each element separately and on the general quality of life and mental 
health well-being. Fifty three studies were deemed relevant and selected for full text 
assessment. Of which, five articles fulfilled the criteria and were selected for qualitative and 
quantitative (meta-analysis) assessment. A flowchart based on PRISMA statement, shows 
the process of articles selection in  
 
Figure 3-1. Studies selection process 
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3.6.2 Study characteristics 
The characteristics of the five included studies for the current review are presented in table 
3-1. Evidence of quality assessment of these studies ranged between moderate to high 
(Table 3-2; Figure 3-2). One study assessed the impact of pSS on smell and taste, with a total 
of 65 participants (Kamel et al., 2009), and three studies evaluated the impact of pSS on 
sexuality, with a total of 201 participants (Ugurlu et al., 2014, Priori et al., 2015, van 
Nimwegen et al., 2015). Three studies (Bongi et al., 2013, van Nimwegen et al., 2015, Priori 
et al., 2015) evaluated the impact of sexual dysfunction on mental health well-being by 
using the Hospital Anxiety and Depression Scale (HADS), and one study (Ugurlu et al., 2014) 
assessed the impact of sexual dysfunction on mental health well-being by using Beck’s 
Depression Inventory (BDI), with a total of 249 and 313 participants to meta-analyse anxiety 
and depression respectively. Four studies (Kamel et al., 2009, Bongi et al., 2013, van 
Nimwegen et al., 2015, Priori et al., 2015) measured the effect of pSS on QoL by using the 
Short Form-36 (SF-36), Short Form-12 (SF-12) and RAND 36-item Health Survey assessment 
tool, with a total of 314 participants. Bongi et al. (2013) assessed the sexual function by 
different instrument modified from Hill questionnaire with no data displayed, therefore, 
this study has not been included in the meta-analysis.   
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Figure 3-2 Quality assessment of the included studies measured by Modified Newcastle Ottawa 
Scale (M-NOS)  
3.6.3 Smell and taste function 
One study (Kamel et al., 2009), of moderate quality involving a total of 28 pSS patients and 
37 healthy participants, compared the chemosensory function of smell and taste, and its 
impact on quality of life in pSS patients versus controls. The two senses had significantly 
deteriorated in pSS patients compared to age and gender matched controls, with about 50% 
of subjects suffering from hyposmia (p=0.002) and 70% suffering from hypogeusia 
(p<0.001). However, salivary flow rate measurement was not employed equally for all 
participants, therefore, information about the relation between the impaired 
chemosensory perception and the degree of salivary glands dysfunction, was not reported. 
In terms of the correlation between both senses, authors of the study found that smell 
function was positively correlated with that of taste (r=0.35, p=0.004). The study also 
proved that age was adversely associated with smell thresholds (r=-0.252; p=0.04), whilst 
no impact was found on taste dysfunction (r=-0.15, p=0.236). Results of this study may not 
be applied to the female population of Sjӧgren’s patients, as there was 11% males recruited 
in the pSS group. This study was the only one that met our inclusion criteria in terms of the 
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Systemic Review and Meta-Analysis 
92 
 
assessment of smell and taste in Sjӧgren’s patients; therefore, there will be no meta-
analysis for these elements in this review.        
3.6.4 Sexual function  
Sexual function has been measured by FSFI in three included studies (Ugurlu et al., 2014, 
van Nimwegen et al., 2015, Priori et al., 2015), and was compared between pSS patients 
(102 patients) and healthy controls (99 participants). Random-effect model was used in all 
domains, and the pooled results displayed significant difference between pSS patients and 
healthy controls. The SMD of the FSFI scores of pSS patients were lower than that of controls 
on each domain of sexual function: Desire (P<0.00001, SMD=-0.72, 95% CI=-1.00 - -0.43), 
Arousal (P<0.00001, SMD=-0.93, 95% CI=-1.22 - -0.64), lubrication (P<0.00001, SMD=-1.07, 
95% CI -1.37 - -0.77), Orgasm (P= 0.001, SMD=-0.60, 95% CI -0.96 to -0.23), Satisfaction (P < 
0.0001, SMD=-0.60, 95% CI=-0.91 to -0.30), Pain (P<0.0001, SMD=-0.92, 95% CI=-1.34 - -
0.51), total FSFI (P<0.00001, SMD=-0.93, 95% CI=-1.22 - -0.64).  
3.6.5 Quality of Life  
The quality of life of pSS patients has been assessed by SF-36, SF-12 and RAND-36 in four 
eligible studies (Kamel et al., 2009, Bongi et al., 2013, van Nimwegen et al., 2015, Priori et 
al., 2015) and was compared between pSS patients (160 patients) and healthy controls (154 
participants). A random-effect model was used in the meta-analysis of the Physical (PCS) 
and Mental Component Summary (MCS) due to statistical heterogeneity between studies 
(P=0.08, I2=55%; P=0.02, I2=70% respectively). 
The pooled results of combining domains’ scores, demonstrate lower quality of life in pSS 
group compared to healthy controls on PCS and MCS (P<0.00001, SMD=-1.28, 95% CI=-1.65 
to -0.90; P=0.0002, SMD=-0.83, 95% CI=-1.27 to -0.40 respectively). 
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3.6.6 Mental health well-being 
Mental health well-being has been measured by HADS in four included studies (Bongi et al., 
2013, Ugurlu et al., 2014, van Nimwegen et al., 2015, Priori et al., 2015) and was compared 
between 132 pSS patients vs. 117 healthy controls in Anxiety (HADS-A), and 164 pSS 
patients vs. 149 healthy controls in Depression (HADS-D) respectively. Random-effect 
model was used in the meta-analysis due to statistical heterogeneity among studies 
(P=0.004, I2=82%; P=0.07, I2=57% respectively).  
The pooled results of HADS-A and HADS-D showed that the SMD was significantly higher in 
pSS patients than in controls (P=0.04, SMD=0.61, 95% CI=0.02 to1.20; P<0.0001, SMD=0.79, 
95% CI=0.43 to 1.15 respectively) (Table 3-3). 
   Table 3-3 Summary of the meta-analysis of included studies 
    NA: not applicable. 
    See appendix 4. 
 
3.6.7 Publication bias and subgroup analysis  
As the number of the included studies in each subgroup is less than ten, funnel plot and 
subgroup analysis were not possible to conduct. 
  
Outcome 
Number of 
studies 
SMD 95% CI I2 
Smell impairment 1 -0.78 -1.29, -0.27 NA 
Taste impairment 1 -1.01 -1.54, -0.49 NA 
Total sexual dysfunction 3 -0.93 -1.22, -0.64 0% 
Physical component summary/ QoL 4 -1.28 -1.65, -0.90 55% 
Mental component summary/ QoL 4 -0.83 -1.27, -0.40 70% 
Anxiety 3 0.61 0.02, 1.20 80% 
Depression 4 0.79 0.43, 1.15 57% 
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3.7 Discussion 
The primary purpose of this review is to systematically assess the effect of the mucosal 
dryness, which is known to be part of pSS, on the senses that share this aspect, and whether 
a dysfunction exists, will be affecting the quality of life of patients.  During our search, there 
was no one study in the literature assessed the impact of pSS on the smell, taste and 
sexuality. Therefore, splitting the study’s aim into three separate goals was considered.   
Of the studies that met our inclusion criteria, Kamel et al. (2009) was the only study that 
measured the effect of pSS on the smell and taste and quality of life in pSS patients. The 
remaining eligible studies (Bongi et al., 2013, Ugurlu et al., 2014, van Nimwegen et al., 2015, 
Priori et al., 2015) assessed the impact of sexual dysfunction on quality of life of pSS 
patients. 
The strength of the current review lies in its methodology that was conducted in accordance 
to PRISMA guidelines, to ensure high quality of studies selection and data extraction. 
Comprehensive literature search including all relevant electronic databases with no 
restriction on language, as well as manual search through references and journals were 
approached. Two reviewers worked independently with an overall agreement rate of 99%. 
Relying on a well-established diagnostic criteria of AECG in classifying pSS patients has 
enriched our inclusion criteria (Vitali et al., 2002). These criteria are valid, reliable and 
present a well-defined group of pSS by discriminating between primary and secondary SS. 
We had to follow restrictive inclusion criteria to reduce heterogeneity among studies that 
used different and unreliable diagnostic criteria to classify pSS patients. 
Our meta-analysis included five studies with a total number of 378 of participants (192 cases 
and 186 controls). The quality of included studies ranged between moderate (Bongi et al., 
2013, Ugurlu et al., 2014) to high (Kamel et al., 2009, van Nimwegen et al., 2015, Priori et 
al., 2015). We were unable to perform funnel plot or subgroup analysis owing to the limited 
number of studies available in each subgroup.  
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 In terms of sexual function, three studies with a total of 201 participants (102 cases and 99 
controls) were included. Not significant heterogeneity was identified on pain domain, whilst 
zero heterogeneity was observed on desire, arousal, lubrication, satisfaction and on the 
total FSFI. There was only one domain (orgasm) with significant heterogeneity between 
studies. Therefore, a random-effect model was applied. In the meta-analysis, a certain 
sexual dysfunction was found in pSS patients compared to healthy controls. However, 
sexual problems tend to be associated with more than one element with this syndrome 
including age, joint pain, fatigue as well as vaginal dryness. 
In the quality of life meta-analysis, heterogeneity was observed in the four included studies 
and random-effect model was applied. The summarised scores of PCS and MCS 
demonstrated lower scores of physical and mental components among individuals with pSS 
than in controls, which denotes to the adverse impact of the syndrome on patients’ quality 
of life as a result of the sexual dysfunction. Yet, in this meta-analysis, the quality of life has 
also been negatively impacted by the deficit of chemosensation that was assessed by Kamel 
et al, 2009. Therefore, we concluded that pSS has more than one aspect that impacts on 
quality of life. However, future studies are needed to determine which aspect is the most 
influencing patients’ well-being.   
Screening of the mental disorders, negative impact of pSS on mental health well-being was 
observed in the patients group compared to controls. Random-effect model was applied 
due to statistical heterogeneity. Three studies were included in the meta-analysis of anxiety 
where higher levels were shown in pSS group compared to controls. Four studies were 
included in the meta-analysis of depression, and was also found to be worse in patients 
compared to controls. Data were pooled at the suggested cut-off point of ≥8 (Snaith RP, 
1994, Brennan et al., 2010) therefore, we concluded that pSS has significantly increased 
anxiety and depression levels in pSS patients compared to controls.  
3.8 Limitations of this study 
The limited number of studies available for the meta-analysis made it difficult to explore 
the potential cause of heterogeneity. However, two probable predictors for heterogeneity 
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is the different age range across studies and the sample size, that is, larger studies 
demonstrate greater accuracy than smaller studies. Additional factors: the different quality 
of the included studies and selection bias in recruiting participants can also explain the 
resulted heterogeneity. Furthermore, it was not possible to adjust for potential 
confounders as we do not have access to studies data at individual level. 
To the best of our knowledge, the present systematic review and meta-analysis is the first 
analysing the impact of pSS on the sexual function in SS patients. We concluded that pSS is 
adversely impacting patients’ sexual life mood status. Future work is needed to look at 
whether psycho-sexual counselling can help women with pSS. Health professionals 
managing cases of pSS should consider enquiring about sexual complaints, since patients 
will not bring up the problem themselves. Research is needed concerning development of 
vaginal dryness treatment for pSS patients.  
3.9 Conclusion 
With this systematic review and meta-analysis we present evidence of the multidimensional 
impact of pSS on patients’ well-being. Further work is required to look at the effect of the 
syndrome on the senses of smell and taste and hence on QoL.   
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4.1 Introduction 
This study followed a matched case-control design, to investigate the impact of pSS on the 
senses of smell and taste, and sexual activity in female patients in the UK. The study was 
sponsored by Queen Mary University of London (QMUL), and was funded by the Ministry 
of Higher Education & Scientific Research in Iraq, as part of the Chief Investigator’s PhD 
fulfilment.  
4.2 Aims of the project 
The aim of this study was to assess the impact of pSS on the smell, taste and sexual functions 
of female patients (primary hypothesis), and on various QoL aspects (General QoL, oral 
health related QoL and mental health well-being) (secondary hypothesis). The models used 
were to obtain data to achieve the primary objectives, which were for hypothesis testing, 
and the secondary objectives, which were for exploratory testing. 
4.3 Objectives 
4.3.1 Primary objectives (Hypothesis testing) 
1. To compare the smell function in pSS group vs healthy volunteers group. 
2. To compare the gustatory function in pSS group vs healthy volunteers group. 
3. To compare the neurosensory threshold of taste in pSS group vs healthy 
volunteers group. 
4. To compare the sexual function in pSS group vs healthy volunteers group. 
5. To compare the general QoL in pSS group vs healthy volunteers group. 
6. To compare the oral health related quality of life in pSS group vs healthy 
volunteers group. 
7. To compare the mental health well-being in pSS group vs healthy volunteers 
group. 
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4.3.2 Secondary objectives (Exploratory testing). 
8. To evaluate the impact of smell, gustatory and sexual functions on QoL and mental 
health well-being in pSS patients.  
9. To investigate whether the acuity of the smell and gustatory function are 
correlated with each other. 
10. To study the correlation of the degree of the smell function to the severity of oral 
dryness in pSS group. 
11. To study the correlation of the degree of the taste function to the severity of oral 
dryness in pSS group. 
12. To investigate the correlation of gustatory function to the neurosensory threshold 
of taste in pSS group. 
13. To investigate whether oral dryness is correlated with the self-reported vaginal 
dryness in pSS group. 
14. To investigate the impact of the self-reported vaginal dryness on the sexual 
function in pSS patients. 
 
4.4 Ethical approval 
An application to the Integrated Research Approval System (IRAS) was submitted on 11th 
November 2015 (IRAS project ID: 186276). A meeting with The Research Ethics Committee 
(REC) of London Bridge was scheduled on the 16th December 2015, where a number of 
minor amendments were requested. After implementing the Committee’s suggestions, an 
ethical approval was obtained on the 10th of February 2016 (Reference number 
15/LO/2064).     
4.5 Participants 
4.5.1 Eligibility criteria 
 Patients  
1. Female patients aged 18 years or older, males were excluded because pSS is a 
predominantly female syndrome. 
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2. Patients with a confirmed diagnosis of primary SS for a minimum of three months, 
in accordance to the revised American-European diagnostic criteria (Vitali et al., 
2002). 
3. Patients with the capacity to provide informed consent as defined by the Mental 
Capacity Act 2005 (The National Archives, 2017). 
4. Patients who are able to understand verbal explanations and written information 
in   English, with the support of the researcher, if needed. 
 Healthy volunteers 
1. Sex matched individuals aged 18 years or older, males were excluded as pSS is a 
predominant female syndrome. 
2. Individuals with the capacity to provide informed consent as defined by the 
Mental Capacity Act 2005 (The National Archives, 2017). 
3. Individuals who are able to understand verbal explanations and written 
information in English, with the support of the researcher, if needed. 
4.5.2 Exclusion criteria 
 Past head, neck and/or lower abdomen radiation treatment. 
 Past chemotherapy treatment.  
 History of having chronic salivary gland disease or swelling. 
 Pregnancy or breast-feeding. 
 Individuals with secondary SS. 
 The presence of confounding signs and symptoms due to other systemic diseases such as 
asthma, sinusitis, nasal polyps, flu, and cold.  
 The presence of oral conditions that are deemed to interfere with smell and taste, 
such as Candidiasis and Lichen planus. 
 Uncontrolled diabetic patients. 
 Significant dental problems. 
 Staff, colleagues and dental students at Barts and the London school of Medicine and 
Dentistry. 
 Individuals who withhold consent. 
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4.5.3 Patients 
Three routes for patients’ recruitment were followed in this study: 
1. Patients approached on clinic in the Multidisciplinary Sjögren’s clinic at the Institute of 
Dentistry, with information of the study.  
2. Patients identified from the Research Clinical Database (RCD) of the Multidisciplinary 
Sjögren’s clinic at the Institute of Dentistry in Whitechapel, and the Rheumatology clinic 
at Mile End Hospital. A database of 337 rheumatic patients was screened. Patients on 
the database were consented in the past to be contacted for research purposes in 
future. Eligible patients were defined as women diagnosed with pSS according to the 
American European Consensus Group (AECG) criteria (Vitali et al., 2002) (Appendix 1). 
If patients’ diagnosis was unclear on the database, the blood test results as well as the 
consultants’ letters were reviewed on the Care Record Service (CRS) to support the 
diagnosis. Postal invitations modified from Dillman methodology (Dillman,  2007) 
were sent to 122 eligible patients identified by this rout.  
3. The project was advertised on the British Sjögren’s Syndrome Association (BSSA) 
website, and interested pSS members were volunteered to take part. 
 
4.5.4 Healthy volunteers 
Healthy volunteers were recruited for comparison from the general population, by 
advertising the project in the Institute of Dentistry. Sex-matched healthy volunteers were 
recruited by advertising the project via posters, recruiting leaflets and information sheets. 
The advertising materials were placed in the lifts and the main entrance of the Institute of 
Dentistry as well as in clinic 6. Recruiting leaflets and information sheets were given to 
individuals who expressed interest in the study, before the consent form was signed. A ratio 
of one to one was used in recruiting patients and healthy volunteers. 
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4.6 Recruitment 
4.6.1 Setting 
The study was based in the Multidisciplinary Sjӧgren’s Clinic, 2nd floor, Clinic 6, at the 
Institute of Dentistry, Barts Health Trust in Whitechapel East London. Both of the Institute 
of Dentistry and Barts Health Trust are major health service providers in the UK.  
4.6.2 Procedures 
During the period between 2nd March and 30th November 2016 recruitment process took 
place. The patients’ and volunteers’ status determined the exposure in the study. Eligible 
patients were sent a postal invitation pack, with detailed information of the research 
project (Appendix 5 and 7). A response form (Appendix 6) along with a stamped self-
addressed envelope were included in the invitation pack. If patients did not show interest 
to take part in the study, they were not contacted again. If the research team received no 
response form, patients were contacted by phone to ensure whether they received the 
invitation.  Otherwise, another invitation letter was sent if patients agreed. If they refused 
to participate, contacting them was suspended.  
Patients, who sent back a response form wishing to take part in the study were contacted 
to arrange an appointment. On the visit day, patients were consented (Appendix 9) and 
asked to fill out the questionnaires and to undergo the clinical tests. If patients failed to 
attend to the appointment, they were contacted to arrange another appointment 
scheduled at their convenience. Patients, who failed to attend twice were not contacted 
again. Figure 4-1 summarises the process of recruiting patients from the CRD.  
As for patients, interested healthy individuals were consented (Appendix 10) and asked to 
attend for one day visit at the Institute of Dentistry, to answer the questionnaires and to 
undergo the clinical tests (Figure 4-2). 
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     Figure 4-1 Flow chart illustrates the recruitment of pSS patients identified from RCD, modified 
from Dillman method 
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Figure 4-2 Flow chart illustrates the study stages 
  
4.7 Test re-test reliability of the clinical measures 
Reliability of the clinical tests was assessed in the study. Nine healthy participants 
underwent the test-retest evaluations of the smell, gustatory function and neurosensory 
threshold assessment tests. Cronbach’s alpha showed good to excellent reliability 
(Cronbach’s alpha = 0.862, 0.752 and 0.942 respectively).  
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4.8 Predictors 
 Unstimulated salivary flow rate (USFR). 
 Stimulated salivary flow rate (SSFR). 
 Clinical oral dryness score (CODS). 
 Item number 11 of the Xerostomia Inventory (XI) of the severity of nasal dryness. 
 Self-reported vagina dryness. 
 
4.9 Outcomes: 
1. Smell function. 
2. Gustatory function. 
3. Neurosensory threshold. 
4. Sexual function. 
5. General quality of life. 
6. Oral health-related quality of life. 
7. Mental health well-being. 
 
4.10 Potential confounders 
 Age 
 Smoking 
 Alcohol intake 
 Mouthwash  
 Appliances 
 Betel leaves  
 Medicines 
 Fatigue 
 Disease duration 
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4.11 Data sources 
The details of assessment methods for each variable of interest in the study were described 
in tables 4-1, 2 and 3. 
Table 4-1 Predictors assessment 
Predictors 
Clinical 
assessment 
Questionnaires Groups 
Nasal dryness -- Item 11 of XI in the CRF1 Patients and volunteers 
Oral dryness 
USFR, SSFR and 
CODS 
XI in the CRF1 Patients and volunteers 
Vaginal dryness -- CRF2 Patients 
   1: Appendix 16, page 10; appendix 17, page 7. 
   2: Appendix 16, page 10. 
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 Table 4-2 Outcomes assessment 
Outcomes 
Clinical 
assessment 
Questionnaires Groups 
Smell 
function 
UPSIT Item 1 of VAS1 Patients and volunteers 
Gustatory 
Function 
TST 
- Items 3,4,5,6 and 7 of VAS1 
- Item 2 of OHIP-142 
Patients and volunteers 
Neurosensory threshold EGM -- Patients and volunteers 
Neuropathy -- Questions 1-4 in the CRF3 Patients 
Sexual 
function 
-- FSFI4 Patients and volunteers 
General 
quality of life 
-- WHOQoL-BRÉF5 Patients and volunteers 
Oral health related 
quality of life 
-- 
OHIP-14 
Item 2 of VAS1 
Patients and volunteers 
Mental health 
well-being 
-- HADS6 Patients and volunteers 
1: Appendix 15 
2: Appendix 12 
3: Appendix 16, page 8. 
4: Appendix 14. 
5: Appendix 11. 
6: Appendix 13. 
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 Table 4-3 Confounders assessment 
Confounders Clinical tests Questionnaires Groups 
Age -- CRF1 
Patients and 
volunteers 
Fatigue -- 
- Item 8 of VAS2 
- CRF3 
Patients and 
volunteers 
Smoking -- CRF4 
Patients and 
volunteers 
Alcohol -- CRF4 
Patients and 
volunteers 
Mouthwash -- CRF4 
Patients and 
volunteers 
Betel leaves -- CRF4 
Patients and 
volunteers 
Medicines -- CRF5 
Patients and 
volunteers 
    1: Appendix 16 and 17, page 2. 
    2: Appendix 15. 
    3: Appendix 16, page 7. 
    4: Appendix 16 and 17, page 4. 
    5: Appendix 16 and 17, page 5.  
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4.12 Description of the clinical tests:  
4.12.1 Smell identification test  
Smell function was assessed by the University of Pennsylvania Smell Identification Test   
(UPSIT) from Sensonics (Doty et al., 1984). This test is a forced choice test for the 
quantitative assessment of the sense of smell, which was developed by Doty and others in 
1984. The test comprises of a standardized 40-item which distributed into four booklets, 
each booklet has ten boxes of embedded microencapsulated odours with four different 
choices provided for each box. Subjects had to scratch each box with the provided pencil 
and to sniff the released smell, then to tick one of the appropriate options provided on the 
relevant page of the booklet (Figure 3-3). A score was then calculated for the final 
recognition of each subject.  
A special version of this test was ordered to match the British cultural norms. According to 
the manual of the test, females were categorized based on their scores to:  
35 – 40 Normal. 
31 – 34 Mild microsmia.  
26 – 30 Moderate microsmia.  
19 – 25 Severe microsmia. 
06 – 18 Total anosmia.  
 
However, in the current study a cut off point for smell dysfunction for all participants was 
given at ≤30. 
    
Methodology 
110 
 
             
                     Figure 4-3 University of Pennsylvania Smell Identification Test (UPSIT)  
4.12.2 Taste tests 
A: Taste strips test  
The gustatory function in the anterior two thirds of the tongue was assessed by the 
validated Taste Strips Test (TST) from Burghart Medical Technologies, Wedel, Germany 
(Mueller et al., 2003, Kamel et al., 2009). The test comprised of paper strips, each strip 
comes in a length of eight cm, and a width of one cm. The strips were previously soaked in 
one of the basic taste solutions: Sweet, sour, salt and bitter (Figure 4-4). The taste solutions 
were prepared with four different concentrations for each tastant, ranged from highest to 
lowest concentration as follows (Mueller et al., 2003): 
 Sweet: 0.4, 0.2, 0.1, 0.05 g/ml sucrose. 
 Sour: 0.3, 0.165, 0.09, 0.05 g/ml citric acid. 
 Salt: 0.25, 0.1, 0.04, 0.016 g/ml sodium chloride. 
 Bitter: 0.006, 0.0024, 0.0009, 0.0004 g/ml quinine hydrochloride. 
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Figure 4-4 Taste Strips Test (TST) 
The strips were placed for 10 seconds on three places of the anterior two thirds of the 
tongue; these were the right, left and the tip. Subjects were asked to recognize the taste of 
each strip irrespective of the taste intensity. Subjects were advised to rinse with water after 
testing with each strip and a confirmation was sought that the previous taste was cleared, 
to eliminate the overlap between tastes. The correct taste identification was scored as one 
point on a scoring sheet (Appendix 23). A total score of less than nine points was considered 
hypogeusia as per the test’s manual.  
B: Electrogustometer  
The neurosensory threshold of taste was assessed quantitatively by electrogustometer 
(EGM) from Sensonics (Krarup, 1958). The device also known by TR-06 Rion (Tokyo, Japan) 
(Figure 4-5). Subjects were familiarised with the equipment after explaining how it works 
and the kind of the taste sensation it stimulates. The device sends faint electrical current 
via the metal sticks to the tongue that stimulates taste, and a lesser chance of tingling 
sensation. The device has two poles, the cathode which was usually placed on the wrist or 
neck of participant, while the anode represented by a metal stick that was put on the tongue 
(Sham et al., 2007). The metal stick was put on the same places that were tested by the TST, 
these were right, left and the tip of the anterior two thirds of the tongue. Two centimetres 
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space was allowed between the borders of the tongue and the tested place. The duration 
of the current that was applied on each place of the tongue was fixed on 1.5 seconds.  
Participants were notified before applying the metal stick on the tongue, and were advised 
to ignore the tingling they could feel on the tongue. Subjects were requested to only report 
the taste sensation or a change in a taste they feel by the current’s stimulation. When 
subjects feet the taste, they were instructed to raise their hands or to click on the buzzy 
button provided, so the readings were recorded for each threshold of perception (Sham et 
al., 2007). A threshold was defined as the point at which an individual can detect a specific 
stimulus, or identify any change of stimulus of a test (Gescheider, 1997). 
Single staircase technique (tow up/one down) that was adopted from Miller et al. (2002) 
and Deeb et al. (2010) was employed in this study. The technique includes starting out at 
the 0.0 dB with three times attempts of bringing the machine on and off, and subject had 
to identify when there was, or was not stimulus generated. If all the three sets of pairs at 
this level were correct, then move down in single step (e.g. from 0 dB to -2 dB). If a miss-
identification occurred at any point before achieving the three sets of pairs, move up two 
steps, (e.g. from 0 to 4.0) and repeat. Continued moving up two more steps until three sets 
of pairs are obtained correctly, and then move down in a single step to achieve the 
minimum threshold. When same point of correct identification was obtained at least twice, 
a taste threshold value was marked. If there was no response to the highest value of 
stimulus, threshold was recorded as 34 dB. The threshold was identified on a particular plot 
paper for each participant (Appendix 18).       
Normal range of neurosensory threshold of taste in the anterior 2/3 of tongue, was 
accepted at <8 dB (Sone et al., 2001, Negoro et al., 2004), and was considered as abnormal 
threshold when values exceeded 30 dB (Ellegard et al., 2007).  
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              Figure 4-5 The electrogustometer for the neurosensory 
assessment of the taste 
 
4.13 Oral dryness assessment 
4.13.1 Unstimulated salivary flow rate  
The test was described by Navazesh (1993) for unstimulated whole salivary flow rate 
(USFR). Participants were asked to spit out for five minutes into a pre-weighed disposable 
screw capped bottle. The amount of saliva was calculated per minute rate. A value of ≤ 1.5 
ml of saliva in 15 minutes (i.e. ≤ 0.1 ml/min) was considered as the cutoff point of the 
unstimulated whole salivary glands function (Speight et al., 1992, Vitali et al., 2002). 
4.13.2 Stimulated salivary flow rate  
The test was described by Navazesh and Christensen (1982) for stimulated whole salivary 
flow rate (SSFR). Participants were asked to chew for five minutes a piece of same size and 
weight of sugar free paraffin wax pellets (CRT Paraffin, Ivoclar Vivadent), and spit the 
produced saliva in a pre-weighed screw capped bottle during chewing time. A significant 
dryness is defined by a cutoff point rate of ≤ 0.6 ml/min of the stimulated whole salivary 
glands function (Bookman et al., 2011). 
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4.13.3 Clinical oral dryness score  
This assessing tool is also known as the Challacombe scale, which comprised of 10 items, 
for the clinical assessment of the severity of mouth dryness (Osailan et al., 2012) (Appendix 
16 page 11, appendix 17 page 8). The scale was one of the routinely used instruments in the 
Multidisciplinary Sjӧgren’s clinic. Mild dryness was indicated to scores ranged one to three. 
Moderate dryness was referred to scores ranged four to six, and sever dryness when the 
score ranged seven to ten. 
4.14 Description of the questionnaires 
4.14.1 World health organisation quality of life-BRÉF 
The questionnaire, also known as WHOQoL-BRÉF, was used to assess the general quality of 
life (QoL) in the previous two weeks period by 26 items. The first question assessed the self-
perceived QoL, “How would you rate your quality of life?” whilst the second question 
assessed satisfaction with health “How satisfied are you with your health?”. The first two 
questions, were given a maximum score of five, to indicate the best QoL. The remaining 24 
items assessed individuals’ QoL in four domains; physical health, psychological, social 
relationships and environment. The items were rated on a Likert scale of one to five in each 
domain score. Raw domain scores were transformed to a 0-100 score according to 
guidelines (World health organisation, 1996). The higher the score, the better QoL was 
perceived. A cut-off value of <60 indicating poor/unsatisfactory QoL was used (Silva PAB, 
2014). The questionnaire was checked for uncoded items and if applicable, participants 
were requested to complete the form. When more than 20% of data was missing, the 
questionnaire was considered invalid (Appendix 11). 
4.14.2 Oral health impact profile-14  
The questionnaire, also known as OHIP-14, was used to assess the oral health related QoL 
within the last twelve months period. This assessing tool comprised of fourteen items 
distributed into seven domains. The domains were functional limitation, physical pain, 
psychological discomfort, physical disability, psychological disability, social disability and 
handicap. Responses were given on a five rating scale: 0=never, 1=hardly ever, 
2=occasionally, 3=fairly often, 4=very often. According to David Locker and Quiñonez (2009) 
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the prevalence of oral health problems were estimated by calculating the percentage of 
respondents reporting one or more impacts of “Fairly often” or “Very often”.  Extent of oral 
health problems were calculated by counting the number of items reported “Fairly often” 
or “Very often”. Severity was calculated by summing the scored 14 items (range 0 – 56) to 
obtain the total score of a participant, where a higher score denotes worse oral health QoL 
(Locker D, 2001, Willumsen et al., 2010). The mean of items that comprised a domain, was 
calculated to obtain each domain score (Anneloes E. Gerritsen et al., 2012). The 
questionnaire was checked for uncoded items and if applicable participants were requested 
to complete the form.  The assessment was considered invalid when responses of more 
than 20% of data were missing (Appendix 12). 
4.14.3 Hospital anxiety and depression scale 
The questionnaire, also known as HADS, was used to assess the mental health status in the 
previous week. This assessing tool comprised of two domains, anxiety (HDAS-A) and 
depression (HADS-D). Each domain consists of seven items, with four coded responses that 
range from zero to three. A simple final sum for each domain was given to the final domain 
scoring value. A score ranged from zero to seven indicates normal mental health status. A 
cut-off point of 8≤ denotes a borderline case of mental impairment (Snaith RP, 1994). The 
questionnaire was checked for uncoded items and if applicable participants were requested 
to complete the form. The assessment was considered invalid when responses of more than 
20% of data were missing (Appendix 13). 
4.14.4 Female sexual function index  
The questionnaire, also known as FSFI, was used to assess the sexual activity in the previous 
three months period. This assessing instrument comprised of 19-item distributed into six 
domains, these were desire, arousal, lubrication, orgasm, satisfaction, and pain. Each 
domain has a certain number of items with coded options, the sum of the codes of each 
domain was multiplied by the domain’s factor described on the FSFI website (Bayer Ag, 
2017). The total score of the questionnaire is 36, where higher scores denote better sexual 
function. A cut-off value of ≤26.55 was adopted from (Wiegel et al., 2005) to identify 
subjects who are at risk of sexual dysfunction. The questionnaire was checked for uncoded 
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items and if applicable participants were requested to complete the form. The assessment 
was considered invalid when responses of more than 20% of data were missing (Appendix 
14). 
4.14.5 Visual analogue scale 
This self-rating questionnaire was used to assess the acuity of smell, gustatory function, oral 
health related quality of life and fatigue. The cut-off value was arbitrarily specified at <50 
for poor rating, over a 100 graded scale (Appendix 17). 
4.14.6 Xerostomia inventory  
This questionnaire was used for the self-assessment of oral dryness in the previous four 
weeks through 11 items. The questions were asked to all participants during taking the 
medical history. Each item has a five-coded options rated on a Likert scale ranging from one 
to five, in which 1 being “never” and 5 being “very often”. The self-ratings were summated 
to give a total score of 55, to indicate the severity of oral dryness. Higher scores denote 
sever oral dryness (Appendix 16, page 10; appendix 17, page 7).  
4.15 Clinical research form  
A Case Report Form (CRF) was designed to collect the required information from all 
participants. Each participant in the study received a CRF based on being in either the 
patients or healthy volunteers group:   
4.15.1 CRF for patients  
Collected information of the following: 
1. Participants’ demographics: This included information of age, sex, address, 
employment, have a partner, education and ethnicity. For the definition of the 
latter, information from the Office for National Statistics were used (Office for 
National Statistics, 2017)(Appendix 16, pages 2-4). 
2. Questions about life style (smoking, pan chewing and alcohol intake) (Appendix 16, 
page 4).  
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3. Questions about the use of mouthwashes (Appendix 16, page 4). 
4. Questions about the existence of oral appliances (partial and/or complete denture 
or orthodontic appliance) (Appendix 16, page 4).   
5. Questions about the medical history and medications (Appendix 16, page 5). 
6. Clinical and laboratory Investigation results related to pSS diagnosis, obtained from 
the Clinical Records System (CRS), including results of: Ro, La, ANA, ENA, Ultra sound 
of the salivary glands and Lip biopsy (Appendix 16, page 5-7) and Schirmer test 
(Appendix 13, page 9). 
7. Questions about fatigue (Appendix 16, page 7). 
8. Questions to assess neuropathy status of pSS patients (Appendix 16, page 8). 
9. Description of the extra oral examination (Appendix 16, page 8). 
10. Open-ended question on whether there was any other aspect in which pSS affected 
patients’ QoL that was not covered in the survey. These questions were established 
based on clinical experience of specialists in the Neurology Department at the Royal 
London Hospital, Barts Health Trust (Appendix 16, page 10). 
11. Self-perceived assessment for severity of mouth dryness by using Xerostomia 
Inventory (XI) (Appendix 16, page 8).  
12. The clinical assessment of oral dryness using the clinical oral dryness score (CODS) 
(Appendix 16, page 11). 
13. Results of the research clinical tests that were ethically approved for the study which 
included results of salivary flow rates (Appendix 13, page 9 of), smell, taste and 
neurology of taste (Appendix 16, page 12). 
4.15.2 CRF for healthy volunteers  
      Contained the following: 
1. Participants’ Demographics: This included information on age, sex, address, 
employment, have a partner, education and ethnicity. For the definition of the latter, 
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information from the Office for National Statistics were used (Office for National 
Statistics, 2017) (Appendix 17, page 2-4). 
2. Questions about life style (Smoking, pan chewing and alcohol) (Appendix 17, page 4).  
3. Questions about the use of mouthwashes (Appendix 17, page 4). 
4. Questions about the existence of oral appliances (partial and/or complete denture or 
orthodontic appliance) (Appendix 17, page 4).   
5. Questions about the medical history and medications (Appendix 17, page 5). 
6. Description of the extra oral examination (Appendix 17, page 5). 
7. Results of the research clinical tests that were ethically approved for the study, which 
included results of salivary flow rates (Appendix 17, page 6), smell, taste and neurology 
of taste (Appendix 17, page 9). 
8. Self-perceived assessment for severity of mouth dryness by using Xerostomia Inventory 
(XI) (Appendix 17, page 7).  
9. The clinical assessment of oral dryness using the clinical oral dryness score (CODS) 
(Appendix 17, page 8). 
 
4.16 Bias 
Bias was avoided in the current study by ensuring the following: 
 One researcher committed participants’ recruitment, clinical testing and data 
collection to eliminate performance bias. 
 The number of recruited participants was almost same as the number at the end of 
the study (two missing per group), this ensured eliminating attrition bias.   
 Participants were recruited from different sources to ensure generalisability. 
 Questionnaires were checked and the uncoded items were requested to be 
completed to ensure data accuracy. 
 Confounders were identified and controlled by using multiregression analysis. 
 Positive and negative results were addressed to eliminate citation bias. 
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 Patients were identified by the validated AECG criteria to eliminate misclassification 
of exposure bias. 
 
4.17 Sample size 
The sample size calculation was performed using OpenEpi, which is an open source 
approach, utilised by epidemiologists and others to provide information about sample size 
and power calculations for different types of study designs. The calculation set the power 
of the test at 90% and CI at 95% with a ratio of sample size 1 to 1. However, the information 
that was obtained from the literature on effect size was varied. For instance, the sample 
size for case-control study, that was obtained based on the mean difference of the smell 
and taste function in Kamel et al. (2009) study was n=72 and n=6 per group respectively. 
For sexual function that was based on mean difference in a study by van Nimwegen et al. 
(2015), the sample was n=59 per group.   
It was therefore decided that we use our own data based on a mean difference for smell, 
taste and sexual function in a pilot study of nine pSS patients and 12 healthy volunteers. 
The mean score ±SD of the smell for patients=26.7 ±8 and volunteers=34.4 ±3.3 was 
calculated. Similarly, the mean score of taste for patients=8.3 ±3.3 and volunteers=13.2 ±1.9 
and the mean score of sexual function for patients=19.8 ±8.7 and volunteers=28.7 ±4.3 was 
identified. Nomogram method (Altman, 1982) was used (shown below by dotted line in 
figure 3-6) to estimate the sample size at power of 90% and level of significance of 5%. 
Pooled standard deviation of both groups was calculated for smell SDpooled=5.8, taste 
SDpooled=2.6 and for sexual function SDpooled=6.8. The minimum acceptable mean difference 
of smell=7.7, taste=4.9 and sexual function=8.9. A large effect size of smell (d=1.3), taste 
(d=2.6) and sexual function (d=1.3) was found between the groups. Accordingly, a total of 
28 subjects (14 cases and 14 healthy volunteers) as was required for the outcomes smell 
and sexual function, and 25 subjects for the outcome of taste. However, based on 
benchmarks suggested by Cohen ( 1988), a moderate effect size of d=7.5 was considered 
more suitable. A power of 90%, level of significance of 5% and a total of 75 subjects (cases 
and healthy volunteers) would be required to detect that level of difference (Solid line in 
figure-6). To consider the possibility of 20% drop out, the sample was inflated to give a 
Methodology 
120 
 
minimum of 90 participants (45 cases and 45 healthy volunteers). The study was powered 
to address one primary analysis, as is normally recommended for hypothesis testing. Other 
analyses may be considered exploratory. 
 
 
 
 
 
 
 
 
 
 
 
4.18 Feasibility study  
A feasibility study was conducted to determine the project’s viability, and the possibility of 
patients’ recruitment within the Multidisciplinary Sjӧgren’s clinic in the Dental Institute/ 
Whitechapel. Six healthy participants volunteered to take part in this study. A suitable place 
to conduct the clinical tests was allocated. To ensure confidentiality, a secured place to 
store participants’ data was offered by the Institute of Dentistry. 
4.19 Results and observations  
 The study worked within the dynamics of the clinic. 
 The clinical tests were reflective of participants’ perception, and were found 
affordable by participants. 
 Participants answered all the questionnaires without reservation including the FSFI, 
despite its intrusive nature. 
 The clinical tests and the questionnaires were conducted in a reasonable time of one 
hour.   
 The electrogustometer was pain free for participants and was of no discomfort.   
Figure 4-6 Nomogram for calculating the sample size of the study 
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4.20 Feedback 
1. Participants were not sure how to respond to the VAS.  
Action taken: rewording the questionnaire and adding of descriptive words at each end 
of the scale to indicate the two extremes of the assessed outcome. 
2. A non-native speaker participant was confused between the word bitter and sour, and 
was reporting the word bitter for sour and vice versa.  
Action taken: Illustrating cards were provided to explain each of the basic tastes, with a 
relevant picture and descriptive word, to facilitate identifying the tastant 
by non-native speakers.  
 
4.21 Data analysis 
Data were analysed using the latest version of Statistical Package for Social Sciences, IBM 
Corporation, SPSS Inc., Chicago, IL, USA version-23 statistical software. Quantitative 
variables were handled as normal and abnormal. Matching of patients and healthy 
volunteers was addressed by using the variables as confounders in the regression model. 
The distribution of data was determined via Shapiro-Wilk test, and level of significance was 
5%. Residual plots were used to assess quality of regression. Continuous variables were 
expressed as mean followed by ± standard deviation, and categorical variables were 
expressed as percent. The following statistical tests were used as follows: 
 To examine objectives one to seven, independent t-test, Chi-square and frequency 
analysis were used. Independent sample t-test was applied to detect the mean 
difference between patients and healthy volunteers groups. Chi-square and 
frequency analysis were used to determine the range pattern of dysfunction in each 
group.  
 To examine objective eight, multiregression analysis was used to identify predictors 
of the quality of life (QoL), and to control for the potential confounding variables. 
The ENTER method was used for data entry, and the independent continuous 
variables were the smell, gustatory and sexual functions, whilst the dependent 
continuous variables in the model were as follows: 
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- Every domain of the general QoL (Physical, psychological, social and environmental) 
measured by WHOQoL-BRÉF.  
- The total score and each domain of the oral health related QoL measured by OHIP-
14 (Functional limitation, physical discomfort, psychological discomfort, physical 
disability, psychological disability, social disability and handicap). 
- Every domain of the mental health well-being (Anxiety and depression) measured 
by HADS. 
- Confounders of smoking, alcohol intake, mouthwash use, appliances, pain relief, 
Gabapentine, other drugs and fatigue were entered as dichotomous variables. 
Whilst age and disease duration were entered as continuous variables.  
- To examine objective nine, Pearson’s correlation and multiregression analysis were 
used to detect the correlation between the smell (independent continuous 
variable) and gustatory function (dependent continuous variable). The ENTER 
method was used for data entry in the regression analysis. Confounders of smoking, 
alcohol intake, mouthwash use, appliances, pain relief, Gabapentine, other drugs 
and fatigue were entered as dichotomous variables. Whilst age and disease 
duration were entered as continuous variables.  
- To examine objectives 10 and 11, multiregression analysis was used to predict the 
smell and gustatory function (dependant continuous variables) from the oral 
dryness assessment tests (independent continuous variables). The ENTER method 
was used for data entry. Confounders of smoking, alcohol intake, mouthwash use, 
appliances, pain relief, Gabapentine and other drugs were entered as dichotomous 
variables. Whilst age and disease duration were entered as continuous variables.  
- To examine objective 12, Pearson’s correlation and multiregression analysis were 
used to detect the association between the gustatory function (dependent 
variable) and the neurosensory threshold of taste (independent variable). The 
ENTER method was used for data entry. Confounders of smoking, alcohol intake, 
mouthwash use, appliances, pain relief, Gabapentine and other drugs were entered 
as dichotomous variables. Whilst age and disease duration were entered as 
continuous variables.  
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 To examine objective 13, frequency analysis was used to determine the rate of the 
self-reported vagina dryness in the patients group. Binary logistic regression was 
used to predict the self-reported vagina dryness (dependant variable) from oral 
dryness measures (independent variable). 
 To examine objective 14, multiregression analysis for a subgroup of the sexually 
active pSS patients was conducted. The analysis was run to predict the sexual 
function (dependant variable) from the self-reported vagina dryness (independent 
variable) and to control for the potential confounders. The ENTER method was used 
for data entry. Confounders of alcohol intake and fatigue were entered as 
dichotomous variables, whilst age and disease duration were entered as continuous 
variables. 
 To examine other results, Pearson’s rank order was used to study the correlation 
between subjective and objective tests. Multiregression analysis was used to predict 
oral, nasal and vaginal dryness (dependant continuous variable) from medicines 
(independent dichotomous variables) taken by patients. The ENTER method was 
used for data entry.  
 To analyse the open-ended questions, frequency analysis was used to determine the 
rate of each reported symptom by patients. 
4.22 Subgroup analysis 
A subgroup of sexually active participants was considered in the analysis to detect the 
impact of the pSS on sexuality. 
4.23 Missing data 
The missing data was considered few (three missing data in the patients group and two in 
the healthy volunteers group). Therefore, the need to adjust the results statistically was not 
deemed necessary. 
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5.1 Demographics of participants 
Out of the 122 invitations that were sent to eligible pSS patients who were selected from 
RCD, 38 patients were interested and attended the clinic to take part in the study, after 
being consented. Twenty more patients were recruited on clinic, of which, four dropped 
out. Fifteen more patients were recruited from BSSA. Excluded patients were those with 
unconfirmed diagnosis, one from RCD and three from BSSA (Figure 5-1). The attendance 
rate was 80%, and the overall response rate of contacted patients from RCD was 31.15%. 
Sixty five healthy volunteers were recruited for comparison, of which, three did not meet 
eligibility criteria and hence excluded, giving a total of 62 healthy volunteers (Figure 5-2).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
65 
 Total patients 
recruitment for the study 
1  
Excluded with 
unconfirmed diagnosis 
37 
Totally recruited from 
RCD  
 
38  
Were interested  
12  
Totally recruited from 
BSSA  
16  
Totally recruited on clinic  
4 
Dropped out (80% 
attendance rate) 
15 
Patients recruited from 
BSSA 
337 
Patients of RCD  
20 
Patients were recruited 
on clinic 
3  
Excluded with 
unconfirmed diagnosis 
122 
Eligible patients were 
selected  
Figure 5-1 Flow diagram illustrates the included and excluded patients from the 
three routs of recruitment and the final number of enrolled eligible patients 
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65  
Participants recruited from  
general population 
62  
 Total healthy 
volunteers recruitment 
for the study 
3  
Did not meeting eligibility 
criteria and were excluded  
 
Figure 5-2 Diagram illustrates the recruitment of 
the healthy volunteers in the study 
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5.2 Sample description 
Sixty five patients and sixty two sex-matched healthy volunteers gave consent and 
participated in the study. The advantage of recruiting more participants than that obtained 
from power calculation was high power of multivariate regression analysis, to avoid 
spurious or false statistical significance due to over drafting. All literate with different levels 
of educational attainment with age mean, (±SD) of patients 59.03 ±12.75 (Patients’ age 
range 24 – 83 years) and healthy volunteers 43.04 ±14.84 (Volunteers’ age range 21 – 93 
years). Ethnicity of patients included 69.23% of White background and 10.76% black, 
13.84% Asian,  1.53%  mixed or multiple background and 4.61% other ethnic group. 
Ethnicity of the healthy volunteers constructed 46.77% White background and 8.06% black, 
20.96% Asian, 19.35% mixed or multiple background and 4.83% other ethnic group. Retired 
patients and controls were 53.84% and 9.67% respectively. Employed patients (30.76%) and 
healthy volunteers (69.35%) were higher than unemployed (15.38% and 19.35% 
respectively) (Table 5-1). 
Patients attended the clinic from outside London constituted 33.84% versus 66.15% from 
London. The latter was distributed to the west (16.27%), east (72.09%) and north London 
(11.62%). Volunteers attended from outside London 6.45% versus 93.54% from London of 
which 41.37%, 51.72% and 6.89% were recruited from southwest, east and north London 
respectively.  
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Table 5-1 Characteristics of patients and healthy volunteers. 
Characteristics 
 
Patients 
n=65 
 
Volunteers 
n=62 
 
Total 
n=127 
Age 
Mean (95%) 
59 (55.8-62.1) 
Mean (95%) 
43 (39.2-46.8) 
Mean (95%) 
51 (48.4-54) 
Ethnicity 
White UK 
White others 
White total 
Mixed 
Asian 
Black 
Other 
N (%) 
41 (63) 
4 (6) 
45 (69) 
1 (1) 
9 (13) 
7 (10) 
3 (4) 
 
N (%) 
14 (22) 
14 (22) 
28 (45) 
4 (6) 
13 (20) 
5 (8) 
12 (19) 
 
N (%) 
55 (43) 
18 (14) 
73 (57) 
5 (3) 
22 (17) 
12 (9) 
15 (11) 
Partner 
Yes 
No 
 
45 (69) 
20 (31) 
 
43 (71) 
19 (31) 
 
88 (70) 
39 (31) 
Education 
Primary 
Secondary 
Tertiary 
 
1 (1) 
23 (35) 
41 (63) 
 
2 (3) 
11 (17) 
49 (79) 
 
3 (2) 
34 (26) 
90 (70) 
Monthly income 
£500-£1000 
£1000-£2000 
more than £2000 
preferred not to say 
Missing 
 
7 (10) 
18 (27) 
33 (50) 
5 (8) 
1 (1) 
7 (11) 
19 (30) 
26 (41) 
10 (16) 
0 
14 (11) 
37 (29) 
59 (46) 
15 (11) 
1 (0.7) 
Employment 
Employed 
Unemployed 
Retired 
Missing 
 
20 (30) 
10 (15) 
35 (53) 
0 
 
43 (69) 
12 (19) 
6 (9) 
1 (1) 
 
63 (49) 
22 (17) 
41 (32) 
1 (0.7) 
Smokers 4 (6) 4 (6) 8 (6) 
Alcoholics 31 (47) 23 (37) 54 (42) 
Betel leaves takers 0 (0) 2 (3) 2 (1) 
Mouthwash users 41 (63) 32 (51) 73 (57) 
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5.3 PRIMARY OUTCOME RESULTS  
5.3.1 Objective 1: To compare the smell function in pSS group vs healthy volunteers group 
All patients (n=65) and all healthy volunteers (n=62) underwent the smell test. The smell 
function was statistically significantly impaired in pSS group (30, ±7.087) compared with 
healthy volunteers group (33.95, ±4.806). The mean difference was 3.9 and 95% CI=1.8 - 6.1 
(Table 5-13). Individuals with hyposmia constructed 41.5% (n=27/65) of pSS patients vs 
24.1% (n=15/62) healthy volunteers. Only 7.3% (n=10) of pSS group who self-assessed their 
smell quality using VAS, were aware of the loss of their smell acuity. 
 
5.3.2 Objective 2: To compare the gustatory function in pSS group vs healthy volunteers 
group tested by TST  
1. Total gustatory function score 
Sixty three patients and 60 healthy volunteers underwent the TST. The average of the three 
sites of the tongue (Tip, right and left) of the taste function was statistically significantly 
impaired in pSS group (8.3, ±3) compared with healthy volunteers group (12.6, ±2.1). The 
mean difference was 4.3 and 95% CI=3.3–5.2 (Table 5-13). Individuals with hypogeusia 
constructed 54% (n=34/63) of pSS group vs 8.3% (n=5/60) of the healthy volunteers group. 
Patients’ self-assessment of their taste quality using VAS, revealed that 21.9% (n=14) were 
aware of the loss of their taste acuity. 
2. Regional gustatory function score  
The function of taste was statistically significantly affected on the three tested places of the 
anterior 2/3 of the tongue in the patients group, compared to the healthy volunteers group. 
The right side scored statistically significantly lower in patients (7.9, ±3.6) compared with 
healthy volunteers (12.9, ±2). The left side of the tongue scored statistically significantly 
lower in the patients group (7.5, ±3.6) compared with healthy volunteers groups (12.1, 
±3.2). The tip of the tongue scored statistically significantly lower in the patients group (9.5, 
±3.3) compared with healthy volunteers group (12.8, ±2.2), although both were within the 
normal range score (Table 5-2). 
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Table 5-2 Comparison of the regional taste function of the tongue tested by TST between pSS 
patients and healthy volunteers 
Tested site 
Mean* 
Patients, n=63 
Healthy volunteers, n=60 
Mean difference 
(95% CI) 
 
p-value 
Tip 
9.5 
12.8 
3.2 
(2.2–4.2) 
 
< 0.05 
Right 
7.9 
12.9 
5 
(3.9–6) 
 
< 0.05 
Left 
7.5 
12.1 
4.5 
(3.3–5.8) 
 
< 0.05 
Total** 
8.3 
12.6 
4.3 
(3.4-5.2) 
 
< 0.05 
       *Normal taste function of ≥9 in 0–16 scale 
       ** See table 4-2 
 
 
In the patients group, there was no significant difference in the results obtained from both 
laterals of the tongue (Mean difference=0.4, 95% CI=0.8–1.6). However, the difference 
between the tip and each lateral of the tongue was statistically significant, where the mean 
score of the tip was the highest (9.5, ±3.3) (Table 5-3). In the healthy volunteers group, there 
was no statistical significant difference between the three tested places of the tongue 
(Table 5-4).  
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     Table 5-3 Comparison of the regional taste function of the tongue tested by TST in the patients 
group 
Tested site Mean* 
Patients, n=63 
Mean difference 
(95% CI) 
p-value 
Right 
Left 
7.9 
7.5 
0.4 
(0.8–1.6) 
0.5 
Right 
Tip 
7.9 
9.5 
1.6 
(0.3–2.8) 
0.01 
Left 
Tip 
7.5 
9.5 
2 
(0.7–3.2) 
< 0.05 
      *Normal taste function of ≥9 in 0–16 scale 
 
  Table 5-4 Comparison of the regional taste function of the tongue tested by TST in the healthy 
volunteers group 
Tested site 
Mean* 
Healthy volunteers, 
n=60 
Mean difference 
(95% CI) 
p-value 
Right 
Left 
12.9 
12.1 
0.8 
(0.1–1.8) 
0.1 
Right 
Tip 
12.9 
12.8 
0.1 
(0.6–0.9) 
0.6 
Left 
Tip 
12.1 
12.8 
0.6 
(0.3–1.6) 
0.1 
     *Normal taste function of ≥9 in 0–16 scale 
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3. The four basic tastes scores  
According to the TST manual, the whole mouth tasting ability is represented by examining 
of the tip of the tongue, and the comparisons were as follow: 
 Sweet 
The ability to taste sweet was statistically significantly impaired in pSS group (2.8, ±1.1) 
compared to healthy volunteers group (3.6, ±0.7).  The mean difference between the groups 
was 0.7 and 95% CI=0.4–1.1 (Table 5-5). 
 Sour 
There was statistical difference in the ability to taste sour in pSS group (2.3, ±0.9) compared 
to healthy volunteers group (2.7, ±0.8). The mean difference between groups was 0.4 and 
95% CI=0.1–0.7 (Table 5-5). 
 Salt 
The ability to taste salt was statistically significantly impaired in pSS group (1.6, ±1.2) 
compared to healthy volunteers group (3.4, ±0.7). The mean difference between groups 
was 1.1 and 95% CI=0.7–1.1 (Table 5-5). 
 Bitter 
The ability to taste bitter was statistically significantly impaired in pSS group (1.6, ±1.2) 
compared to healthy volunteers group (3.1, ±0.9). The mean difference between groups 
was 0.9 and 95% CI=0.5–1.3 (Table 5-5). 
The ability to taste sour, salt and bitter differed statistically significantly (p=0.00) from the 
ability to taste sweet, but not significantly with each other.  
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Table 5-5 Comparison of the whole mouth testing of the four basic tastes between pSS patients 
and healthy volunteers 
Taste category 
Mean* 
Patients, n=63 
Healthy volunteers, n=60 
Mean difference 
(95% CI) 
p-value 
Sweet 
2.8 
3.6 
0.7 
(0.4–1.1) 
 
 
< 0.05 
Sour 
2.3 
2.7 
0.4 
(0.1–0.7) 
 
< 0.05 
Salt 
2.2 
3.3 
1 
(0.7–1.1) 
 
< 0.05 
Bitter 
2 
3 
0.9 
(0.5–1.3) 
 
< 0.05 
  *Range score of each taste is 0-4  
 
4. The rate of identifying the lowest concentration of each taste 
The number of patients, who were able to identify each of the four basic tastes at the lowest 
concentrations, was statistically less than that of healthy volunteers (Table 5-6). 
  Table 5-6 Comparison of identifying rate of the lowest concentration of each taste between 
patients and healthy volunteers  
Taste 
category 
Tip 
Patients 
Healthy 
volunteers 
 
p-value 
Right 
Patients 
Healthy 
volunteers 
 
p-value 
Left 
Patients 
Healthy 
volunteers 
 
p-value 
Sweet 
39.7%, n=25/63 
78.3%, n=47/60 
 
< 0.05 
38.1%, n=24/63 
78.3%, n=47/60 
 
< 0.05 
33.3%, 
n=21/63 
73.3%, 
n=44/60 
 
< 0.05 
Sour 
7.9%, n=5/63 
16.7%, n=10/60 
 
0.1 
7.9%, n=5/63 
25%, n=15/60 
 
< 0.05 
6.3%, n=4/63 
18.3%, 
n=11/60 
 
< 0.05 
Salt 
14.3%, n=9/63 
51.7%, n=31/60 
 
< 0.05 
6.3%, n=4/63 
33.3%, n=20/60 
 
< 0.05 
3.2%, n=2/63 
45%, n=27/60 
 
< 0.05 
Bitter 
9.5%, n=6/63 
35%, n=21/60 
 
< 0.05 
6.3%, n=4/63 
46.7%, n=28/60 
 
< 0.05 
14%, n=9/63 
40%, n=24/60 
 
< 0.05 
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5.3.3 Objective 3: To compare the neurosensory threshold of taste in pSS group vs 
healthy volunteers group 
1. Total neurosensory threshold score 
Sixty three patients and 61 healthy volunteers underwent the EGM test. The total score of 
the neurosensory threshold was three times higher (p=0.00) in pSS group (5.7, ±8.4, n=63) 
compared to healthy volunteers group (-0.4, ±6.6, n=61). The mean difference was 6.1 and 
95% CI=3.4–8.8, where highest mean score indicates worse function (Table 5-13).  
2. Regional neurosensory threshold score  
 Right side (Right patients-right healthy volunteers) 
The neurosensory threshold on the right side of anterior 2/3 of the tongue was statistically 
significantly impaired in the pSS group (7.4, ±10.5) compared with that of the healthy 
volunteers group (-0.1, ±6.5). The highest mean score indicates worse function.  
 Left side (Left patients-left healthy volunteers) 
Similarly, the neurosensory threshold of the left side of the tongue was statistically 
significantly impaired in the pSS group (6.2, ±10.3) compared with that of the healthy 
volunteers group (-0.6, ±6). The highest mean score indicates worse function. 
 Tip of the tongue (Tip patients-tip healthy volunteers) 
The neurosensory threshold on the tip of the tongue was less affected by the syndrome 
than the laterals of the tongue. Furthermore, the neurosensory threshold of the tip of the 
tongue was statistically significantly impaired in the patients group (3.7, ±10.3) compared 
to the tip of the tongue in the healthy volunteers (-0.8, ±7.5) (Table 5-7).  
In a comparison between the neurosensory thresholds of the three tested places of the 
tongue in each group, there was no statistical significant difference between the right and 
left, right and tip, left and tip in the patients and healthy volunteers separately (Tables 5-8 
and 5-9). 
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Table 5-7 Comparison of the regional neurosensory threshold of taste tested by EGM 
between pSS patients and healthy volunteers 
Tested site 
Mean* 
Patients, n=64 
Healthy volunteers, n=61 
Mean difference 
(95% CI) 
p-value 
Tip 
3.7 
-0.8 
4.5 
(1.3–7.7) 
 
< 0.05 
Right 
7.4 
-0.1 
7.4 
(4.3–10.6) 
 
< 0.05 
Left 
6.2 
-0.6 
6.9 
(3.9–10) 
 
< 0.05 
Total 
5.7 
-0.3 
6.1 
(3.4–8.8) 
 
< 0.05 
     *Normal score of neurosensory function of taste <8 in a scale of -6–34 
 
3. Comparison of the regional scores of the tongue 
 Patients 
In the pSS group, there was no difference in the neurosensory threshold when the right and 
left laterals of the tongue were compared with each other or when the left and the tip of 
the tongue were compared. However, the mean score of the tip (3.7, ±10.3) was statistically 
significantly less than the mean score of the right lateral (7.4, ±10.5) (Table 5-8).  
 Healthy volunteers 
In the healthy volunteers group, there was no statistical significant difference in the 
neurosensory threshold between the three tested sites of the tongue (Table 5-9). 
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  Table 5-8 Comparison of the three places of the tongue tested by EGM in the pSS group 
Tested site 
Mean* 
Patients, n = 64 
Mean difference 
(95% CI) 
p-value 
Right 
Left 
7.4 
6.2 
1.1 
(-2.5 – 4.7) 
0.5 
Right 
Tip 
7.4 
3.7 
3.4 
(-7 – 0.2) 
0.05 
Left 
Tip 
6.2 
3.7 
2.5 
(-6.2 – 1) 
0.1 
 
Table 5-9 Comparison the three places of the tongue tested by EGM in the healthy volunteers 
group 
Tested site 
Mean* 
Healthy volunteers, 
n=61 
Mean difference 
(95% CI) 
p-value 
Right 
Left 
-0.2 
-0.7 
0.5 
(-1.7–2.8) 
0.6 
Right 
Tip 
-0.2 
-0.9 
0.9 
(-3.3–1.7) 
0.4 
Left 
Tip 
-0.7 
-0.9 
-0.1 
(-2.6–2.2) 
0.8 
 
5.3.4 Objective 4: To compare the sexual function in pSS group vs healthy volunteers group 
Forty three percent of the pSS group (n=28) and 67.7% (n=42) of the healthy volunteers 
were sexually active and therefore were included in the statistical analysis. Out of the 
sexually active participants, 82.1% of patients (n=23/28) and 33.3% of healthy volunteers 
(n=14/42) had sexual dysfunction as measured by FSFI. The total score of the sexual function 
was impaired significantly in the sexually active pSS group (19.1, ±7.7) compared with the 
sexually active healthy volunteers group (28.4, ±4.9). The mean difference of the total score 
was 9.3, 95% CI=6–12.6 (Figure 5-3). The percentage rate was calculated for the lowest 
score in each domain. The lowest scores were determined by the validated scoring system 
of the FSFI questionnaire. 
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Domain 1: Desire 
The sexually active patients had statistically less sexual desire (2.3, ±1) than the sexually 
active healthy volunteers (3.7, ±1). The mean difference was 1.3 and the 95% CI=0.8–1.8 
(Table 5-10). 
2. Domain 2: Arousal 
The sexual arousal in the sexually active patients was statistically impaired in the sexually 
active patients (3.1, ±1.6) compared to the sexually active healthy volunteers (4.5, ±0.9). 
The mean difference was 1.4 and the 95% CI=0.7–2 (Table 5-10). 
  
Figure 5-3 Comparison of the mean difference of the total FSFI and each of the 
six domains between pSS patients and healthy volunteers. Bars indicating SD. 
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3. Domain 3: Lubrication 
The ability to lubricate in a sexual activity was statistically impaired in the sexually active 
patients (3.1, ±1.5) compared to the sexually active healthy volunteers (5.3, ±0.9). The mean 
difference was 2.2 and the 95% CI=1.5–2.8 (Table 5-10). 
4. Domain 4: Orgasm 
The ability to reach orgasm in the sexually active pSS group was statistically less (3.7, ±1.7) 
compared to the sexually active healthy volunteers group (4.9, ±1.2), the mean difference 
was 1.3 and the 95% CI=0.5–2 (Table 5-10). 
5. Domain 5: Satisfaction 
The sexually active patients were statistically less satisfied with their sexual life (3.7, ±1.6) 
compared to the sexually active healthy volunteers group (4.8, ±1.4). The mean difference 
was 1.1 and the 95% CI=0.4–1.8 (Table 5-10). 
6. Domain 6: Pain 
The sexually active patients had more sexual pain (3.3, ±1.9) compared with the sexually 
active healthy volunteers group (5.2, ±1.4). The mean difference was 2 and the 95% CI=1.1–
2.8. Higher scores in this domain denotes the absence of pain (Table 5-10). 
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     Table 5-10 Percentage of the lowest scores of the FSFI domains in each group. 
FSFI Domains 
pSS patients 
Sexually active 
Healthy volunteers 
Sexually active Mean  
difference 
(95% CI) 
p-value 
Mean 
Minimal scoring rate,  
n of minimal scoring  
Mean 
Minimal scoring rate, 
n of minimal scoring 
Desire 
(Score range 1.2–6) 
2.38 
32%, n=9/28 
3.7 
2.4%, n=1/42 
1.3 
(0.8–1.8) 
< 0.05 
Arousal 
(Score range 0–6) 
3.1 
0%, n=28/28 
4.4 
0%, n=42/42 
1.3 
(0.7–2) 
< 0.05 
Lubrication 
(Score range 0–6) 
3.1 
3.6%, n=1/28 
5.2 
0%, n=42/42 
2.1 
(1.5–2.7) 
< 0.05 
Orgasm 
(Score range 0 – 6) 
3.6 
0%, n=28/28 
4.9 
0%, n=42/42 
1.2 
(0.5–2) 
< 0.05 
Satisfaction 
(Score range 0.8–6) 
3.7 
0%, n=28/28 
4.7 
0%, n=42/42 
1 
(0.3–1.7) 
< 0.05 
Pain 
(Score range 0–6) 
3.2 
6.7%, n=2/28 
5.2 
2.4%, n=1/42 
1.9 
(1.1–2.7) 
< 0.05 
Total score 
19 
82.1%, n=23/28 
28.3 
33.3%, n=14/42 
9.23 
(6–12.6) 
< 0.05 
 
    
5.3.5 Objective 5: To compare the general QoL in pSS group vs healthy volunteers group 
The self-perceived assessment of the general QoL measured by the first global question 
“How do you rate your quality of life?” of the questionnaire, was statistically significantly 
lower in pSS group (3.5, ±0.9) compared to that of the healthy volunteers group (4.3, ±0.5), 
with a mean difference of 0.8 and 95% CI=0.6–1.1. Similarly, the second global question that 
assesses individual’s satisfaction of health “How satisfied are you with your health?” was 
statistically significantly lower in pSS group (2.8, ±0.9) compared with healthy volunteers 
group (4.1, ±0.7) with a mean difference of 1.2 and 95% CI=0.95–1.5. 
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1. Domain 1: Physical   
Patients’ physical life quality was statistically significantly impaired (55.4, ±19) compared 
with healthy volunteers group (80, ±12.7). The mean difference was 24.7 and 95% CI=19–
30.3 (Table 5-13). 
2. Domain 2: Psychological  
Psychologically, patients were statistically significantly affected (61.8, ±15.6) compared with 
healthy volunteers group (73.7, ±11.7). The mean difference was 11.8 and 95% CI=7–16.7 
(Table 5-13). 
3. Domain 3: Social  
The social domain was statistically significantly impaired in the patients group (61.6, ±20) 
compared with healthy volunteers group (73.6, ±17.2). The mean difference was 11.9 and 
95% CI=5.2–18.8 (Table 5-13). 
4. Domain 4: Environmental  
Patients’ environmental life quality was statistically significantly affected (69.5, ±16.1) 
compared with that of the healthy volunteers group (75.6, ±12.8). The mean difference was 
6 and 95% CI=1–11.2 (Table 5-13). 
5.3.6 Objective 6: To compare the oral health related quality of life in pSS group vs 
healthy volunteers group 
The total score of OHIP-14 assessing tool was statistically significantly higher in pSS group 
(20.4.7, ±11) compared with healthy volunteers group (6.7, ±6.6). Higher scores denotes 
worse OHRQoL. The mean difference was 13.7 and 95% CI=10.5–16.9. Table 5-11 illustrates 
the prevalence, extent and severity of the oral health problems in the study’s population. 
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Table 5-11 The prevalence, extent and severity of self- perceived oral health problems in the pSS 
and healthy volunteers groups 
Variable pSS group 
N=65 
Healthy 
volunteers group 
N=61 
95% CI P-value 
Prevalence (%) 69.2% 14% 0.4–0.7 < 0.05 
Extent (mean score) 2.6 0.3 1.6–3.2 < 0.05 
Severity (mean score) 20.4 6.7 10.5–16.9 < 0.05 
  
1. Domain 1: Functional limitation 
The oral function was statistically significantly impaired in the pSS group (1.5, ±1.1) 
compared with healthy volunteers group (0.1, ±0.4). The mean difference was 1.4 and 95% 
CI=1.1–1.7 (Table 5-12). 
2. Domain 2: Physical discomfort 
The physical discomfort was statistically significantly higher in the pSS group (1.8, ±1) 
compared with healthy volunteers group (0.8, ±1.2). The mean difference was 1 and 95% 
CI=0.7–1.5 (Table 5-12). 
3. Domain 3: Psychological discomfort 
The psychological discomfort was statistically significantly higher in the pSS group (1.9, ±1.2) 
compared with healthy volunteers group (0.9, ±0.9). The mean difference was 1 and 95% 
CI=0.6–1.4 (Table 5-12). 
4. Domain 4: Physical disability 
The physical disability was statistically significantly higher in pSS group (1.4, ±1) compared 
with healthy volunteers group (0.4, ±0.6). The mean difference was 0.9 and 95% CI=0.7–1.2 
(Table 5-12). 
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5. Domain 5: Psychological disability 
The psychological disability was statistically significantly higher in pSS group (1.5, ±1) 
compared with healthy volunteers group (0.6, ±0.7). The mean difference was 0.9 and 95% 
CI=0.6–1.2 (Table 5-12). 
6. Domain 6: Social disability 
The social disability was statistically significantly higher in pSS group (1, ±0.9) compared 
with healthy volunteers group (0.4, ±0.6). The mean difference was 0.6 and 95% CI=0.4–0.9 
(Table 5-12). 
7. Domain 7: Handicap 
Patients were statistically significantly more orally handicapped (1, ±1) compared with 
healthy volunteers group (0.2, ±0.5). The mean difference was 0.8 and 95% CI=0.5–1.1 
(Table 5-12). 
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    Table 5-12 Comparison of the OHIP-14 domains between pSS patients and healthy volunteers  
OHIP-14 domains 
Patients, n=65 
Healthy volunteers, n=61 
Mean* 
Mean difference 
(95% CI) 
p-value 
Functional limitation 
Patients 
Healthy volunteers 
1.5 
0.1 
1.3 
(1.1–1.6) 
 
< 0.05 
Physical pain 
Patients 
Healthy volunteers 
1.8 
0.8 
1 
(0.6–1.4) 
 
< 0.05 
Psychological discomfort 
Patients 
Healthy volunteers 
1.8 
0.8 
0.9 
(0.6–1.3) 
 
< 0.05 
Physical disability 
Patients 
Healthy volunteers 
1.3 
0.4 
0.9 
(0.6-1.2) 
 
< 0.05 
Psychological disability 
Patients 
Healthy volunteers 
1.5 
0.6 
0.8 
(0.5–1.1) 
 
< 0.05 
Social disability 
Patients 
Healthy volunteers 
1 
0.3 
0.6 
(0.3–0.9) 
 
< 0.05 
Handicap 
Patients 
Healthy volunteers 
1 
0.2 
0.8 
(0.5–1) 
 
< 0.05 
Total score 
Patients 
Healthy volunteers 
20.4 
6.7 
13.7 
(10.5–16.9) 
 
< 0.05 
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5.3.7 Objective 7: To compare the mental health well-being in pSS group vs healthy 
volunteers group 
1. Anxiety 
Patients group was statistically significantly more anxious (8, ±3.8) compared with the 
healthy volunteers group (5.2, ±3.3). The mean difference was 2.8 and 95% CI = 1.6 – 4.1 
(Table 5-13).  
2. Depression 
Patients group was statistically significantly more depressed (5.9, ±3.8) compared with 
healthy volunteers group (2.4, ±2.5). The mean difference was 3.5 and 95% CI=2.4–4.7 
(Table 5-13). 
5.3.8 Summary results of the primary outcomes 
The rate of hyposmia in the pSS group was significantly higher (41.5%) than that in the 
healthy volunteers (24.7%) group. Similarly, hypogeusia was found in 34 patients compared 
to five in the healthy volunteers. The neurosensory threshold of taste was three times 
higher in pSS group compared with healthy volunteers group (p=0.00). The number of 
patients with sexual dysfunction (n=28) was significantly higher than that of the healthy 
volunteers (n=42). The QoL was significantly impaired, eight times physically (D1), five times 
psychologically (D2), twice socially (D3) and environmentally. Oral health problems were 
significantly more in the patients group (69.2%) compared with the healthy volunteers 
group (14.8%). The mental health well-being was affected, and the number of anxious 
patients (58.5%) was more than that of the healthy volunteers (21%). Additionally, patients 
were four times more depressed (p=0.00) than healthy volunteers (Table 5-13). 
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Table 5-13 Comparison of percentage of the dysfunction rate of the outcome of interest in pSS 
patients compared with healthy volunteers 
Test pSS group 
Healthy 
volunteers group 
Mean 
difference 
(95% CI) 
P-value Type of test 
Smell function1 41.5% (n=27/65) 24.1% (n=15/62) 
3.9 
(1.8-6) 
 
< 0.05 
Clinical 
Gustatory 
function2 
54% (n=34/63) 8.3% (n = 5/60) 
4.3 
(3.4-5.2) 
< 0.05 
Clinical 
Neurosensory 
threshold of 
taste 3 
31.7% (n=20/63) 9.8% (n=6/61) 
6.1 
(3.4–8.8) 
< 0.05 
Clinical 
Sexual function4 82.1% (n=23/28) 33.3% (n=14/42) 
9.2 
(5.9-12.6) 
< 0.05 
Questionnaire 
Quality of life5 
Physical domain 
(D1) 
53.8% (n=35/65) 6.6% (n=4/61) 
24.7 
(18.9–30.3) 
 
< 0.05 
Questionnaire 
Quality of life5 
Psychological 
domain 
(D2) 
47.7% (n=31/65) 9.8% (n=6/61) 
11.8 
(6.9–16.6) 
 
< 0.05 Questionnaire 
Quality of life5 
Social domain 
(D3) 
44.6% (n=29/65) 21.3% (n=13/61) 
11.9 
(5.2–18.7) 
 
< 0.05 
Questionnaire 
Quality of life5 
Environmental 
domain (D4) 
21.5% (n=14/65) 9.8% (n=6/61) 
6 
(0.9–11.2) 
< 0.05 Questionnaire 
Oral health 
problems6 (total 
score) 
69.2% (n=45/65) 14.8% (n=9/61) 
13.7 
(10.5–16.9) 
< 0.05 Questionnaire 
Mental health 
well-being7 
Anxiety 
58.5% (n=38/65) 21% (n=13/61) 
2.8 
(1.5–4) 
< 0.05 Questionnaire 
Mental health 
well-being7 
Depression 
32.3% (n=21/65) 8.2% (n=5/61) 
3.5 
(2.3–4.6) 
< 0.05 Questionnaire 
1: Calculated as normal smell function of ≥ 30 in 0 – 40 scale; 2: Normal taste function of ≥ 9 in 0 – 16 scale; 3: 
Normal score of neurosensory function of taste < 8 in a scale of - 6 – 34; 4: Normal sexual function ≥ 26.5 in a 
scale of 0-36; 5: Overall QoL ≥ 60 in a scale of 0 - 100; 6: No oral health problems = never, hardly ever and 
occasionally vs fairly often and very often; 7: Normal HADS scores < 8.  
**See tables 3-1, 3-2 and 3-3 of data sources measurement. 
Results 
146 
 
5.3.9 Age groups  
1. Comparison of two age groups between patients and healthy volunteers 
The patients were sub-grouped into two age groups based on menopausal age. A group of 
20-50 years and 51-100 years old, which were compared to the corresponding age groups 
in the healthy volunteers in terms of smell, taste, sexuality, QoL and mental health status. 
In both comparisons, the pSS group showed worse function compared with the healthy 
volunteers group. Both age groups comparisons showed that smell did not differ statistically 
significantly between patients and healthy volunteers, although patients group had lower 
mean than that of the healthy volunteers group (Tables 5-14 and 5-15). A significant 
difference was found between patients and healthy volunteers in the 20-50 age group in 
terms of taste, neurosensory threshold, sexual function, QoL and mental health status. 
Similarly, significant difference was observed between patients and healthy volunteers in 
the 51-100 age group in taste, sexual function, QoL (Except the social domain in the 
WHOQoL-BRÉF) and the mental health status (Table 5-15).  
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  Table 5-14 Comparison of percentage of the dysfunction rate according to the cut-off points of 
each outcome of interest in the 20-50 years old age group between pSS patients compared 
with healthy volunteers  
Test 
20–50 years old 
Mean difference 
(95% CI) 
P-value pSS group 
Mean, SD 
Healthy volunteers 
Mean, SD 
Smell1 
31.2% (n=5/16) 
31, ±9 
23.4% (n=11/47) 
34.4, ±3.7 
3.3 
(-8.2–1.5) 
0.1 
Taste2 
37.5% (n=6/16) 
10.2, ±3.2 
4.4% (n=2/45) 
13.1, ±1.8 
2.9 
(-4.6- -1.1) 
 
< 0.05 
Neurosensory 
threshold of 
taste 3 
31.2% (n=5/16) 
6, ±8.9 
6.5% (n=3/46) 
-0.7, ±6.4 
6.8 
(2.6–10.9) 
 
< 0.05 
Sexual 
function4 
77.7% (n=7/9) 
20.5, ±9.5 
33.3% (n=13/39) 
28.4, ±4.7 
7.9 
(-15.3- -0.5) 
 
< 0.05 
Quality of life5 
Physical 
domain 
(D1) 
62.5% (n=10/16) 
50.1, ±20.7 
4.3% (n=2/46) 
81.1, ±12.9 
31 
(-42.6- -19.5) 
 
< 0.05 
Quality of life5 
Psychological 
domain 
(D2) 
37.5% (n=6/16) 
60.6, ±15.9 
6.5% (n=3/46) 
74.4, ±11.5 
13.8 
(-21.2- -6.4) 
 
< 0.05 
Quality of life5 
Social domain 
(D3) 
26.6% (n=4/15) 
59.2, ±24 
15.2% (n=7/46) 
74.5, ±16.7 
15.3 
(-29.3- -1.2) 
 
< 0.05 
Quality of life5 
Environmental 
domain 
(D4) 
26.6% (n=4/15) 
63.8, ±17.5 
10.8% (n=5/46) 
74.5, ±12.7 
10.7 
(-19- -2.3) 
 
< 0.05 
Oral health 
problems6 
43.7% (n=7/16) 
16.5, ±8.8 
15.2% (n=7/46) 
7, ±6.8 
9.5 
(5.2– 13.8) 
 
< 0.05 
Anxiety7 
81.2% (n=13/16) 
9.1, ±3.9 
23.9% (n=11/46) 
5.3, ±3.1 
3.8 
(1.9–5.8) 
 
< 0.05 
Depression7 
25% (n=4/16) 
6.6, ±5.4 
6.5% (n=3/46) 
2.3, ±2.2 
4.2 
(1.3–7.2) 
 
< 0.05 
1: Calculated as normal smell function of ≥30 in 0–40 scale; 2: Normal taste function of ≥ 9 in 0–16 scale;  
3: Normal score of neurosensory function of taste < 8 in a scale of - 6–34; 4: Normal sexual function ≥26.5 
in a scale of 0-36; 5: Overall QoL≥60 in a scale of 0-100; 6: No oral health problems = never, hardly ever 
and occasionally vs fairly often and very often; 7: Normal HADS scores <8.   
       **See tables 3-1, 3-2 and 3-3 of data sources measurement. 
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Table 5-15 Comparison of percentage of the dysfunction rate of the outcome of interest in the 51-
100 years old age group between pSS patients compared with healthy volunteers  
Test 
51-100 years old 
Mean difference 
(95% CI) 
P-value pSS group 
Mean, SD 
Healthy volunteers 
Mean, SD 
Smell1 
44.8% (n=22/49) 
29.6, ±6.4 
26.6% (n=4/15) 
32.4, ±7 
2.7 
(-6.6-1.1) 
0.1 
Taste2 
61.7% (n=29/47) 
7.7, ±2.7 
20% (n=3/15) 
11.2, ±2.2 
3.5 
(-5.1- -1.9) 
< 0.05 
Neurosensory 
threshold of taste3 
31.9% (n=15/47) 
5.3, ±8.5 
20% (n=3/15) 
0.7,±7.4 
4.6 
(-0.3-9.5) 
0.3 
Sexual function4 
89.4% (n=17/19) 
18.3, ±6.7 
33.3% (n=1/3) 
26.7, ±8.5 
8.3 
(-17.3-0.7) 
0.06 
Quality of life5 
Physical domain 
(D1) 
51% (n=25/49) 
57.1, ±18.3 
6.6% (n=1/15) 
76.7, ±11.6 
19.5 
(-29.6- -9.5) 
 
< 0.05 
Quality of life5 
Psychological domain 
(D2) 
42.8% (n=21/49) 
62.2, ±15.5 
20% (n=3/15) 
71.2, ±12.4 
9 
(-17.8- -0.2) 
 
< 0.05 
Quality of life5 
Social domain 
(D3) 
48.9% (n=24/49) 
61.7, ±19.8 
33.3% (n=5/15) 
70.9, ±19.1 
9.1 
(-20.8-2.4) 
0.1 
Quality of life5 
Environmental 
domain 
(D4) 
20.4% (n=10/49) 
63.8, ±17.5 
6.6% (n=1/15) 
74.5, ±12.7 
10.7 
(-19- -2.3) 
 
< 0.05 
Oral health problems6 
77.5% (n=38/49) 
21.6, ±11.4 
13.3% (n=2/15) 
5.6, ±6 
16 
(11.4-20.5) 
 
< 0.05 
Anxiety7 
51% (n=25/49) 
7.6, ±3.7 
13.3% (n=2/15) 
4.8, ±3.9 
2.8 
(0.6-5) 
 
< 0.05 
Depression7 
34.6% (n=17/49) 
5.6, ±3.2 
13.3% (n=2/15) 
2.4, ±3.3 
3.2 
(1.2-5.1) 
 
< 0.05 
1: Calculated as normal smell function of ≥30 in 0–40 scale; 2: Normal taste function of ≥9 in 0–16 scale; 3: 
Normal score of neurosensory function of taste <8 in a scale of -6 – 34; 4: Normal sexual function ≥26.5 in a 
scale of 0-36; 5: Overall QoL≥60 in a scale of 0-100; 6: No oral health problems = never, hardly ever and 
occasionally vs fairly often and very often; 7: Normal HADS scores <8.  
 **See table 3-1, 3-2 and 3-3 of data sources measurement. 
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5.4 SECONDARY OUTCOME RESULTS  
5.4.1 Objective 8: To evaluate the effect of smell, taste and sexual functions on QoL in 
pSS patients  
A: Impact on general QoL  
1. Physical domain 
The coefficients table shows no significant positive correlation between the sexual function 
(β=0.2, 95% CI=-0.8–2.1) of the sexually active patients and the physical life quality. Neither 
smell nor gustatory function impairment had an important effect on the physical domain in 
the pSS group (Table 5-16). 
Table 5-16 Coefficients’ table of the impact of the smell, gustatory and sexual functions on the 
physical domain of the WHOQoL-BRÉF. 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 45.302 53.484  .847 .412 -70.244 160.849 
Smell -.049 .635 -.018 -.078 .939 -1.421 1.322 
Gustation* .099 1.845 .016 .054 .958 -3.888 4.085 
FSFI** .647 .714 .260 .906 .381 -.895 2.190 
Age .236 .446 .158 .530 .605 -.728 1.200 
Smoking -10.498 20.361 -.134 -.516 .615 -54.485 33.490 
Alcohol 2.224 9.361 .059 .238 .816 -18.000 22.448 
Mouthwash -4.200 9.748 -.108 -.431 .674 -25.260 16.860 
Appliances 6.386 10.484 .142 .609 .553 -16.264 29.036 
Pain relief -6.181 10.490 -.154 -.589 .566 -28.844 16.482 
Gabapentin -11.830 15.865 -.181 -.746 .469 -46.104 22.444 
Other drugs -1.958 9.608 -.054 -.204 .842 -22.716 18.799 
Fatigue -10.056 17.243 -.154 -.583 .570 -47.308 27.196 
Dis duration -.166 .297 -.137 -.558 .587 -.807 .476 
 
R2=0.35 
Dependent Variable: Physical domain 
*Gustatory function measured by TST 
**FSFI for sexually active patients 
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2. Psychological domain  
The coefficients table shows no significant correlation between the sexual dysfunction 
(β=0.4, 95% CI=-0.4–2.1) of the sexually active pSS patients and the psychological domain 
of the patients’ life quality. The impairment of the smell and gustatory function did not have 
an important effect on the psychological domain in pSS group (Table 5-17). 
Table 5-17 Coefficients’ table of the impact of the smell, gustatory and sexual functions on the 
psychological domain of the WHOQoL-BRÉF 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 33.352 45.120  .739 .473 -64.124 
130.82
7 
Smell .253 .536 .115 .473 .644 -.904 1.410 
Gustation* .146 1.557 .029 .094 .927 -3.217 3.509 
FSFI** .897 .602 .442 1.489 .160 -.404 2.198 
Age .136 .376 .111 .361 .724 -.677 .949 
Smoking -11.015 17.177 -.171 -.641 .533 -48.123 26.093 
Alcohol 2.183 7.897 .070 .276 .787 -14.879 19.244 
Mouthwash -5.494 8.224 -.173 -.668 .516 -23.260 12.272 
Appliances -.509 8.845 -.014 -.058 .955 -19.616 18.599 
Pain relief -2.769 8.850 -.084 -.313 .759 -21.887 16.350 
Gabapentin 2.437 13.384 .046 .182 .858 -26.477 31.350 
Other drugs 5.308 8.106 .179 .655 .524 -12.203 22.819 
Fatigue -2.138 14.547 -.040 -.147 .885 -33.564 29.288 
Dis duration -.072 .251 -.073 -.287 .779 -.613 .469 
 
R2=0.31 
Dependent Variable: Psychological domain 
*Gustatory function measured by TST 
**FSFI for sexually active patients 
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3. Social domain 
The sexual function of the sexually active patients (β=0.6, 95% CI=0.3–3.3), appears to 
correlate significantly with this domain. The gustatory function (β=-0.2, 95% CI=-5.3-2.3) 
appears to have negative correlation with this domain but not statistically significant in pSS 
group. The smell had no important effect on the social life quality in pSS group (Table 5-18). 
Table 5-18 Coefficients’ table of the impact of the smell, gustatory and sexual functions on the social 
domain of the WHOQoL-BRÉF 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for  
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 37.640 51.502  .731 .478 -73.624 148.904 
Smell .326 .611 .110 .533 .603 -.995 1.646 
Gustation* -1.502 1.777 -.220 -.845 .413 -5.340 2.337 
FSFI** 1.860 .688 .679 2.706 .018 .375 3.346 
Age -.052 .430 -.032 -.121 .905 -.980 .876 
Smoking -9.339 19.606 -.108 -.476 .642 -51.696 33.018 
Alcohol .792 9.015 .019 .088 .931 -18.683 20.266 
Mouthwash .720 9.387 .017 .077 .940 -19.559 21.000 
Appliances -1.860 10.096 -.038 -.184 .857 -23.671 19.951 
Pain relief 5.403 10.101 .122 .535 .602 -16.420 27.226 
Gabapentin 2.399 15.277 .033 .157 .878 -30.605 35.403 
Other drugs 7.975 9.252 .199 .862 .404 -12.013 27.963 
Fatigue -11.150 16.604 -.155 -.672 .514 -47.022 24.721 
Dis duration .090 .286 .067 .313 .759 -.528 .708 
 
R2=0.51 
Dependent Variable: Social domain 
*Gustatory function measured by TST 
**FSFI for sexually active patients 
 
 
  
Results 
152 
 
4. Environmental domain 
The coefficients table shows that the sexual function (β=0.2, 95% CI=-0.7–1.9) and alcohol 
intake (β=0.2, 95% CI=-10.4–24.2) had correlated with the environmental living quality in 
the pSS group but not statistically significant. Neither smell nor gustatory function had an 
important effect on this domain in the pSS group (Table 5-19). 
Table 5-19 Coefficients’ table of the impact of the smell, gustatory and sexual functions on the 
environmental domain of the WHOQoL-BRÉF 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
 Interval for B 
B Std. Error Beta 
Lower  
Bound 
Upper  
Bound 
 (Constant) 53.897 46.581  1.157 .268 -46.735 154.529 
Smell .137 .553 .060 .248 .808 -1.057 1.331 
Gustation* -.423 1.607 -.081 -.263 .797 -3.895 3.049 
FSFI** .600 .622 .286 .966 .352 -.743 1.944 
Age .137 .389 .109 .352 .730 -.703 .976 
Smoking -11.099 17.733 -.167 -.626 .542 -49.409 27.211 
Alcohol 7.134 8.153 .223 .875 .397 -10.480 24.747 
Mouthwash -6.256 8.490 -.191 -.737 .474 -24.598 12.086 
Appliances -.596 9.131 -.016 -.065 .949 -20.322 19.131 
Pain relief -3.654 9.136 -.108 -.400 .696 -23.391 16.083 
Gabapentin 8.988 13.817 .163 .650 .527 -20.862 38.838 
Other drugs 4.973 8.368 .162 .594 .563 -13.105 23.051 
Fatigue -2.148 15.018 -.039 -.143 .888 -34.591 30.296 
Dis. duration -.143 .259 -.140 -.551 .591 -.702 .416 
R2=0.31 
Dependent Variable: Environmental domain 
*Gustatory function measured by TST 
**FSFI for sexually active patients 
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B: Impact on oral health related QoL  
1. Total score of OHIP-14 
Age (β=0.4, 95% CI=0.1–0.6) and alcohol intake (β=-0.3, 95% CI=-12.7–-1.4) were 
independent variables that had an effect on the oral health quality measured by OHIP-14. 
Gustatory function did not seem to have an important effect on the total oral health 
problems (Table 5-20). 
Table 5-20 Coefficients’ table of the impact of the gustatory function on the total score of OHIP-
14 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
 Interval for B 
B Std. Error Beta 
Lower  
Bound 
Upper  
Bound 
 (Constant) -4.024 11.859  -.339 .736 -27.868 19.820 
Gustation .388 .592 .108 .657 .515 -.801 1.578 
Age .378 .135 .437 2.789 .008 .105 .650 
Smoking 1.509 6.463 .033 .234 .816 -11.485 14.503 
Alcohol -7.055 2.808 -.322 -2.513 .015 -12.701 -1.410 
Mouthwash 5.373 2.971 .239 1.809 .077 -.601 11.347 
Appliances 1.542 3.342 .059 .461 .647 -5.178 8.262 
Pain relief -.393 3.093 -.017 -.127 .900 -6.611 5.826 
Gabapentin 3.984 5.011 .105 .795 .431 -6.092 14.060 
Other drugs -4.495 3.012 -.214 -1.492 .142 -10.551 1.562 
Dis. duration -.049 .091 -.070 -.542 .591 -.232 .133 
R2=0.27 
Dependent Variable: OHIP-14 total 
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2. Functional limitation  
Age (β=0.3, 95% CI=0.0–0.0) and mouthwash (β=0.2, 95% CI=0–1.1) were independent 
factors that affected the oral health function. The gustatory function did not have an 
important effect on this domain in the pSS group (Table 5-21).  
Table 5-21 Coefficients’ table of the impact of the gustatory function on the functional 
limitation of OHIP-14 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
 Interval for B 
B Std. Error Beta 
Lower 
 Bound 
Upper 
Bound 
 (Constant) -.038 1.159  -.032 .974 -2.369 2.293 
Gustation* -.036 .058 -.104 -.631 .531 -.153 .080 
Age .029 .013 .341 2.183 .034 .002 .056 
Smoking .444 .632 .099 .702 .486 -.827 1.714 
Alcohol -.460 .275 -.214 -1.676 .100 -1.012 .092 
Mouthwash .599 .290 .272 2.063 .044 .015 1.183 
Appliances .396 .327 .155 1.211 .232 -.261 1.053 
Pain relief .027 .302 .012 .090 .928 -.581 .635 
Gabapentin -.356 .490 -.096 -.727 .471 -1.341 .629 
Other drugs -.066 .294 -.032 -.225 .823 -.659 .526 
Dis.duration -.004 .009 -.062 -.476 .636 -.022 .014 
R2=0.27 
Dependent Variable: Functional limitation 
*Gustatory function measured by TST 
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3.  Physical pain  
Miscellaneous drugs that were grouped as “Other drugs” had the highest effect on the 
prediction of this domain, however, this variable was not considered as a predicting factor 
as it consists of a number of drugs with different effects on the body (Table 5-22). 
Table 5-22 Coefficients’ table of the impact of the gustatory function on the physical pain of OHIP-14 
Model 
Unstandardized  
coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interal for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) .655 1.116  .587 .560 -1.588 2.899 
Gustation* -.001 .056 -.005 -.027 .979 -.113 .110 
Age .022 .013 .278 1.722 .092 -.004 .048 
Smoking .642 .608 .154 1.056 .296 -.580 1.865 
Alcohol -.299 .264 -.149 -1.132 .263 -.830 .232 
Mouthwash .465 .280 .226 1.662 .103 -.097 1.027 
Appliances -.358 .314 -.151 -1.140 .260 -.991 .274 
Pain relief .213 .291 .100 .732 .468 -.372 .798 
Gabapentin .391 .472 .113 .830 .411 -.557 1.339 
Other drugs -.673 .283 -.350 -2.373 .022 -1.243 -.103 
Dis duration -.005 .009 -.074 -.551 .584 -.022 .012 
 
R2=0.22 
Dependent Variable: Physical pain 
*Gustatory function measured by TST 
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4. Psychological discomfort 
Age (β=0.3, 95% CI=0-0) and Gabapentin (β=0.3, 95% CI=0.1–2.2) followed by alcohol intake 
(β=-0.2, 95% CI=-1.1–0) were independent factors that had affected the psychological 
discomfort domain. The gustatory function had no important effect on this domain in the 
pSS group (Table 5-23). 
Table 5-23 Coefficients’ table of the impact of the gustatory function on the psychological 
discomfort of OHIP-14 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) -.361 1.239  -.291 .772 -2.851 2.130 
Gustation* .060 .062 .159 .969 .337 -.064 .184 
Age .032 .014 .358 2.294 .026 .004 .061 
Smoking -.102 .675 -.021 -.151 .881 -1.459 1.255 
Alcohol -.609 .293 -.265 -2.077 .043 -1.199 -.019 
Mouthwash .324 .310 .138 1.044 .302 -.300 .948 
Appliances .434 .349 .160 1.243 .220 -.268 1.136 
Pain relief -.193 .323 -.079 -.598 .553 -.842 .456 
Gabapentin 1.244 .523 .314 2.377 .021 .192 2.297 
Other drugs -.477 .315 -.216 -1.518 .136 -1.110 .155 
Dis duration -.010 .009 -.132 -1.018 .314 -.029 .009 
 
R2=0.27 
Dependent Variable: Psychological discomfort 
*Gustatory function measured by TST 
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5. Physical disability 
Age (β=0.4, 95% CI=0-0) followed by alcohol intake (β=-0.2, 95% CI=-1–0) appear to have an 
effect on patients’ oral physical ability in this model. The gustatory function (β=0.2, 95% 
CI=0–0.1) associated with this domain but not statistically significant (Table 5-24). 
Table 5-24 Coefficients’ table of the impact of the gustatory function on the physical disability of 
OHIP-14 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) -.918 1.045  -.878 .384 -3.018 1.183 
Gustation* .072 .052 .233 1.373 .176 -.033 .176 
Age .033 .012 .450 2.794 .007 .009 .057 
Smoking .223 .569 .057 .392 .697 -.921 1.368 
Alcohol -.544 .247 -.289 -2.199 .033 -1.041 -.047 
Mouthwash .386 .262 .200 1.475 .147 -.140 .912 
Appliances -.196 .294 -.088 -.664 .510 -.787 .396 
Pain relief -.070 .272 -.035 -.257 .798 -.618 .478 
Gabapentin -.349 .441 -.108 -.791 .433 -1.237 .538 
Other drugs -.356 .265 -.197 -1.342 .186 -.890 .177 
Dis duration -.006 .008 -.101 -.756 .453 -.022 .010 
 
R2=0.23 
Dependent Variable: Physical disability 
*Gustatory function measured by TST 
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6. Psychological disability 
Alcohol intake (β=-0.3, 95% CI=-0.3 - -0.1) appears to be an independent factor that had an 
effect on this domain in the pSS group. The gustatory function had no important effect on 
the psychological disability of the oral health quality in the pSS group (Table 5-25). 
Table 5-25 Coefficients’ table of the impact of the gustatory function on the psychological 
disability of OHIP-14 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Intervalfor B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) -.040 1.098  -.036 .971 -2.248 2.169 
Gustation* .042 .055 .128 .766 .447 -.068 .152 
Age .024 .013 .305 1.916 .061 -.001 .049 
Smoking -.300 .599 -.072 -.501 .619 -1.503 .904 
Alcohol -.652 .260 -.326 -2.506 .016 -1.175 -.129 
Mouthwash .255 .275 .124 .925 .359 -.299 .808 
Appliances .438 .310 .185 1.416 .163 -.184 1.061 
Pain relief -.305 .286 -.144 -1.066 .292 -.881 .271 
Gabapentin .560 .464 .163 1.206 .234 -.374 1.493 
Other drugs -.326 .279 -.170 -1.169 .248 -.887 .235 
Dis duration -.004 .008 -.062 -.468 .642 -.021 .013 
 
R2=0.24 
Dependent Variable: Psychological disability 
*Gustatory function measured by TST 
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7. Social disability 
Alcohol intake (β=-0.3, 95% CI=-1–0) appears to have significant effect on this domain. The 
gustatory function had no important effect on the social disability of the oral health quality 
in pSS group (Table 5-26). 
Table 5-26 Coefficients’ table of the impact of the gustatory function on the social disability 
domain of OHIP-14 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) -.475 1.007  -.472 .639 -2.499 1.549 
Gustation* .033 .050 .114 .662 .511 -.068 .134 
Age .021 .011 .303 1.848 .071 -.002 .044 
Smoking -.423 .549 -.115 -.772 .444 -1.526 .680 
Alcohol -.550 .238 -.309 -2.309 .025 -1.030 -.071 
Mouthwash .402 .252 .220 1.595 .117 -.105 .909 
Appliances .111 .284 .053 .392 .697 -.459 .682 
Pain relief -.133 .263 -.070 -.505 .616 -.660 .395 
Gabapentin .222 .425 .072 .521 .605 -.634 1.077 
Other drugs -.144 .256 -.084 -.563 .576 -.658 .370 
Dis duration .000 .008 -.003 -.023 .981 -.016 .015 
 
R2=0.2 
Dependent Variable: Social disability 
*Gustatory function measured by TST 
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8.   Handicap 
The gustatory function had no important effect on this domain. None of the variables in the 
model had an independent effect on the outcome (Table 5-27).  
Table 5-27 Coefficients’ table of the impact of the gustatory function on the handicap domain of 
OHIP-14 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) -.825 1.150  -.717 .477 -3.138 1.488 
Gustation* .034 .057 .104 .591 .557 -.081 .149 
Age .024 .013 .312 1.861 .069 -.002 .051 
Smoking .168 .627 .041 .267 .790 -1.093 1.428 
Alcohol -.431 .272 -.217 -1.583 .120 -.979 .116 
Mouthwash .303 .288 .149 1.053 .298 -.276 .883 
Appliances .219 .324 .093 .674 .503 -.433 .870 
Pain relief .265 .300 .126 .885 .381 -.338 .869 
Gabapentin .275 .486 .081 .567 .574 -.702 1.253 
Other drugs -.205 .292 -.108 -.703 .485 -.793 .382 
Dis duration .003 .009 .053 .383 .704 -.014 .021 
 
R2=0.16 
Dependent Variable: Handicap 
*Gustatory function measured by TST 
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C: Impact on mental health well-being  
1. Anxiety  
Anxiety appears to be negatively affected by the sexual function of the sexually active 
patients (β=-0.5, 95% CI=-0.5–0), however, the correlation was not statically significant. 
Neither smell nor gustatory dysfunction had increased anxiety symptoms in the pSS group 
(Table 5-28).  
Table 5-28 Coefficients’ table of the impact of the smell, taste and sexual functions on anxiety 
assessed by HADS  
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 21.460 11.209  1.915 .080 -2.963 45.883 
Smell .055 .144 .103 .385 .707 -.259 .370 
Gustation* -.240 .380 -.193 -.633 .538 -1.067 .587 
FSFI** -.278 .146 -.555 -1.903 .081 -.596 .040 
Age -.093 .091 -.310 -1.023 .327 -.292 .105 
Smoking .714 4.169 .045 .171 .867 -8.370 9.799 
Alcohol -1.153 1.925 -.151 -.599 .560 -5.346 3.040 
Mouthwash .348 2.065 .044 .168 .869 -4.151 4.846 
Appliances .763 2.142 .085 .356 .728 -3.903 5.430 
Topical .715 1.569 .120 .456 .657 -2.704 4.133 
Pain relief -.337 2.165 -.042 -.155 .879 -5.054 4.381 
Gabapentin -.529 3.259 -.040 -.162 .874 -7.630 6.573 
Other drugs -1.980 1.965 -.270 -1.007 .334 -6.262 2.303 
Fatigue -2.113 3.543 -.161 -.596 .562 -9.833 5.607 
Dis duration .006 .061 .024 .095 .926 -.126 .138 
 
R2=0.39 
Dependent Variable: Anxiety 
** FSFI for sexually active patients 
*Gustatory function measured by TST 
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2. Depression  
Depression symptoms seem to be associated with the sexual dysfunction of the sexually 
active patients (β=-0.5, 95% CI=-0.5–0). However, the correlation was not statistically 
significant. Neither smell nor gustation dysfunction had important effect on the severity of 
depression symptoms in pSS group (Table 5-29).  
 
Table 5-29 Coefficients’ table of the impact of smell, taste and sexual functions on depression 
assessed by HADS 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 (Constant) 15.112 10.435  1.448 .173 -7.625 37.849 
Smell -.064 .134 -.118 -.476 .642 -.356 .228 
Gustation* -.007 .353 -.005 -.019 .985 -.777 .763 
FSFI ** -.282 .136 -.563 -2.077 .060 -.578 .014 
Age -.041 .085 -.138 -.489 .634 -.226 .143 
Smoking .714 3.882 .045 .184 .857 -7.743 9.171 
Alcohol -.703 1.792 -.092 -.392 .702 -4.607 3.201 
Mouthwash 1.038 1.922 .132 .540 .599 -3.150 5.226 
Appliances -.038 1.994 -.004 -.019 .985 -4.383 4.306 
Topical .206 1.461 .035 .141 .890 -2.976 3.389 
Pain relief .956 2.016 .118 .474 .644 -3.436 5.348 
Gabapentin -2.013 3.034 -.153 -.663 .520 -8.624 4.598 
Other drugs -1.865 1.830 -.254 -1.019 .328 -5.852 2.121 
Fatigue .251 3.299 .019 .076 .941 -6.937 7.438 
Dis. duration .023 .056 .094 .405 .693 -.100 .146 
R2=0.47 
Dependent Variable: Depression 
*Gustatory function measured by TST 
         ** FSFI for sexually active patients  
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5.4.2 Objective 9: To investigate whether the senses of smell and gustatory function are 
correlated with each other. 
 pSS group 
In the correlation test between the smell and gustatory function, no significant correlation 
was found in the patients group (r=0.05, p=0.6) (Figure 5-4).  
In the regression model, age (β=-0.0, 95% CI=-0.1–0) followed by pain relief medicines 
(β=0.2, 95% CI=0.2–3.2) had contributed to the prediction of gustation. Smell did not 
correlate with gustation in the pSS group (Table 5-30).  
Table 5-30 Coefficients’ table of the relation of the smell and gustation in the pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 16.779 2.816  5.959 .000 11.111 22.447 
Smell -.024 .055 -.056 -.440 .662 -.135 .087 
Age -.122 .029 -.507 -4.201 .000 -.181 -.064 
Smoking -1.387 1.607 -.109 -.863 .392 -4.622 1.847 
Alcohol .111 .716 .018 .154 .878 -1.331 1.553 
Mouthwash -1.468 .770 -.234 -1.907 .063 -3.017 .081 
Appliances -1.048 .815 -.145 -1.287 .205 -2.689 .592 
Topical  -.476 .605 -.100 -.786 .436 -1.694 .742 
Pain relief 1.731 .730 .267 2.370 .022 .261 3.201 
Gabapentin -1.795 1.233 -.170 -1.455 .152 -4.278 .688 
Other drugs 1.285 .722 .219 1.779 .082 -.169 2.739 
Fatigue -.115 1.294 -.011 -.089 .929 -2.719 2.489 
Dis duration .025 .023 .130 1.115 .270 -.020 .071 
 
R2=0.45 
Dependent Variable: Total gustatory score. 
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Figure 5-4 Correlation of the smell and the total score 
of gustatory function in pSS group 
 
 Healthy volunteers group 
In the correlation test between the smell and gustation, a significant positive correlation was 
found in the healthy volunteers group (r=0.2) (Figure 5-5). In the regression model, age (β=-0.3, 
95% CI=0–0) was independent variable that contributed to the prediction of taste. Smell did not 
contribute to the prediction of gustation in this group (Table 5-31).  
Table 5-31 Coefficients’ table of the relation of the smell and gustation in the healthy volunteers  
 group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 11.765 2.513  4.681 .000 6.724 16.805 
Smell .085 .060 .193 1.409 .165 -.036 .206 
Age -.049 .019 -.342 -2.513 .015 -.088 -.010 
Smoking -.758 1.053 -.089 -.720 .475 -2.870 1.354 
Alcohol -.223 .551 -.051 -.405 .687 -1.329 .882 
Mouthwash .512 .522 .122 .982 .330 -.534 1.559 
Appliances .047 .586 .010 .081 .936 -1.129 1.223 
R2=0.23 
Dependent Variable: Total gustatory score  
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Figure 5-5 Correlation of the smell and taste in 
 the healthy volunteers group 
 
 
 Total population 
In the correlation test between the smell and gustation, a significant positive correlation 
was found in the total population of the study (r=0.29) (Figure 5-6). In the regression model, 
age (β=-0.5, 95% CI=-0.1–0) was the only variable that contributed to the prediction of taste. 
Smell did not contribute to the prediction of taste in the total population of the study (Table 
5-32).  
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Table 5-32 Coefficients’ table of the relation of the smell and gustation in the total population 
 of the study 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 15.781 1.822  8.664 .000 12.174 19.388 
Smell .048 .041 .089 1.170 .245 -.033 .128 
Age -.116 .017 -.543 -6.892 .000 -.150 -.083 
Smoking -1.040 1.000 -.075 -1.041 .300 -3.020 .939 
Alcohol -.337 .501 -.049 -.672 .503 -1.329 .656 
Mouthwash -.815 .494 -.119 -1.649 .102 -1.794 .164 
Appliances -1.054 .654 -.118 -1.611 .110 -2.350 .242 
 
R2=0.40 
Dependent Variable: Total gustatory score of total population 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Figure 5-6 Correlation of the smell and gustation in the total  
         population of the study 
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5.4.3 Objective 10: To study the correlation of the degree of smell function and the 
severity of oral dryness 
The severity of oral dryness that was assessed by USFR, SSFR and CODS had no important 
contribution to the prediction of smell function in pSS group. The topical medicines appear 
to have an independent effect on the smell in the three models. Disease duration showed 
no correlation with the smell function in pSS group (Table 5-33, 34 and 35).  
Table 5-33 Coefficients’ table of the impact of the USFR on the smell function in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta   Lower 
Bound 
Upper 
Bound 
  (Constant) 32.452 4.674  6.944 .000 23.078 41.826 
 USFR 1.931 6.534 .039 .296 .769 -11.174 15.036 
 Age -.049 .074 -.088 -.661 .511 -.196 .099 
 Smoking -.645 3.858 -.022 -.167 .868 -8.384 7.094 
 Alcohol 1.628 1.779 .115 .915 .364 -1.939 5.196 
 Topical -4.465 1.395 -.406 -3.200 .002 -7.263 -1.666 
 Dis. duration .036 .057 .081 .640 .525 -.078 .151 
R2=0.19 
Dependent Variable: Smell 
 
      Table 5-34 Coefficients’ table of the impact of the SSFR on the smell function in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 
(Constant) 31.204 4.802  6.497 .000 21.571 40.836 
SSFR 1.190 1.400 .116 .850 .399 -1.618 3.999 
Age -.041 .074 -.074 -.555 .581 -.188 .107 
Smoking -.814 3.798 -.028 -.214 .831 -8.432 6.804 
Alcohol 1.904 1.799 .135 1.059 .295 -1.704 5.512 
Topical -4.288 1.395 -.390 -3.074 .003 -7.085 -1.490 
Dis. duration .042 .057 .094 .738 .464 -.072 .157 
R2=0.2 
Dependent Variable: Smell 
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Table 5-35 Coefficients’ table of the impact of CODS on the smell function in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 (Constant) 33.548 4.640  7.230 .000 24.237 42.858 
 CODS -.205 .485 -.057 -.422 .675 -1.179 .769 
 Age -.043 .076 -.078 -.568 .572 -.196 .110 
 Smoking -.383 3.830 -.013 -.100 .921 -8.069 7.302 
 Alcohol 1.535 1.778 .109 .863 .392 -2.033 5.103 
 Topical -4.405 1.420 -.400 -3.102 .003 -7.254 -1.555 
 Dis. duration .040 .058 .088 .683 .498 -.077 .156 
R2=0.19 
Dependent Variable: Smell 
 
5.4.4 Objective 11: To study the correlation of the degree of taste function to the severity 
of oral dryness  
A: Gustatory function in the pSS group  
1. Total gustation score 
Oral dryness that was assessed by USFR, SSFR and CODS did not correlate with the gustatory 
function in pSS group. Age, mouthwash and pain relief medicines appeared to have 
independent effect on the tasting ability in the three models. Disease duration showed no 
correlation with gustation in pSS group (Tables 5-36, 5-37 and 5-38). 
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Table 5-36 Coefficients’ table of the impact of USFR on the total gustatory function in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 16.303 1.924  8.474 .000 12.435 20.172 
USFR -1.816 2.516 -.085 -.722 .474 -6.875 3.243 
Age -.125 .028 -.518 -4.425 .000 -.182 -.068 
Smoking -1.047 1.590 -.083 -.658 .513 -4.244 2.150 
Alcohol -.033 .691 -.005 -.048 .962 -1.421 1.355 
Mouthwash -1.397 .699 -.223 -1.999 .051 -2.802 .008 
Appliances -1.152 .805 -.159 -1.431 .159 -2.772 .467 
Pain relief 1.622 .714 .251 2.272 .028 .187 3.058 
Gabapentin -1.879 1.202 -.178 -1.563 .125 -4.296 .538 
Other drugs 1.266 .708 .216 1.788 .080 -.158 2.689 
Dis. duration .024 .022 .123 1.104 .275 -.020 .068 
 
R2=0.44 
Dependent Variable: Total gustation 
 
Table 5-37 Coefficients’ table of the impact of SSFR on the total gustatory function in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 16.206 1.949  8.315 .000 12.287 20.125 
SSFR -.297 .539 -.067 -.550 .585 -1.380 .787 
Age -.125 .028 -.517 -4.380 .000 -.182 -.067 
Smoking -1.208 1.566 -.095 -.772 .444 -4.357 1.941 
Alcohol -.033 .698 -.005 -.047 .963 -1.437 1.372 
Mouthwash -1.361 .697 -.217 -1.952 .057 -2.762 .041 
Appliances -1.134 .807 -.157 -1.404 .167 -2.757 .490 
Pain relief 1.705 .717 .263 2.379 .021 .264 3.146 
Gabapentin -1.784 1.194 -.169 -1.494 .142 -4.184 .616 
Other drugs 1.348 .719 .230 1.876 .067 -.097 2.794 
Dis. duration .023 .022 .117 1.042 .303 -.021 .067 
 
R2=0.44 
Dependent Variable: Total gustation 
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Table 5-38 Coefficients’ table of the impact of CODS on the total gustatory function in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
(Constant) 15.482 1.853  8.358 .000 11.758 19.207 
CODS .122 .217 .079 .564 .576 -.314 .558 
Age -.128 .030 -.530 -4.262 .000 -.188 -.067 
Smoking -1.426 1.583 -.112 -.901 .372 -4.610 1.757 
Alcohol .092 .687 .015 .133 .895 -1.290 1.473 
Mouthwash -1.455 .724 -.232 -2.009 .050 -2.912 .001 
Appliances -1.216 .841 -.168 -1.446 .155 -2.907 .475 
Pain relief 1.739 .725 .269 2.399 .020 .282 3.197 
Gabapentin -1.610 1.220 -.153 -1.319 .193 -4.063 .843 
Other drugs 1.421 .750 .242 1.895 .064 -.087 2.929 
Dis. duration .022 .022 .114 1.007 .319 -.022 .067 
 
R2=0.44 
Dependent Variable: Total gustation 
 
2. Sweet 
The whole mouth tasting ability is represented by examining the tip of the tongue, as per 
the TST manual instructions. The severity of oral dryness that was tested by USFR, SSFR and 
CODS did not contribute to the ability to taste sweet in pSS group. Age and pain relief 
medicines appear to affect the ability of tasting sweet. Duration of the disorder showed no 
effect on tasting sweet (Table 5-39, 5-40 and 5-41). 
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Table 5-39 Coefficients’ table of the impact of USFR on the sweet tasting ability in pSS 
group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 
(Constant) 5.126 .817  6.274 .000 3.483 6.769 
USFR -.693 1.069 -.086 -.648 .520 -2.841 1.456 
Age -.031 .012 -.341 -2.604 .012 -.055 -.007 
Smoking .454 .675 .094 .672 .505 -.904 1.812 
Alcohol -.435 .293 -.188 -1.483 .145 -1.025 .155 
Mouthwash -.328 .297 -.138 -1.105 .275 -.925 .269 
Appliances -.344 .342 -.125 -1.006 .319 -1.032 .344 
Pain relief .575 .303 .234 1.897 .064 -.035 1.185 
Gabapentin -.821 .510 -.205 -1.608 .114 -1.847 .206 
Other drugs .076 .301 .034 .251 .803 -.529 .680 
Dis. duration .005 .009 .071 .570 .571 -.013 .024 
R2=0.3 
Dependent Variable: Sweet (tip of the tongue) 
 
Table 5-40 Coefficients’ table of the impact of SSFR on the sweet tasting ability in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 
(Constant) 4.992 .829  6.021 .000 3.325 6.659 
SSFR -.047 .229 -.028 -.203 .840 -.508 .414 
Age -.030 .012 -.333 -2.514 .015 -.055 -.006 
Smoking .377 .666 .078 .566 .574 -.963 1.716 
Alcohol -.417 .297 -.180 -1.403 .167 -1.014 .181 
Mouthwash -.310 .297 -.130 -1.045 .301 -.906 .286 
Appliances -.322 .344 -.117 -.938 .353 -1.013 .369 
Pain relief .598 .305 .243 1.960 .056 -.015 1.211 
Gabapentin -.778 .508 -.195 -1.533 .132 -1.799 .243 
Other drugs .092 .306 .042 .302 .764 -.522 .707 
Dis. duration .005 .009 .070 .550 .585 -.014 .024 
R2=0.3 
Dependent Variable: Sweet (tip of the tongue) 
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Table 5-41 Coefficients’ table of the impact of CODS on the sweet tasting ability in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
T Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) 4.767 .784  6.078 .000 3.190 6.344 
CODS .066 .092 .112 .721 .474 -.118 .251 
Age -.033 .013 -.364 -2.623 .012 -.059 -.008 
Smoking .285 .670 .059 .425 .672 -1.062 1.633 
Alcohol -.380 .291 -.164 -1.308 .197 -.966 .205 
Mouthwash -.368 .307 -.155 -1.200 .236 -.985 .248 
Appliances -.392 .356 -.143 -1.102 .276 -1.108 .323 
Pain relief .632 .307 .257 2.058 .045 .014 1.249 
Gabapentin -.695 .517 -.174 -1.345 .185 -1.733 .344 
Other drugs .157 .318 .071 .494 .623 -.481 .795 
Dis. duration .004 .009 .058 .455 .651 -.015 .023 
   R2=0.31 
   Dependent Variable: Sweet (tip of the tongue) 
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3. Sour 
None of the oral dryness tests (USFR, SSFR and CODS) contributed to the prediction of the 
ability to taste sour in the pSS group. Age appears to have an independent effect on tasting 
sour (Tables 5-42, 5-43 and 5-44). 
Table 5-42Coefficients’ table of the impact of USFR on the sour tasting ability in pSS group 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 
     
   (Constant) 3.598 .665  5.406 .000 2.260 4.936 
   USFR .547 .870 .086 .629 .532 -1.202 2.297 
   Age -.021 .010 -.294 -2.170 .035 -.041 -.002 
   Smoking -.276 .550 -.073 -.502 .618 -1.382 .830 
   Alcohol -.238 .239 -.130 -.996 .324 -.718 .242 
   Mouthwash .015 .242 .008 .062 .951 -.471 .501 
   Appliances -.222 .279 -.102 -.796 .430 -.782 .338 
    Pain relief .195 .247 .101 .790 .434 -.302 .691 
   Gabapentin -.585 .416 -.186 -1.406 .166 -1.421 .251 
   Other drugs .510 .245 .291 2.084 .042 .018 1.003 
   Dis. duration .000 .008 -.002 -.018 .986 -.015 .015 
R2=0.26 
Dependent Variable: Sour (tip of the tongue) 
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Table 5-43 Coefficients’ table of the impact of SSFR on the sour tasting ability in pSS group 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
  
   (Constant) 3.490 .669  5.219 .000 2.145 4.834 
   SSFR .183 .185 .137 .989 .327 -.189 .555 
   Age -.020 .010 -.282 -2.080 .043 -.040 -.001 
   Smoking -.249 .537 -.066 -.464 .645 -1.330 .831 
   Alcohol -.213 .240 -.116 -.887 .379 -.694 .269 
   Mouthwash .010 .239 .005 .041 .968 -.471 .491 
   Appliances -.206 .277 -.095 -.745 .460 -.763 .351 
   Pain relief .158 .246 .081 .641 .525 -.337 .652 
   Gabapentin -.604 .409 -.192 -1.476 .146 -1.428 .219 
   Other drugs .465 .247 .265 1.885 .065 -.031 .961 
  Dis. duration .001 .008 .011 .087 .931 -.014 .016 
R2=0.27 
Dependent Variable: Sour (tip of the tongue) 
 
Table 5-44 Coefficients’ table of the impact of CODS on the sour tasting ability in pSS group 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 
  (Constant) 3.511 .629  5.583 .000 2.246 4.775 
  CODS .105 .074 .226 1.427 .160 -.043 .253 
  Age -.027 .010 -.381 -2.701 .010 -.048 -.007 
  Smoking -.335 .537 -.088 -.623 .536 -1.415 .746 
  Alcohol -.225 .233 -.123 -.963 .340 -.694 .244 
  Mouthwash -.098 .246 -.052 -.399 .691 -.593 .396 
  Appliances -.375 .285 -.174 -1.315 .195 -.949 .198 
  Pain relief .246 .246 .127 .999 .323 -.249 .741 
  Gabapentin -.496 .414 -.158 -1.199 .237 -1.329 .336 
  Other drugs .624 .255 .355 2.449 .018 .112 1.136 
  Dis.duration -.002 .007 -.033 -.260 .796 -.017 .013 
R2=0.28 
Dependent Variable: Sour (tip of the tongue) 
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4. Salt 
The severity of oral dryness that was assessed by USFR, SSFR and CODS did not contribute 
to the prediction of the salt tasting ability in pSS group. Age showed an independent effect 
on tasting salt in the three models (Tables 5-45, 5-46 and 5-47).  
Table 5-45 Coefficients’ table of the impact of USFR on the salt tasting ability in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 
  (Constant) 4.579 .839  5.459 .000 2.893 6.266 
  USFR .584 1.097 .069 .533 .597 -1.621 2.790 
  Age -.039 .012 -.402 -3.130 .003 -.063 -.014 
  Smoking .780 .693 .155 1.125 .266 -.614 2.174 
  Alcohol .244 .301 .101 .812 .421 -.361 .850 
  Mouthwash -.533 .305 -.214 -1.749 .087 -1.146 .080 
  Appliances -.350 .351 -.122 -.997 .324 -1.056 .356 
  Pain relief .520 .311 .202 1.671 .101 -.106 1.146 
  Gabapentin -.422 .524 -.101 -.805 .425 -1.475 .632 
  Other drugs -.130 .309 -.056 -.420 .677 -.750 .491 
  Dis. duration .006 .009 .076 .618 .539 -.013 .025 
R2=0.33 
Dependent Variable: Salt (tip of the tongue) 
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    Table 5-46 Coefficients’ table of the impact of SSFR on the salt tasting ability in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 
(Constant) 4.772 .850  5.612 .000 3.062 6.481 
SSFR -.014 .235 -.008 -.061 .951 -.487 .458 
Age -.040 .012 -.415 -3.200 .002 -.065 -.015 
Smoking .857 .683 .170 1.255 .216 -.517 2.231 
Alcohol .215 .305 .088 .704 .485 -.398 .827 
Mouthwash -.551 .304 -.221 -1.812 .076 -1.163 .060 
Appliances -.381 .352 -.132 -1.081 .285 -1.089 .328 
Pain relief .508 .313 .197 1.625 .111 -.120 1.137 
Gabapentin -.463 .521 -.111 -.888 .379 -1.510 .584 
Other drugs -.132 .314 -.057 -.421 .676 -.763 .499 
Dis. duration .006 .010 .074 .597 .553 -.014 .025 
R2=0.33 
Dependent Variable: Salt (tip of the tongue) 
 
    Table 5-47 Coefficients’ table of the impact of CODS on the salt tasting ability in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower 
Bound 
Upper 
Bound 
 
(Constant) 4.931 .803  6.141 .000 3.316 6.545 
CODS -.076 .094 -.124 -.812 .421 -.265 .113 
Age -.036 .013 -.373 -2.750 .008 -.062 -.010 
Smoking .947 .686 .188 1.380 .174 -.433 2.327 
Alcohol .191 .298 .079 .642 .524 -.408 .790 
Mouthwash -.480 .314 -.193 -1.529 .133 -1.111 .151 
Appliances -.284 .364 -.099 -.780 .439 -1.017 .448 
Pain relief .460 .314 .179 1.464 .150 -.172 1.092 
Gabapentin -.552 .529 -.132 -1.045 .301 -1.616 .511 
Other drugs -.221 .325 -.095 -.681 .499 -.875 .432 
Dis. duration .007 .010 .091 .736 .465 -.012 .026 
R2=0.34 
Dependent Variable: Salt (tip of the tongue) 
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5. Bitter 
Among the three oral dryness tests (USFR, SSFR and CODS), only the unstimulated salivary 
flow rate had contributed to the ability to taste bitter in the pSS group. Age and oral 
appliances were independent factors in the three models (Tables 5-48, 5-49 and 5-50).   
Table 5-48 Coefficients’ table of the impact of USFR on the bitter tasting ability in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) 5.862 .737  7.949 .000 4.379 7.345 
USFR -2.060 .964 -.245 -2.136 .038 -3.999 -.121 
Age -.058 .011 -.608 -5.365 .000 -.080 -.036 
Smoking -.803 .609 -.160 -1.318 .194 -2.028 .422 
Alcohol .238 .265 .098 .899 .373 -.294 .770 
Mouthwash -.434 .268 -.175 -1.622 .111 -.973 .104 
Appliances -.789 .309 -.275 -2.555 .014 -1.409 -.168 
Pain relief .274 .274 .107 1.001 .322 -.276 .824 
Gabapentin .012 .461 .003 .025 .980 -.915 .938 
Other drugs .461 .271 .199 1.700 .096 -.084 1.007 
Dis. duration .007 .008 .088 .817 .418 -.010 .024 
R2=0.48 
Dependent Variable: Bitter (The tip of the tongue) 
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Table 5-49 Coefficients’ table of the impact of SSFR on the bitter tasting ability in pSS 
group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) 5.376 .779  6.904 .000 3.811 6.942 
SSFR -.081 .215 -.046 -.375 .709 -.514 .352 
Age -.055 .011 -.578 -4.847 .000 -.078 -.032 
Smoking -1.046 .626 -.208 -1.671 .101 -2.304 .213 
Alcohol .308 .279 .127 1.102 .276 -.254 .869 
Mouthwash -.378 .279 -.152 -1.356 .182 -.938 .182 
Appliances -.710 .323 -.248 -2.200 .033 -1.359 -.061 
Pain relief .333 .286 .130 1.164 .250 -.243 .909 
Gabapentin .144 .477 .034 .302 .764 -.815 1.103 
Other drugs .499 .287 .215 1.737 .089 -.079 1.076 
Dis. 
duration 
.007 .009 .087 .764 .448 -.011 .024 
R2=0.43 
Dependent Variable: Bitter (tip of the tongue) 
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    Table 5-50 Coefficients’ table of the impact of CODS on the bitter tasting ability in pSS 
group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) 5.025 .731  6.870 .000 3.555 6.496 
CODS .099 .086 .160 1.152 .255 -.073 .271 
Age -.059 .012 -.621 -5.007 .000 -.083 -.035 
Smoking -1.185 .625 -.236 -1.895 .064 -2.441 .072 
Alcohol .365 .271 .151 1.345 .185 -.181 .910 
Mouthwash -.464 .286 -.187 -1.621 .111 -1.039 .111 
Appliances -.812 .332 -.284 -2.446 .018 -1.480 -.145 
Pain relief .382 .286 .149 1.336 .188 -.193 .958 
Gabapentin .269 .482 .065 .559 .579 -.699 1.238 
Other drugs .593 .296 .255 2.001 .051 -.003 1.188 
Dis. 
duration 
.005 .009 .071 .625 .535 -.012 .023 
R2=0.44 
Dependent Variable: Bitter (tip of the tongue) 
 
 
B: Gustatory function in the pooled population 
Additional regression analyses were added to the Appendices (Appendix 27, page: 339-340) 
in the thesis, where the outcome was the gustatory function, the control participants were 
included in the analysis, and the physiological measures (Stimulated Salivary Flow, 
Unstimulated Salivary Flow and CODS) were entered into the prediction. The severity of oral 
dryness that was measured by USFR and CODS had significant contribution (β=0.2 and β=0.4 
respectively) to the gustatory function of taste in the total population of the study, unlike 
the SSFR, which had no significant contribution to the taste deterioration in the total 
population (Appendix 27). Age had moderated the association between the oral dryness 
and gustation with significant R2 change (USFR=17%, SSFR=20% and CODS=8%).     
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C: Neurosensory threshold in the pSS group 
The severity of oral dryness that was measured by USFR, SSFR and CODS did not contribute 
to the prediction of the neurosensory threshold of taste in pSS group. Mouthwash was 
independent factor on the prediction of the neurosensory threshold in the three models 
(Tables 5-51, 5-52 and 5-53). 
Table 5-51 Coefficients’ table of the impact of USFR on the neurosensory function of taste in 
pSS group 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
          
(  Constant) -1.173 6.349  -.185 .854 -13.945 11.599 
UUSFR -2.953 8.302 -.048 -.356 .724 -19.655 13.748 
    Age .114 .093 .165 1.226 .226 -.073 .301 
    Smoking 9.844 5.247 .270 1.876 .067 -.711 20.399 
    Alcohol -3.726 2.279 -.212 -1.635 .109 -8.310 .859 
   Mouthwash 6.161 2.306 .343 2.672 .010 1.522 10.801 
   Appliances 1.392 2.657 .067 .524 .603 -3.954 6.737 
   Pain relief -2.666 2.356 -.143 -1.132 .263 -7.405 2.073   
   Gabapentin 1.347 3.966 .045 .340 .736 -6.632 9.326 
   Other drugs -4.454 2.336 -.264 -1.907 .063 -9.153 .246 
   Dis. duration -.083 .072 -.149 -1.162 .251 -.228 .061 
R2=0.28 
Dependent Variable: EGM total 
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  Table 5-52 Coefficients’ table of the impact of SSFR on the neurosensory function of taste in 
pSS group  
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) -1.430 6.421  -.223 .825 -14.347 11.488 
SSFR -.415 1.776 -.032 -.234 .816 -3.988 3.158 
Age .115 .094 .167 1.229 .225 -.073 .304 
Smoking 9.566 5.160 .263 1.854 .070 -.815 19.947 
Alcohol -3.707 2.301 -.211 -1.611 .114 -8.336 .923 
Mouthwash 6.225 2.297 .346 2.710 .009 1.604 10.845 
Appliances 1.437 2.660 .069 .540 .592 -3.915 6.789 
Pain relief -2.541 2.361 -.137 -1.076 .287 -7.292 2.209 
Gabapentin 1.508 3.933 .050 .383 .703 -6.404 9.419 
Other drugs -4.334 2.368 -.257 -1.830 .074 -9.099 .431 
Dis. duration -.085 .072 -.152 -1.175 .246 -.230 .060 
R2=0.28 
Dependent Variable: EGM total 
 
   Table 5-53 Coefficients’ table of the impact of CODS on the neurosensory function of taste 
in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) -3.895 6.029  -.646 .521 -16.023 8.234 
CODS .787 .705 .176 1.116 .270 -.632 2.206 
Age .080 .098 .115 .818 .418 -.116 .276 
Smoking 8.509 5.152 .234 1.652 .105 -1.856 18.874 
Alcohol -3.313 2.237 -.189 -1.481 .145 -7.812 1.187 
Mouthwash 5.524 2.357 .307 2.343 .023 .781 10.267 
Appliances .570 2.737 .027 .208 .836 -4.936 6.075 
Pain relief -2.119 2.359 -.114 -.898 .374 -6.865 2.628 
Gabapentin 2.487 3.971 .082 .626 .534 -5.501 10.475 
Other drugs -3.536 2.441 -.210 -1.449 .154 -8.447 1.374 
Dis. duration -.096 .072 -.172 -1.336 .188 -.241 .049 
R2=0.3 
Dependent Variable: EGM total 
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5.4.5 Objective 12: To investigate the association of the gustatory function to the 
neurosensory threshold of taste in pSS group 
Our novel finding in the present study represented in the negative significant correlation 
between the neurosensory threshold of taste (β=-0.4, 95% CI=-0.2–0) and the gustatory 
function in the pSS group. Age (β=-0.4, 95% CI=-0.1–0) was independent factor in this model 
(Table 5-54).  
 
 
Table 5-54 Coefficients’ table of the relation between tasting ability and the neurosensory 
function of taste in pSS group 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) 15.178 1.543  9.838 .000 12.075 18.282 
EGM total -.171 .040 -.478 -4.231 .000 -.252 -.090 
Age -.097 .025 -.403 -3.922 .000 -.147 -.047 
Smoking .369 1.402 .029 .263 .794 -2.451 3.189 
Alcohol -.467 .602 -.076 -.777 .441 -1.678 .743 
Mouthwash -.140 .665 -.022 -.210 .835 -1.477 1.198 
Appliances -.949 .689 -.131 -1.377 .175 -2.336 .438 
Pain relief 1.193 .625 .184 1.907 .063 -.065 2.450 
Gabapentin -1.515 1.030 -.144 -1.470 .148 -3.588 .558 
Other drugs .523 .638 .089 .821 .416 -.759 1.806 
Dis. duration .008 .019 .040 .407 .686 -.031 .046 
R2=0.59 
Dependent Variable: Total gustatory function 
 
5.4.6 Objective 13: To investigate whether oral dryness is correlated with the self-
reported vagina dryness in pSS group 
Oral dryness in pSS patients was found in 78.4% (n=51/65) using USFR, 64.6% (n=42/65) 
using SSFR and 84.6% (n=55/64) using CODS. The self-reported vagina dryness was present 
in 87% (n=54/62) of pSS patients who answered the question of whether or not they suffer 
from vaginal dryness. Out of the 28 sexually active pSS patients, 26 (92.8%) reported vagina 
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dryness, one patient declined to answer, and one patient reported no vagina dryness. The 
sexually inactive patients were 37, out of which, 75.6% (n=28) reported dry vagina.  
In terms of the association between the severity of oral dryness and the self-reported vagina 
dryness, the unstimulated (β=0.7, 95% CI=12.9- -11.5) and stimulated (β=-0.4, 95% CI=2– -
2) salivary flow rate appear to associate with vaginal dryness. However, this association was 
not statistically significant (Tables 5-55 and 5-56). No important association was found 
between CODS (β=0, 95% CI=0.4- -0.4) and vaginal dryness in pSS group (Table 5-55).  
Table 5-55 Variables in the equation of a logistic regression between USFR and the self-reported 
vagina dryness in pSS group 
Variables B S.E. Wald df Sig. Exp(B) 
95% CI for 
EXP(B) 
Lower Upper 
Step 1 
USFR .726 3.528 .042 1 .837 2.066 .002 2081.22 
Age -.005 .034 .021 1 .885 .995 .932 1.063 
Dis. duration .064 .045 2.049 1 .152 1.066 .977 1.165 
Alcohol .242 .820 .087 1 .768 1.274 .255 6.362 
Constant 1.103 2.184 .255 1 .614 3.012   
Variable(s) entered on step 1: USFR, Age, Dis. duration, Alcohol. 
 
Table 5-56 Variables in the equation of a logistic regression between SSFR and the self-reported 
vagina dryness in pSS group. 
Variables B S.E. Wald df Sig. Exp (B) 
95% CI for 
EXP(B) 
Lower Upper 
Step 1 
SSFR -.450 .537 .702 1 .402 .637 .222 1.828 
Age -.015 .033 .212 1 .645 .985 .924 1.050 
Alcohol .078 .853 .008 1 .928 1.081 .203 5.752 
Dis. duration .059 .044 1.820 1 .177 1.061 .973 1.157 
Constant 2.239 2.135 1.100 1 .294 9.382   
Variable(s) entered on step 1: SSFR, Age, Alcohol, Dis. duration. 
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Table 5-57 Variables in the equation of a logistic regression between CODS and the self-reported 
vagina dryness in pSS group. 
Variables B S.E. Wald df Sig. Exp (B) 
95% CI for EXP(B) 
Lower Upper 
Step 1 
CODS .079 .203 .154 1 .695 1.083 .728 1.610 
Age -.012 .032 .133 1 .715 .988 .929 1.052 
Alcohol .202 .836 .058 1 .809 1.224 .238 6.305 
Dis. duration .061 .045 1.860 1 .173 1.063 .973 1.162 
Constant 1.155 1.837 .395 1 .530 3.174   
Variable(s) entered on step 1: CODS, Age, Alcohol, Disease duration. 
 
5.4.7 Objective 14: To investigate the impact of the self-reported vaginal dryness on the 
sexual function in pSS patients 
Pain during sexual activity appears to be associated with vagina dryness (n=26/28) in the 
sexually active patients (β=-0.2, 95% CI=-6.2 – 1.8), although this correlation was not 
statistically significant. Fatigue correlated with the FSFI global, sexual desire, arousal, 
orgasm and satisfaction, however, its effect was not statistically significant. Disease 
duration appears to associate with lubrication (β=0.3, 95% CI=0-0) and satisfaction (β=0.2, 
95% CI=0-0) of the sexual activity, but this association was not statistically significant (Tables 
5-58 to 5-64).   
               Table 5-58 Coefficients’ table of the relation between vaginal dryness and the sexual  
function in the sexually active pSS patients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 (Constant) 27.424 12.626  2.172 .041 1.167 53.681 
Vagina dryness 
.223 8.070 .006 .028 .978 -16.560 17.006 
Age -.108 .135 -.165 -.799 .433 -.388 .172 
Alcohol 4.056 3.236 .263 1.253 .224 -2.674 10.786 
Fatigue -7.209 6.035 -.247 -1.195 .246 -19.761 5.342 
Disease 
duration 
.076 .089 .175 .851 .404 -.110 .261 
                R2=0.18 
                Dependent Variable: Global FSFI for sexually active patients 
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Table 5-59 Coefficients’ table of the relation between vaginal dryness and the sexual 
desire in the sexually active pSS patients. 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta Lower Bound 
Upper 
Bound 
 
(Constant) 4.423 1.720  2.571 .018 .846 8.001 
Vagina dryness -.672 1.100 -.126 -.611 .548 -2.959 1.615 
Age -.008 .018 -.096 -.455 .654 -.047 .030 
Alcohol .260 .441 .126 .590 .561 -.657 1.177 
Fatigue -1.191 .822 -.304 -1.448 .162 -2.901 .519 
Disease 
duration 
.000 .012 .004 .018 .986 -.025 .025 
R2=0.15 
Dependent Variable: D1 (Desire) for the sexually active patients 
 
Table 5-60 Coefficients’ table of the relation between vaginal dryness and arousal in the 
sexually active pSS patients. 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(  Constant) 4.443 2.557  1.737 .097 -.875 9.761 
   Vagina dryness .348 1.635 .043 .213 .833 -3.051 3.747 
    Age -.016 .027 -.119 -.577 .570 -.072 .041 
    Alcohol .809 .655 .259 1.234 .231 -.554 2.172 
    Fatigue -1.666 1.222 -.281 -1.363 .187 -4.208 .876 
Disease duration .012 .018 .136 .660 .516 -.026 .050 
R2=0.18 
Dependent Variable: D2 (Arousal) for the sexually active patients 
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Table 5-61 Coefficients’ table of the relation between vaginal dryness and lubrication in the  
sexually active pSS patients. 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 (Constant) 3.501 2.461  1.423 .170 -1.617 8.619 
Vaginal dryness .406 1.573 .053 .258 .799 -2.865 3.678 
Age -.032 .026 -.252 -1.214 .238 -.086 .023 
Alcohol .821 .631 .274 1.301 .207 -.491 2.133 
Fatigue -.119 1.176 -.021 -.101 .921 -2.565 2.328 
Disease 
duration 
.028 .017 .328 1.587 .127 -.009 .064 
R2=0.17 
Dependent Variable: D3 (Lubrication) for the sexually active patients 
 
 
 
 
Table 5-62 Coefficients’ table of the relationship between vaginal dryness and orgasm in the 
sexually active pSS patients. 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) 3.041 2.910  1.045 .308 -3.012 9.093 
Vaginal dryness 1.374 1.860 .157 .738 .468 -2.495 5.243 
Age .006 .031 .044 .204 .840 -.058 .071 
Alcohol .469 .746 .138 .629 .536 -1.082 2.021 
Fatigue -1.442 1.391 -.224 -1.036 .312 -4.335 1.452 
Disease duration .000 .021 .001 .007 .995 -.043 .043 
R2=0.1 
Dependent Variable: D4 (Orgasm) for the sexually active patients 
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Table 5-63 Coefficients’ table of the relationship between vaginal dryness and satisfaction 
in the sexually active pSS patients. 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 (Constant) 3.544 2.486  1.425 .169 -1.627 8.714 
Vaginal dryness 1.357 1.589 .164 .854 .403 -1.948 4.662 
Age -.011 .027 -.080 -.406 .689 -.066 .044 
Alcohol .945 .637 .295 1.482 .153 -.381 2.270 
Fatigue -1.794 1.189 -.296 -1.509 .146 -4.265 .678 
Disease duration .027 .018 .295 1.510 .146 -.010 .063 
R2=0.26 
Dependent Variable: D5 (Satisfaction) for the sexually active patients 
 
           Table 5-64 Coefficients’ table of the relationship between vaginal dryness and pain in the 
sexually active pSS patients. 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) 7.555 3.047  2.480 .022 1.220 13.891 
Vaginal dryness -2.163 1.947 -.219 -1.111 .279 -6.213 1.886 
Age -.046 .032 -.283 -1.405 .175 -.113 .022 
Alcohol 1.064 .781 .279 1.362 .188 -.560 2.688 
Fatigue -.799 1.456 -.110 -.549 .589 -3.827 2.230 
Disease duration .019 .022 .177 .885 .386 -.026 .064 
            R2=0.22 
Dependent Variable: D6 (Pain) for the sexually active patients 
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5.5 OTHER RESULTS 
1. The correlation between the subjective and objective assessments in the pSS group. 
A. Correlation between smell function measured by UPSIT and the self-assessment of 
smell measured by VAS in the pSS group 
A positive significant correlation was found between smell and VAS smell in the patients 
group (r=0.7, p=0.00). 
B. Correlation between gustatory function measured by TST and the self-assessment of 
taste measured by VAS in the pSS group  
 
 Total score 
No significant correlation was found between the gustatory function and VAS taste 
in the patients group (r=0.1).  
 Sweet 
No significant correlation was found between the gustatory function of tasting 
sweet and VAS sweet in the patients group (r=0.1). 
 Sour 
No significant correlation was found between the gustatory function of tasting sour 
and VAS sour (r=0.1). 
 Salt 
No significant correlation was found between the gustatory function of tasting salt 
and the VAS salt (r=0.1). 
 Bitter 
No significant correlation was found between the gustatory function of tasting 
bitter and VAS bitter (r=0.2). 
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C. Correlation between oral dryness tests and the self-perception of oral dryness 
measured by Xerostomia Inventory in the pSS group 
 Unstimulated salivary flow rate and Xerostomia Inventory 
   A significant negative correlation was found between USFR and XI (r=-0.4) (Figure 5-7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
                      Figure 5-7 Correlation between USFR and XI in the pSS group 
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  Stimulated salivary flow rate and Xerostomia Inventory 
A significant negative correlation was found between SSFR and XI (r=-0.2) (Figure 5-8).  
 
 
 
 
 
 
 
 
                           
Figure 5-8 Correlation between SSFR and XI in the pSS group 
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 Clinical oral dryness score (CODS) and XI  
 A significant positive correlation was found between CODS and XI (r=0.3) (Figure 5-9).  
 
 
 
 
 
 
 
 
 
 
Figure 5-9 Correlation between USFR and XI in the pSS group 
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D. Correlation of the self-assessment of the nasal dryness measured by XI and the smell 
function in the pSS group 
No significant correlation was found between the self-assessment of the nasal dryness and 
the smell function (r=-0.02) in the patients group (Figure 5-10). 
Figure 5-10 Correlation between the self-assessment of the  
nasal dryness and the smell function in the pSS patients 
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2. The taste map  
A: Comparison of the four basic tastes between the right and left laterals of the tongue 
in the total population of the study 
The results showed no statistical significant difference in the tasting ability of the four taste 
categories (Sweet, sour, salt and bitter) between the right and the left laterals of the 
anterior two thirds of the tongue.   
B: Comparison of the four taste categories between the tip and laterals of the tongue in 
the total population of the study 
 Sweet and sour 
The results showed no statistical significant difference in the tasting ability between the tip 
and the laterals of the tongue (Right and left laterals) in tasting sweet and sour. 
 Salt 
A statistical significant difference was found between the tip and the laterals in tasting salt, 
the highest mean was for the tip (Mean score of the tip=2.8, mean score of the lateral 
right=2.3, 95% CI=0.1–0.7, mean score of the lateral left=2.2, 95% CI=0.2–0.8).  
 Bitter 
There was no statistical significant difference between the tip and the right lateral (Mean 
score of the right lateral=2.3, 95% CI=-0.1–0.5). Significant difference was found between 
tip of the tongue and the left lateral in tasting bitter. The highest mean score being for the 
tip (Mean score of the tip=2.5, mean score of the left lateral=2.1, 95% CI=0–0.7). 
3. Effect of medicines on mucosal dryness, smell and gustation in the patients group 
A: Impact on oral dryness 
Topical medicines group (β=0.4, 95% CI=0.3–2.2) was a good predictor of the oral dryness 
that was tested by CODS. A group of “other drugs” had an effect on the oral dryness that 
was measured by CODS, however, this variable has not been considered as a predicting 
factor as it consists of a number of drugs with different effects on the body (Table 5-65). 
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Table 5-65 Coefficients table of the regression analysis between oral dryness and the 
medicines taken by pSS patients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B 
Std. 
Error 
Beta Lower 
Bound 
Upper 
Bound 
 
(Constant) 6.150 .459  13.383 .000 5.223 7.076 
Hydroxychloroquine -.585 .507 -.149 -1.154 .255 -1.608 .437 
Pilocarpin 1.760 .998 .239 1.764 .085 -.252 3.771 
Supplements -.351 .588 -.088 -.598 .553 -1.536 .834 
Antidepressant -1.349 .844 -.233 -1.599 .117 -3.051 .352 
immunosuppressant .126 .567 .032 .223 .825 -1.016 1.269 
Anticoagulants 1.760 1.366 .188 1.288 .204 -.995 4.516 
Antihistamine -.345 1.157 -.042 -.299 .767 -2.678 1.987 
Antihyperthyroid .260 .660 .053 .394 .696 -1.072 1.592 
Antihypothyroid 1.832 1.173 .224 1.561 .126 -.534 4.198 
Antibiotics -.318 1.039 -.039 -.306 .761 -2.414 1.778 
Angiotensin .223 .526 .053 .423 .674 -.839 1.284 
Pain relief -.807 .543 -.194 -1.486 .145 -1.902 .288 
Antistomach acid .552 .697 .109 .792 .433 -.854 1.957 
Antihypoglycaemic .148 .584 .030 .253 .802 -1.030 1.325 
Inhalers -2.085 1.466 -.223 -1.422 .162 -5.040 .871 
P. biliary cirrhosis 
drugs 
1.095 1.177 .117 .931 .357 -1.278 3.468 
Overactive bladder 
drugs 
-2.348 1.588 -.251 -1.478 .147 -5.550 .855 
Topical 1.289 .485 .420 2.657 .011 .311 2.267 
Gabapentin -.230 .980 -.034 -.235 .816 -2.207 1.747 
Other drugs -1.098 .534 -.291 -2.056 .046 -2.174 -.021 
R2=0.45 
Dependent Variable: CODS 
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B: Impact on nasal dryness 
The nasal dryness that was assessed subjectively by item 11 of the Xerostomia Inventory. It 
was found that Hydroxychloroquine (β=0.4, 95% CI=0-2.1) and supplements (β=-0.3, 95% 
CI=0- -2) had affected the nasal dryness significantly (Table 5-66). 
        Table 5-66 Coefficients table of the regression analysis between nasal dryness and the 
medicines taken by pSS patients 
Model 
Unstandardize
d Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B 
Std. 
Error 
Beta Lower 
Bound 
Upper 
Bound 
 
(Constant) 3.606 .400  9.014 .000 2.799 4.413 
Hydroxychloroquine 1.269 .441 .420 2.874 .006 .379 2.159 
Pilocarpin -.005 .868 -.001 -.006 .995 -1.757 1.746 
Supplements -1.005 .512 -.329 -1.965 .056 -2.037 .026 
Antidepressant .262 .735 .059 .357 .723 -1.219 1.744 
Immunosuppressant -.171 .493 -.057 -.347 .730 -1.166 .824 
Anticoagulants 1.914 1.189 .266 1.609 .115 -.485 4.313 
Antihistamine -.445 1.007 -.071 -.442 .661 -2.475 1.586 
Antihyperthyroid  -.257 .575 -.068 -.447 .657 -1.417 .902 
Antihypothyroid -.583 1.021 -.093 -.571 .571 -2.643 1.477 
Antibiotics -.288 .905 -.046 -.319 .752 -2.113 1.537 
Angiotensin .064 .458 .020 .139 .890 -.860 .988 
Pain relief -.103 .473 -.032 -.219 .828 -1.057 .850 
Antistomach acid -.319 .607 -.082 -.526 .601 -1.543 .904 
Antihypoglycaemic -.570 .508 -.153 -1.122 .268 -1.595 .455 
Inhalers -1.896 1.276 -.263 -1.486 .145 -4.469 .678 
P. biliary cirrhosis 
drugs 
-.228 1.024 -.032 -.222 .825 -2.293 1.838 
Overactive bladder 
drugs 
.999 1.382 .139 .723 .474 -1.789 3.787 
Topical -.007 .422 -.003 -.016 .988 -.858 .845 
Gabapentin -.408 .853 -.078 -.478 .635 -2.129 1.313 
Other drugs .286 .465 .098 .615 .542 -.651 1.223 
            R2=0.29 
Dependent Variable: nasal dryness 
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C: Impact on smell 
Topical medicines group (β=-0.4, 95% CI=-8.8 - -0.7) was a good predictor of the smell 
function in pSS group, where a negative correlation was found between topical medicines 
and the smell function (Table 5-67). 
  Table 5-67 Coefficients table of the regression analysis between smell function and the 
medicines taken in pSS patients. 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B 
Std. 
Error 
Beta 
Lower 
Bound 
Upper 
Bound 
 
 
(Constant) 30.641 1.855  16.515 .000 26.902 34.380 
Hydroxychloroquine 2.128 2.047 .151 1.039 .304 -1.999 6.254 
Pilocarpin 4.142 4.028 .157 1.028 .309 -3.976 12.260 
Supplements -.190 2.373 -.013 -.080 .936 -4.972 4.591 
Antidepressant 1.029 3.407 .050 .302 .764 -5.837 7.895 
Immunosuppressant -2.706 2.288 -.193 -1.183 .243 -7.317 1.905 
Anticoagulants .646 5.517 .019 .117 .907 -10.472 11.764 
Antihistamine 1.415 4.670 .048 .303 .763 -7.997 10.827 
Antihyperthyroid -3.057 2.667 -.174 -1.147 .258 -8.431 2.317 
Antiypothyroid -1.120 4.737 -.038 -.236 .814 -10.668 8.427 
Antibiotics 1.031 4.196 .035 .246 .807 -7.427 9.488 
Angiotensin .134 2.125 .009 .063 .950 -4.148 4.417 
Pain relief .425 2.193 .028 .194 .847 -3.995 4.844 
Antistomach acid .225 2.814 .012 .080 .937 -5.447 5.896 
Antihypoglycaemic -.724 2.357 -.042 -.307 .760 -5.475 4.027 
Inhalers -2.661 5.918 -.079 -.450 .655 -14.589 9.266 
P. biliary cirrhosis 
drugs 
-1.053 4.751 -.031 -.222 .826 -10.627 8.521 
Overactive bladder 
drugs 
2.528 6.412 .075 .394 .695 -10.394 15.450 
Topical -4.679 1.959 -.425 -2.389 .021 -8.626 -.731 
Gabapentin -.535 3.958 -.022 -.135 .893 -8.511 7.441 
Other drugs .845 2.156 .062 .392 .697 -3.500 5.189 
             R2=0.28 
             Dependent Variable: Smell 
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D: Impact on taste  
Pain relief was a good predictor in this model (β=0.3, 95% CI=0.1-3.8) where a positive 
association was found between this group of medicines and the taste function. Gabapentin 
(β=-0.2, 95% CI=-6.4 – 0.3) and inhalers (β=-0.2. 95% CI=-8.8-1.2) seem to correlate with 
tasting ability, however, the correlation was not significant (Table 5-68). 
Table 5-68 Coefficients table of the regression analysis between taste function and the 
medicines taken in pSS patients. 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 
(Constant) 8.328 .784  10.61 .000 6.745 9.911 
Hydroxychloroquine .832 .866 .136 .961 .342 -.915 2.579 
Pilocarpin 1.677 1.703 .147 .985 .330 -1.760 5.114 
Supplements -.781 1.003 -.127 -.779 .440 -2.806 1.243 
Antidepressant -.256 1.441 -.028 -.178 .860 -3.163 2.651 
Immunosuppressant .255 .967 .042 .264 .793 -1.697 2.207 
Anticoagulants -2.731 2.333 -.188 -1.171 .248 -7.438 1.977 
Antihistamine -1.784 1.975 -.141 -.903 .372 -5.769 2.202 
Antihyperthyroid .002 1.128 .000 .002 .999 -2.273 2.277 
Antihypothyroid -.976 2.003 -.077 -.487 .629 -5.018 3.067 
Antibiotics -.777 1.774 -.061 -.438 .664 -4.358 2.804 
Angiotensin -.339 .898 -.052 -.377 .708 -2.152 1.475 
Pain relief 2.012 .927 .311 2.169 .036 .140 3.883 
Stomach acid drugs -.319 1.190 -.041 -.268 .790 -2.720 2.083 
Hypoglycaemic -.810 .997 -.107 -.812 .421 -2.822 1.202 
Inhalers -3.807 2.502 -.262 -1.522 .136 -8.858 1.243 
Primary bil cirrhosis 
drugs 
-2.643 2.009 -.182 -1.316 .195 -6.697 1.411 
Overactive bladder 
drugs 
.465 2.711 .032 .172 .865 -5.006 5.936 
Topical -.266 .828 -.056 -.321 .750 -1.937 1.406 
Gabapentin -3.031 1.673 -.288 -1.811 .077 -6.408 .346 
Other drugs 1.910 .912 .326 2.096 .042 .071 3.750 
R2=0.35 
Dependent Variable: Gustatory function 
Results 
198 
 
 
4. Open-ended questions 
Hundred percent of our pSS group answered the open-ended questions on their visit day. 
Analysis showed that the top two reported symptoms of burden were the oral dryness 
(n=28/65) and fatigue (n=20/65). One patient reported the frequency of using the toilet 
because of the higher intake of water due to constant feeling of oral dryness. The same 
patient also reported having painful intercourse due to vaginal dryness, but that the oral 
dryness was the worst one symptom that affected her life quality. Another patient reported 
that “social anxiety” and “inability to plan ahead” were the most two problems with her 
condition that affected her life quality (Table 5-69).  
Overall, three patients thought that oral dryness was the worst symptom among other 
symptoms of pSS they have, four patients rated eyes dryness as the worst among other 
symptoms and two patients described fatigue as the worst over other symptoms that 
affected their life quality.  
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                Table 5-69 Ranking of the symptoms affecting the quality of life as reported  
by pSS patients 
Symptoms N (%) 
Oral dryness n=28/65, 43% 
Fatigue n=20/65, 30.7% 
Eyes dryness n=18/65, 27.6% 
Non-specified “dryness” n=10/65, 15.3% 
Joint pain n=5/65, 7.6% 
Vagina dryness n=1/65, 1.5% 
Smell dysfunction n=1/65, 1.5% 
Ears dryness n=1/65, 1.5% 
Burning mouth sensation n=1/65, 1.5% 
Painful salivary glands n=2/65, 3% 
Neuropathy n=1/65, 1.5% 
Anxiety and inability to plan ahead n=1/65, 1.5% 
Frequency to use the toilet n=1/65, 1.5% 
No symptoms n=1/65, 1.5% 
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5. Self-reported neuropathy symptoms 
Sixty four pSS patients out of 65 (98.4%) responded to the following questions that 
evaluated the rate of the neuropathy symptoms (Table 5-70): 
 Have you lost feeling in your hands and/or feet? 
 Do you have tingling in your hands and/or feet (pins and needles)? 
 Do you have numbness in your hands and/or feet? 
 Have you suffered from clumsiness? 
 
                      Table 5-70 Neuropathy symptoms reported by pSS patients 
Neuropathy symptoms N (%) 
Lost feeling n=26/64, 40.5% 
Tingling n=40/64, 62.5% 
Numbness n=30/64, 46.8% 
Clumsiness n=35/64, 54.6% 
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CAHPTER 6: DISCUSSION
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A. Key results 
This study was designed to assess the functions of the smell, taste and sexuality in a group 
of pSS patients, with special focus on assessing the association of the impairment of these 
functions with the severity of mucosal dryness, and the consequences this may have on 
quality of life and mental health well-being. Our results demonstrated that pSS patients 
were affected and that their smell, taste, sexual function, quality of life and mental health 
well-being were significantly impaired. The dryness of mucosal surfaces was not the key 
factor in deteriorating the smell, taste and sexual functions as it was alleged before. 
Patients’ life quality and mental health status were compromised by the SD.  
B. Strengths and limitations  
 Strengths 
1. The study was conducted at Barts Health Trust, the largest trust and a major service 
provider in the UK. 
2. The literature review was structured according to the conceptual model of health 
related quality of life by Wilson and Cleary (1995). 
3. The study report was structured according to STROBE statement checklist for 
combined studies (Case-control and cross-sectional studies) (Fernandez, 2005). 
4. The power of the study (90%) and the sample size (Patients n=65, healthy 
volunteers n=62) was large enough to come out to a conclusion.   
5. The clinical criteria for diagnosing pSS patients was based on the recommended 
American European Consensus Group Criteria, which ensured identifying a pure 
group of patients. 
6. The clinical tests used for the assessment of the smell and taste are validated and 
reliable. 
7. Screening the functions of the smell, taste and sexual activity was performed 
regardless of the severity of the disease. 
8. The range of the questionnaires used ensured collecting the necessary information 
from participants. 
9. Data were collected by one researcher, which ensured avoiding performance bias. 
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 Limitations  
1. Patients and healthy volunteers were not age matched, which may have resulted in 
an overestimation of the significance of the results. However, when the data was 
analysed according to age groups, the results were similar to that when the study 
group data was analysed collectively.    
2. The nasal and vaginal mucosa were not assessed clinically for dryness. The 
researcher for practical reasons did not perform these assessments. Testing the 
nasal dryness would have involved using a nasal douche, which can be 
uncomfortable for the patient and associated with complications.  To examine for 
vaginal dryness, suitable private clinical setting and training of the operator would 
have been necessary. Therefore, patients were asked to self-report the dryness of 
the nose and vagina as an alternative.  
3. Healthy volunteers were invited to take part in the study by advertising in the 
hospital’s waiting rooms, in schools and at the British Sjögren’s Syndrome 
Association (BSSA) website. All interested volunteers that met the criteria were 
recruited. The mean age of this group was 43 years, which was less than the patients 
group (mean 50 years). 
4. The power calculation was based on the mean difference of the primary outcomes 
only. Hence, unpowered regression analysis for the patients’ group to investigate 
the secondary objectives was done. 
5. The UPSIT used to test the smell test, requires a pencil to scratch each box in the 
booklet to release a smell, a technique recommended in the manufacturer’s 
instruction. However, an observed limitation is that a lead layer from the pencil may 
incur covering the embedded microencapsulated odours. This might have affected 
the final score.    
6. The TST used for the taste, was reported by a number of participants to have 
exacerbated the dryness due to applying paper strips on the tongue.  Although this 
was uncomfortable for patients, it is unlikely that it affected the results. The other 
limitation of using this test was the scoring procedure, where a number of 
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participants could not identify the full scale of the full range of concentrations of a 
particular taste. Nevertheless these individuals could correctly tick nine tastants on 
the scoring sheet, and therefore were scored as “normal” as per the test’s validated 
cut-off point. There is a need for a different scoring system and/or different cut-off 
point of the test to enable researchers or clinicians to assess individual’s ability to 
identify the basic tastes accurately. 
7. The EGM was used to assess the neurosensory threshold of taste, which is the only 
quantitative device available to date for the assessment of the neural function of the 
taste sensation performed by chorda tympani nerve. A limitation of the EGM is that 
the presence of saliva on the tongue may increase the conductivity of the generated 
current to the nerve. Our data showed no evidence that the presence of saliva had 
an effect on the results, as a group of pSS patients with normal salivary flow, had 
impaired nerve function reading, indicating that the abundance of saliva does not 
necessary have an input on the device performance. However, further studies with 
this regards are needed.  
8. A limitation of the FSFI questionnaire reported by a number of our participants, who 
observed that the four weeks’ time limit period in assessing the women’s sexual 
activity is not realistic. Some participants commented that their sexual life changed 
with losing their partners rather than due to health reasons or declined desire. It 
should be acknowledged that the FSFI is a brief questionnaire for the assessment of 
sexual function in women. It was not designed as a diagnostic tool, or to assess the 
sexual experience, knowledge, attitudes or interpersonal functioning in women. For 
more detailed studies, a more comprehensive questionnaire to assess sexual 
function over longer period of time should be used.  
9. Impact of choice of methods: Wilson and Cleary (1995) model is the most widely 
cited conceptual framework of the HRQoL that integrates both biological and 
psychological aspects of health outcomes (Ojelabi et al., 2017). The model provides 
theoretical approach to conceptualising HRQoL as a multidimensional construct and 
is useful to guide the development of new theories. Therefore, it was decided to 
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apply Wilson and Cleary approach in the study. Lack of use of other models is noted 
as a limitation in the study. 
10. There is a potentially selection bias for patients entering the study, as patients are 
more likely to have problems with dryness if they are seen at the Dental Hospital, 
and/or if they have expressed interest in the study. 
C. Interpretation of the findings 
1. Smell  
In this study, we found that 41.5% of pSS patients exhibited disturbance in smell function 
compared to that of the healthy volunteers (24.1%), which is an indication of the impact of 
the syndrome on these patients. Interestingly, the majority of pSS patients reported no 
change in their smell function or acuity, which shows that these patients were coping and 
not aware of the problem before being clinically tested.   
Henkin et al. (1972) and Kamel et al. (2009) suggested a correlation of the deterioration of 
the smell function in pSS patients due to the nasal mucosa dryness, in particular, to the 
reduction in the nasal mucin secretion. However, our research contradicted the 
aforementioned studies, and revealed that the smell dysfunction in the pSS group was not 
impacted by the dryness of the mucosal linings. Additionally, a correlation between the 
smell function and oral dryness could not be established in our pSS group. Moreover, smell 
impairment was not correlated with the severity of the nasal dryness that was subjectively 
reported by patients. These findings support a previous study by Rasmussen et al. (1986) 
which demonstrated no correlation between smell thresholds and the severity of the 
dryness of the nasal mucosa in pSS patients. 
Nevertheless, the sample size of the present study was planned to explore the mean 
difference between patients and healthy volunteers. Therefore, in order to explore the 
impact of the dryness of the nasal mucosa on the smell function accurately, a study with 
sample size that is specifically designed to detect the effect of dryness is required. 
The prevalence of the neuropathy, which is known to be part of pSS symptoms, was 
reported by 81.2% of our pSS population. The reported symptoms ranged from “Lost 
feeling” to “Tingling”, “Numbness” or “Clumsiness”. We, therefore, suggest a possible 
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correlation between the neuropathy and the smell impairment in pSS patients. Our results 
supported findings by Welge-Lussen et al. (2004) who found that the integrity of the 
neurological function of olfaction was important for smell acuity. Our study agreed with 
Heckmann et al. (2009), who found that a large number of polyneuropathic patients 
recorded smell disturbances. However, assessing the nerve function of the smell sensation 
was beyond the remit of the present study, and there is a need for more studies with this 
regards. 
In an attempt to find a correlation between the medicines taken by pSS patients and the 
impairment of smell function, we found that the topical medicines (Eye drops, Eye gels, 
Viscotears –liquid gel-, Skin creams and Telmesteine) were the most affecting medicines 
(β=-0.4, 95% CI=-8.6 - -0.7) on the smell function. This can possibly indicate that patients 
with severe symptoms of pSS would suffer from smell dysfunction and tend to use more 
from topical medicines, rather than the influence of the topical medicine itself on smell 
acuity. We found no association between antihypertensive drugs and the smell function as 
it was previously reported (Deems et al., 1991, Doty et al., 2003). Due to the rarity of pSS 
patients, it was difficult to exclude patients on medications, which would otherwise limit 
the pool of subjects required for research investigation. When confidence intervals were 
reported, the interpretation was aided by the knowledge of range of possible results rather 
than a single p-value. Bonferroni correction may have been considered in the future. 
Moreover, age was not correlated with smell in our pSS group, which contradicts a previous 
statement of the negative correlation between age and smell in pSS patients (Kamel et al., 
2009). However, in our healthy volunteers group, there was significant negative correlation 
between age and smell, which is an anticipated normal regression of the smell function 
with age (Doty and Kamath, 2014, Thesen and Murphy, 2001, Doty et al., 1984). The lack 
of association between the smell and age in our pSS group indicated the presence of other 
factors that abolished the impact of age on olfaction, which in our study can be referred to 
the neuropathy.  
Additionally, smoking was found to have no important association with the smell function 
in the patients and volunteers groups. This finding supports Kamel et al. (2009) and 
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contradicts Frye et al. (1990) and Vennemann et al. (2008), who demonstrated a correlation 
between heavy smoking and smell deficit. Interestingly, our data showed that the highest 
score of the smell test (39/40) was recorded by a heavy smoker healthy volunteer, who 
reported smoking a total of 20 cigarettes per day. The subject reported that the smell acuity 
has not been changed, which can be referred to the continuous renewing process of the 
nasoepithelium due to the exposure to the smoke particles. Disease duration had no 
significant influence on smell function in the patients group. We are not aware of a study 
that has investigated the association of the disease duration with the smell function before 
in pSS patients, therefore, studies for comparison are not applicable.  
In the early stages of the study, it was decided to use the phenyl ethyl alcohol detection 
threshold test (Smell Threshold Test). But after consulting Professor Chris Hawkes (adviser) 
and Professor Richard Doty, we decided to use the University of Pennsylvania Identification 
Test (UPSIT-40) was chosen for the following reasons: 
1. The test was validated and widely used for research purposes compared with the former 
test. 
2. The test is reliable and highly correlated with the Smell Threshold Test. It is worth to note 
that the threshold, discrimination and identification abilities of smell are correlated with 
each other, and that when one of these abilities affected, the other is affected as well 
(Hummel T et al., 1997). 
3. Unlike Sniffin Sticks and the Smell Threshold Tests, UPSIT is hygienic. It is also 
straightforward to achieve, cheaper, can be self-administered and it employs familiar 
odours. 
Professor Chris Hawkes had also advised to moisten the nasal cavity before testing the 
smell in the patients group. Professor Antje Welge-Lüssen, University of Basel, Germany 
who was contacted with this regards, also supported this suggestion. However, after 
consulting the supervisors of the present study, we found that the need to moisten the 
nasal cavity was negated by the presence of the healthy volunteers group, which provides 
information of the smell function without being affected by the nasal dryness. Also by using 
the nasal douche, the study will be complicated and participants will be overburdened with 
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further procedures, which may raise potential ethical issue, and above all the study will go 
out of the target. 
In the present study, our sample was representative of our database population, but it does 
not represent a prevalence of the smell and taste in all pSS patients. However, our results 
showed that patients with a confirmed diagnosis of pSS were more likely to have impaired 
smell function compared with healthy volunteers, which agree with Kamel et al. (2009). 
2. Taste  
The present study shows high degree of impairment in the taste function in pSS patients 
compared with healthy volunteers. Anecdotally, patients with pSS have been observed 
developing taste deterioration. However, it has not been established yet whether it is 
related to the syndrome manifestations or not. 
Our findings agreed with Henkin et al. (1972), Weifenbach et al. (1995), Gomez et al. (2004), 
Negoro et al. (2004) and Kamel et al. (2009) who reported that taste function was 
significantly deteriorated in SS patients compared to controls. We proved taste disorder in 
54% of pSS group (n=34 of 63) vs 8.3% in the healthy volunteers group (n=5 of 60). This rate 
differs from the last stated by Kamel et al (Kamel et al., 2009) who reported 71% hypogeusic 
SS patients (n=28, 25 females/ 3 males) vs 13% of their controls group (n=37, 35 females/ 
2 males). The difference in the taste dysfunction rate between studies can be referred to 
the difference in the sample size recruited. Additionally, the results of Kamel et al’s study 
may not be applied to the female population of SS patients, as there was 11% males 
recruited in the pSS group.  
In our study, the number of patients who were aware of the loss of their taste acuity 21.9% 
(n=14 of 64) was approximately half of the number of patients who recorded taste 
dysfunction objectively. This suggests that patients were coping with the slowly growing 
problems of taste.  
Our systematic search in five medical databases from inception to June 2015 (Al-Ezzi et al., 
2016), showed five studies in which taste threshold was assessed in SS patients, and 
therefore comparable to our study (Henkin et al., 1972, Weifenbach et al., 1995, Gomez et 
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al., 2004, Negoro et al., 2004, Kamel et al., 2009).  Henkin et al’s research is a pioneering 
study in the field of assessing the smell and taste in pSS patients. However, most of its 
methodology relied on the clinical experience of the researchers at the time, which 
nowadays are guided by validated criteria and scales. However, due to the lack of the 
available resources for comparisons, this study was cited in the review. 
It is important to note that the study by Kamel et al. (2009) was the only one that met our inclusion 
criteria in the systematic review and meta-analysis, although there was no information about the 
severity of oral dryness. The other four studies have investigated the correlation between the oral 
dryness and taste function; however, patients’ sampling was not based on the recommended 
criteria (AECG) (Vitali et al., 2002) for diagnosing SS patients. The Systematic Review showed that 
the data available in the literature was limited and heterogeneous. 
A systematic review differs from traditional literature review in several ways. The 
traditional reviews are generally descriptive, without systematic search of the literature, 
and hence focused on studies chosen based on their availability or author’s selection. 
Therefore, the literature review although informative, can have a tendency of selection 
bias, and can also be confusing when similar studies have diverging results and conclusions. 
Systematic reviews (SR), as the name implies, involve detailed and comprehensive search 
strategy, planned by a team of at least three people usually, with the intention of reducing 
bias by identifying, appraising and synthesizing all relevant studies according to a peer 
reviewed protocol. The topic in the SR is focused on a single question that is usually PICO 
based, which gives the SR a narrow but specific focused scope that helps to answer a 
research question (Uman, 2011). Therefore, we started with literature review as a broad 
approach and once decided on the subject we want to address, we conducted a 
comprehensive focused systematic review. 
The regional assessment of the gustatory function on three tested places of the anterior 
2/3 of the tongue (Tip, right and left) revealed that tasting ability of the laterals was worse 
than the tip in the pSS group. Whilst in the healthy volunteers, the three tested sites of the 
tongue did not differ significantly between each other. These findings indicate impairment 
in interpreting or transmitting of the taste stimulations to the higher brain centres. Our 
results agreed with others who found that the function of the laterals of the tongue was 
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better only at higher threshold of taste than other sites of the tongue in patients with 
burning mouth syndrome and Parkinson’s disease respectively (Just et al., 2010, Doty et al., 
2015). In our study, the function of the tip of the tongue was more sensitive in identifying 
the four basic tastes than the laterals of the tongue. This is the first study to report regional 
taste assessment of the tongue in pSS patients. 
A comparison of each tastant of the four basic tastes was conducted on the tip of the 
tongue to represent the whole mouth testing ability, as was indicated by the TST manual. 
We proved that the tip was more sensitive and better in reflecting tasting ability of the four 
basic tastes than the laterals of the tongue. The ability to taste sweet in the patients group 
was statistically significantly impaired compared to the healthy volunteers. Our results 
contradicted previous studies in which no difference between pSS patients and controls in 
tasting sweet was reported, and that the ability to taste sweet was the least affected in pSS 
patients (Gomez et al., 2004, Kamel et al., 2009).  We found that the ability to taste sweet 
in the pSS group was minimally affected only when compared to other tastants in the 
patients group. Our findings were in agreement with others who believed that the quality 
of tasting sweet was independent of other tastants, and was not affected by saliva 
depletion or higher brain function (Henkin et al., 1972, Kaneda et al., 2000, Kamel et al., 
2009).  
The ability to taste sour, salt and bitter did not differ significantly between each other in 
the patients group, but differed significantly from tasting sweet, indicating that sour, salt 
and bitter were affected equally. In the present study, these tastes (Sour, salt and bitter) 
were shown to be more vulnerable in the pSS group, in agreement to previous reports who 
found that the three tastants were more affected compared to sweet (Gomez et al., 2004, 
Kamel et al., 2009). 
The number of patients who were able to identify the full range of concentrations of each 
tastant (low to high), varied significantly between patients and healthy volunteers. 
Identifying the lowest concentration of sweet recorded better frequency than the other 
three tastants on the three tested places of the tongue in both groups. However, patients 
were less able to identify the lowest concentration of sweet, as indicated by the half 
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frequency compared to healthy group in table 5-6. The tip of the tongue in the patients 
group was more sensitive in identifying the lowest concentrations in the patients group, as 
we proved above. The lack in studies investigating individuals’ ability to identify the lowest 
concentrations of the basic tastes precluded any comparisons.  
In light of anecdotal evidence that certain classes of drugs may be associated with 
alteration of tasting ability, we sought to establish whether such associations present in the 
pSS group. We found no association between antihypertensive drugs and taste 
deterioration in the pSS group as it was previously reported (Deems et al., 1991, Doty et 
al., 2003). Pain relief medicines (Naproxen, Painkiller, Paracetamol, Aspirin, Codein, Co-
codamol, Diclofenac, Fentanyl) that were reported by patients, appeared to be associated 
with the taste impairment. Apart from pain relief medicines, no important correlations 
were found between drugs used to treat asthma, depression and sleeping problems and 
taste deterioration as it was reported by Casaburi et al. (2002), Godara et al. (2011) and 
Suliburska et al. (2012). Our binary data were not showing the dosage and timing of the 
medicines taken by patients, making the analysis of limited value. Nevertheless, this 
preliminary assessment of the effect of the medicines on the tasting ability sheds a light on 
the importance of conducting a study with adequate information regarding the impact of 
the medicines taken on the tasting ability in pSS patients. The “other drugs” category 
although analysed, its results were not interpreted in the Discussion section as it contains 
miscellaneous drugs and the analysis was found to be of limited value. This was explained 
in the results section page 155.      
Participants in the current project were recruited from the largest Trust in the UK, which 
attracts patients from different places in the country, including the rural areas. However, 
the environmental impact is not a factor that can be adjusted statistically, unless using 
specific instruments to assess certain environmental effect, which is beyond the scope of 
the current study.  
Taste was evaluated by testing the gustatory function and the neurosensory threshold of 
taste. The gustatory function is represented by the function of the taste buds, and the 
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neurosensory threshold of taste is represented by testing the threshold of the chorda 
tympani nerve, which innervates the taste buds in the anterior 2/3 of the tongue. 
Measuring taste function by these two methods provided comprehensive assessment that 
helped to draw conclusion for the etiology of the taste dysfunction in the pSS group. 
Burghart Medical Technologies was contacted to seek their advice about the best taste test. 
The company suggested using GU002 gustometer, which is a computer-controlled machine 
that presents programmed concentrations of different tastants inside the patient’s mouth. 
The machine is precise and reliable in assessing the taste threshold and it was used in a 
number of studies. However, the space requirement for the machine and economic cost 
precluded its use in the study. Therefore, we opted to assess the gustatory function by the 
Taste Strips Test (TST), Burghart Messtechnik, Germany, over other tests. TST exhibits 
regional tongue assessment, which is not offered by other tests. Additionally, it is easy to 
conduct with a long shelf life and it provides clinical assessment in approximately ten 
minutes time for a single region, which is clinically favourable. Provided that the test-retest 
reliability (0.68) of the TST is comparable with other well established test of the three-drop-
technique (Mueller et al., 2003) that supports its reliability. The TST was also used in two 
studies that assessed the sense of taste and had proved its practicality in groups of SS 
patients (Negoro et al., 2004, Kamel et al., 2009).  
3. The taste map 
In this comparison, tasting ability was assessed by identifying any concentration of the taste 
strips of each tastant in the total population of the study. Our results showed that the 
laterals of the tongue functioned equally in tasting the four tastants in the total population 
of the study. There was no statistical difference between both laterals in tasting the sweet, 
sour, salt and bitter.  
In a comparison between the tip and the laterals, there was no statistical difference 
between the three sites of the tongue in tasting sweet and sour, indicating that the sweet 
and sour can be identified equally at these places. These findings contradicted the oft-
repeated popular belief, which limited tasting sweet to the tip of the tongue, while tasting 
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sour on the posterior laterals of the tongue. Our study presents evidence of an equal tasting 
ability of the four fundamental tastes on all the regions of the tongue.  
In terms of tasting salt, there was statistical difference between the tip and both laterals, 
where the tip recorded the highest mean scores, indicating that the tip was the most 
sensitive among the three places in tasting salt. Our findings contradicted the oft-quoted 
concept of the tongue map in that tasting salt can only be felt on the anterior laterals of 
the tongue. 
Tasting bitter was of same quality on the tip and the right lateral, but was at its lowest level 
on the left lateral. The tip was the most sensitive among the three tested places of the 
tongue. These findings also contradicted the previous statement in that tasting bitter was 
confined to the posterior laterals of the tongue.  
The tip was the most sensitive place of the tongue in tasting the four basic tastes, therefore, 
we recommend testing the tip for the clinical and research studies as it reflects the whole 
mouth tasting ability, and can taste the four fundamental tastes better than the laterals.    
4. The neurosensory threshold of taste 
Our results showed that the total average of the neurosensory threshold of taste was 
significantly higher in the patients’ group compared with the healthy volunteers, indicating 
that the neurological impairment was prevalent in pSS patients and associated with the 
syndrome. The neurosensory function of taste reflects the sensitivity of the chorda tympani 
nerve, which is responsible for the taste sensation in the anterior 2/3 of the tongue. 
Therefore, high neurosensory threshold reflects a deficit in the function of chorda tympani. 
We reported 31.7% dysfunction rate of the neurosensory threshold in our pSS group (mean 
score=5.7, SD=±8.4, n=20/63) which was three times higher than that of the healthy 
population who scored 9.8% dysfunction (mean score=-0.3, SD=±6.6, n=6/61). Our results 
were consistent with others who reported neurological taste disorders in 27% (Mean score 
=4.9, SD=±11.1, n=31) in a group of both primary and secondary SS (Negoro et al., 2004). 
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However, authors of the study did not use reliable criteria for diagnosing SS patients, and 
patients with sicca symptoms might have been included in the study.  
The scores of pSS group ranged within the positive scale (range=3.7–7.4) compared with 
the scores of the healthy population group which ranged well within the negative scale 
(range=-0.8 - -0.1), indicating that the healthy volunteers required minimal amount of the 
current generated by EGM to stimulate the sensation of the tongue.   
In a comparison of the regional testing of the tongue (tip, right and left of the anterior 2/3 
of tongue) between patients and healthy volunteers, the current study presents evidence 
of significant regional variations of the neurological threshold of taste in the anterior 2/3 
of the tongue. We found that the tip functioned significantly better than the laterals of the 
tongue, and that the laterals recorded same level of dysfunction with no significant 
difference in the pSS group. In the healthy volunteers group, we proved that the three 
tested regions had same performance with no significant difference between each other. 
Our findings of the healthy volunteers group contradicted others who found in a small 
study of non-smoking healthy subjects (n=16), that the tip of the tongue was more sensitive 
than the laterals (Shawn L. Miller, 2002). To our knowledge, there is no study of the regional 
testing of the neurosensory taste threshold in pSS patients. 
Several studies suggested that peripheral neuropathy was involved in the pathogenesis of 
SS and was known to be part of the syndrome (Svein I. Mellgren et al., 1989 , Koike and 
Sobue, 2013, Indart et al., 2017). Our findings of the gustatory function that was assessed 
by TST, revealed that the laterals of the tongue worked worse than the tip. This implies that 
the impaired gustatory function in the laterals of the tongue was precipitated by the 
significant neurosensory deterioration of the laterals in pSS group.  
The neurosensory threshold of taste was assessed by the electrogustometer (EGM), which 
is a validated and well-established battery operated clinical device (Miller et al., 2002, 
Berling et al., 2011), that measures nerve thresholds in a range of -6 to 34 decibel (dB). The 
machine presents faint electrical currents to the tongue (See Methodology 3.12.2.B) to 
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assess the neurosensory threshold of taste. Since it was developed in the 1950s, it has been 
used in a number of studies (Krarup, 1958, Fons, 1970, Kikuchi et al., 1988, Stillman et al., 
2003). The EGM is a portable small size device, with no preparation or storage 
requirements needed, therefore it is generally practical. It is also pain free on use, and does 
not require rinsing or expectoration between trials.  
Shorter durations of 0.5 or 1 seconds were insufficient to produce taste sensation for some 
of our participants. Therefore, a duration of 1.5 second was chosen as it was detected by 
all participants in the current study. 
To avoid reporting the sensation by the trigeminal nerve, it was explained to the 
participants to ignore tingling and that only a taste or change of taste should be reported. 
Testing by this machine was conducted on the anterior two thirds of the tongue, where the 
sensory innervation is supplied by the chorda tympani nerve (Ian Shaw et al., 2010). This 
device has no risk of harm (Tomita and Ikeda, 2002), and it has been in use in the Neurology 
department at the Royal London Hospital, for the regional mapping of the taste sensation. 
The device was approved by the Physics department at Barts Health Trust, The Royal 
London Hospital, to be used in this research.  
5. Salivary flow rate 
The present study provides evidence of sever oral dryness in our pSS group. Saliva was 
collected by means of USFR and SSFR. These methods are easily conducted and affordable 
by clinicians and patients, widely used in clinical studies, provided that the saliva collected 
by these methods reflect natural oral environment. As expected, oral dryness was 
statistically significantly higher in the pSS group than that in the healthy volunteers’.  
It has been observed that the USFR was influenced by a number of factors, the main ones 
being hydration, body posture, olfactory stimulation, seasons and light exposure 
(Navazesh, 1993). Shannon (1972) compared USFR under different body postures in his 
study group, and concluded that standing position had higher values of USFR than in laying 
position, in comparison with sitting posture. Therefore, it was necessary to unify the 
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collection posture for all participants in the present study, and it was decided to consider 
the upright sitting position as the position of choice. Additionally, subjects were advised to 
refrain from eating, drinking and smoking 1-2 hours prior to the test term. It was suggested 
to set a certain time of the day and/or time of the year to collect USFR to avoid bias 
(Navazesh, 1993). However, due to the rarity of pSS, it was difficult to manage collecting 
saliva in a certain season and at a particular time of the day.  
Despite of its objectivity, USFR test is prone to individuals’ willing to spit, therefore this test 
is also subjective which affects its reliability. Hence, it was decided to measure the 
stimulated SSFR as well as USFR, in order to be able to understand the impact of pSS on 
patients’ salivation.  
It was suggested to use Lashley Cup method in the current project, for the local saliva 
collection from the Parotid gland as a substitution for the SSFR. However, the procedure of 
saliva collection by this technique is troublesome for participants and complicated if 
compared with the aforementioned methods. Additionally, Lashley cup method provides 
localized saliva collection, while SSFR allows testing whole saliva, which reflects natural oral 
environment.  
6. Lack of association between taste and oral dryness 
In the multivariate regression model, we found no association between the oral dryness 
and the patients’ gustation as it was previously reported (Henkin et al., 1972, Negoro et al., 
2004, Kamel et al., 2009). Our findings supported previous studies, which demonstrated 
that normal salivation was not necessary for maintaining normal taste function 
(Weifenbach et al., 1995, Gomez et al., 2004). Another small study (n=8) by Weiffenbach 
et al. (1986) tested the correlation of the taste threshold with the severity of oral dryness 
in patients with xerostomia. The same study further supported the lack of association 
between normal salivary gland function and normal taste perception.   
The number of variables included in the regression analysis in the current project was 
considered sufficient according to (Austin and Steyerberg, 2015) Austin and Steyerberg 
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(2015) who recommended a minimum of two cases per variable, where in our study, the 
number of cases per variable ranged from three to 13.  
When assessing the effect of oral dryness on the ability to taste each of the four basic 
tastants, we found that oral dryness was not a good predictor for tasting sweet or sour, but 
only tasting bitter was affected by the oral dryness in the patients’ group. These findings 
supported others who suggested a possible impact of these two tastants by the time of the 
syndrome’s evolution or by the severity of oral dryness (Gomez et al., 2004). Oral 
homeostasis depends largely on the proteins composition in saliva, and hence, individuals 
with reduced amount of saliva showed reduced amounts of salivary proteins on the 
anterior tongue (Pramanik et al., 2010). Therefore, a correlation between tasting bitter and 
oral dryness supports the theory of the association between proteolysis and the 
interpretation of the bitter taste (Dsamou et al., 2012).  
We also found that the oral dryness did not affect the neurosensory thresholds of taste 
measured by EGM, in agreement with others where a correlation between SFR and the 
neurosensory function of taste in a group of primary and secondary SS patients could not 
be established (Negoro et al., 2004). This lack of association indicates that oral dryness has 
no impact on the nerve endings of the chorda tympani in the pSS group, and that the low 
performance of the chorda tympani during taste function can be referred to the 
neuropathy associated with the syndrome. These findings supported Negoro et al. (2004), 
who found that a group of patients with Sicca Syndrome (non SS) did not show association 
between oral dryness and taste impairment. This is an indication of the impact of the 
neuropathy, which is known to be part of SS, and the deterioration of the taste function.  
We sought to investigate the effect of the severity of oral dryness on the gustatory function 
of taste in the total population of the study (n=127). A significant association was observed 
between the oral dryness that was measured by USFR and CODS, with the gustatory 
function of taste, indicating that oral dryness is deteriorating the taste function. Age, in this 
association, had a significant moderating role on the relationship between the oral dryness 
and taste. This was anticipated since that age was not controlled, which is a limitation in 
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the study. It is worth noting that when the regression analysis was run with the total 
population of the study, a significant impact of the oral was observed on the deterioration 
of the taste function, whilst when the regression was run on the pSS group only, there was 
lack of association between the oral dryness and the taste. This lack of association supports 
our previous suggestion of the possibility of association between the deterioration of taste 
and the neuropathy.  
A moderator is a qualitative (e.g., sex, race class) or quantitative (e.g., level of reward) 
variable that affects the direction and/or the strength of the association between a 
predictor and a dependent variable(Reuben M. Baron and Kenny, 1986) (Baron and Kenny, 
1986). Whereas a mediator explains how external physical events take on internal 
significance. When a moderator variable specifies when certain effects will hold, mediators 
indicate how and why such effects occur (ibid).  
 
We hypothesised that the gustatory function is moderated by age and mouthwash when 
the USFR is an independent variable. Since age and mouthwash have had significant effect 
on the gustatory function in the total population. Therefore, appendix 28, page 339 
illustrated the change in the standardised coefficient of beta when USFR was the predictor, 
and age and mouthwash were added alternately to the model. The coefficient was changed 
by β=0.252 and β=0.003 when age followed by mouthwash was added respectively to the 
model, indicating that age and mouthwash had moderated the model. We did not have 
adequate power to test for mediation analysis; therefore, we recommend powered sample 
size to test for mediation in the future.        
 
7. Gustation and neurosensory threshold of taste 
Peripheral neuropathy is well documented and one of the frequent manifestations of pSS 
(Svein I. Mellgren et al., 1989 , Goransson et al., 2006). Our results of the multivariate 
regression analysis demonstrated that high neurosensory thresholds of taste were 
associated with the gustatory impairment that was measured by TST in pSS group. 
Therefore, the present study suggests a possible contribution of the neuropathy to the 
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aetiology of the taste dysfunction in pSS patients. This is a novel finding of the present study 
that sheds light on the possible aetiology of the taste impairment in pSS patients. This 
finding was confirmed when the regression analysis was run with the total population of 
the study, and a significant impact of the oral dryness was observed on the deterioration 
of the taste function. Whilst when the regression was run on the pSS group only, there was 
lack of association between the oral dryness and the taste. This lack of association confirms 
our previous finding of the possibility of association between the deterioration of taste and 
the neuropathy. 
Small fibre neuropathy is a recognised complication of SS.  The burning sensation of the 
tongue/loss of taste in the general population has been shown related to small fibre 
neuropathy. However, the aetiology of burning tongue/loss of taste has not been 
established in pSS.  Therefore, we investigated whether taste loss in pSS patients is related 
to neuropathy of the tongue. Our results showed that compared with healthy controls, pSS 
patients had higher neurosensory threshold readings (indicating neuropathy), and this 
correlated with taste dysfunction. Our results indicates that neuropathy should be 
considered as a possible contributor to taste dysfunction in SS 
Our open-ended questions that evaluated the rate of the neuropathy symptoms, revealed 
that all of the pSS subjects who responded to these questions (n=64/65) experienced 
peripheral neuropathy, which supports our assumption of the neuropathy effect on the 
taste dysfunction. The symptoms ranged from “Lost feeling”, “Tingling”, and “Numbness” 
to “Clumsiness” in hands and/or feet. All pSS patients reported one or more manifestations 
of neuropathy. The information we obtained by employing the routinely asked questions 
in the Neurology Department at the Royal London Hospital, shed a light on the need to 
explore in greater depth the impact of pSS on nerve function.  
Five of our pSS patients were able to taste the taste strips, but were unable to identify the 
category of taste, which can be referred to the impaired function of the nerve endings in 
the taste buds, and that these nerve endings were unable to transmit the taste stimuli to 
the brain centres for interpretation.  
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In this study, we found that age was a common confounder that interfered with the tasting 
ability of the four taste categories in pSS group, in agreement with a recent large study 
(n=1000) of general population, where taste was found to decline significantly with age 
(Doty et al., 2017). Previous studies on healthy subjects arrived to a conclusion in line to 
ours with regards to the correlation of age with taste impairment (Mojet et al., 2005, 
Suchecka et al., 2012). Our findings contradict others who reported no association between 
taste and age in SS patients (Gomez et al., 2004, Kamel et al., 2009). However, even if age 
had a strong contribution to the taste perception in the pSS group, our results presented 
evidence of significant impairment of the taste in our pSS group compared to the healthy 
volunteers when age was adjusted.   
Mouthwash use was the only variable that had an impact on the neurosensory tasting 
ability. This association suggested a possible damage to the nerve endings by the frequent 
use of mouthwash. Of our notes during the study, one of the healthy volunteers had an 
extremely impaired taste although no health problems were reported. The patient was 
found to have several fixed bridges and therefore she tended to use alcoholic mouthwash 
twice daily to maintain a good oral hygiene. We instructed the patient to reduce the rinsing 
administration to once before bedtime, and to refrain from rinsing completely three days 
prior to the re-testing day. When the patient was re-tested, her taste score was significantly 
improved and was as normal as other healthy subjects in the study were. We therefore 
speculate that alcoholic mouthwash can exert adverse but reversible effect on tasting 
ability. 
In the current study, a group of pSS patients who demonstrated normal salivary flow rate, 
scored high with the Electrogustometer, indicating impaired function of the nerve. This is 
suggestive that there is limited association between salivary flow rate and the conductivity 
of the electric current on the chorda tympani function. Experts have also shown in an 
unpublished study (personal communication with Professor Hawkes, Neurology 
Department Barts Health, UK, and Professor Doty, University of Pennsylvania, USA) that 
drying the tongue did not seem to affect the results of electrogustometer. This was 
confirmed when the regression analysis was run on the total population of the study, when 
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a significant impact of the oral dryness was observed on the deterioration of the gustatory 
function, while when the regression was run on the pSS group only, there was lack of 
association between the oral dryness and gustation.  However, further research is needed 
to confirm our findings. Other variables such as smoking and appliances (e.g. dentures, 
night guards or orthodontic appliances) were also found to associate with the impaired 
tasting ability in pSS patients. A group of “Other medicines” (Tidilan, Carbocistene, Epilim, 
Cough suppressant syrup, GTN spray, Atravastine, Migraleve, Alendronic acid, Hormone 
replacement therapy, Contraception, Lymecycline, Naltrexone, Pregabalin and antianxiety) 
was not taken into account in interpreting the results as it contained miscellaneous kinds 
of drugs that had different impacts on patients’ health status. 
8. Correlation between smell and taste 
The evidence in the literature is conflicting on whether a correlation between smell and 
taste exists. Our study revealed significant positive correlation between smell and taste in 
our healthy volunteers group (n=62) and in the total study population (n=127), but no 
correlation was found between smell and taste when data was analysed in the patients 
group only. The lack of the association between the smell and taste in the patients group 
can be attributed to the presence of underlined factors impeded the correlation of both 
variables in this group, which in our study can be referred to the neuropathy.  
When the whole study population was analysed with a total of 127 subjects, a correlation 
between the smell and taste was presented (r=0.2). However, only 40% of the variance was 
explained in the regression model, which did not strongly support the statement of the 
smell and taste being correlated. Our results supported others who reported no meaningful 
influence of the smell loss on taste function in patients with chemosensory disturbance 
(Stinton et al., 2010, Fasunla et al., 2012, Ros et al., 2012), and contradicted previous 
findings of a correlation between the smell and taste (Dzaman et al., 2005, Kamel et al., 
2009). 
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9. Sexual function 
The present study demonstrated that the prevalence of the SD in the sexually active pSS 
women, was double of that in the healthy volunteers. We found high proportion of patients 
were not sexually active (57%, n=37/65) which was higher than the previously reported 
(28.2%) in a study of 46 pSS females (van Nimwegen et al., 2015). This high proportion of 
the sexually inactive patients indicates that pSS patients were affected by the syndrome. 
Furthermore, using a cut-off score of 26.5, a total of 23/28 patients (82.1%) and 14/42 
healthy volunteers (33.3%) were considered to have impaired sexual function. This 
proportion is comparable to a previous report where 20/24 (83.3%) patients, and 9/24 
(37.5%) healthy volunteers reported SD (Priori et al., 2015).  
The score of zero of an individual domain indicates that the subject reported having no 
sexual activity during the past four weeks. Any values above zero, indicates sexual 
functionality.  The results showed obvious impairment of sexual function in the pSS group 
compared with the healthy volunteers.  
We found that all FSFI domains (Desire, arousal, lubrication, orgasm, satisfaction, pain and 
total FASI) have been affected significantly in women with pSS, and showed more sexual 
impairment compared with healthy volunteers. We further found that the inability to 
lubricate and the feel of pain were the most prominent symptoms that pSS patients suffer 
from during the sexual function, with the greatest mean difference of 2.1 and 1.9 
respectively between patients and healthy volunteers. Our findings supported others who 
reported that lubrication and pain were of the most affected domains in pSS patients (van 
Nimwegen et al., 2015, Priori et al., 2015).  
Vaginal dryness is frequently reported by pSS patients, and the present study confirmed 
that, and was consistent with others who reported that dry vagina was a common symptom 
in pSS patients (Marchesoni et al., 1995, Mulherin et al., 1997, Bongi et al., 2013). Large 
proportion (92.8%, n=26/28) of our sexually active patients have had dry vagina. Likewise, 
75.6% (n = 28/37) of the sexually inactive patients have also reported vagina dryness. 
Therefore, it appears that dry vagina was not a major factor affecting sexual activity, as the 
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sexually active and inactive patients reported having the symptom. This perhaps is an 
indication for the lack of association between vagina dryness and sexual activity.  
Vaginal dryness was subjectively assessed by asking patients whether or not they suffer 
from the symptom. This approach, albeit of being less complicated for patients than 
referring them to gynaecologist for a clinical assessment, we found it was not a sensitive 
measure to assess the severity of vaginal dryness (Appendix 24).  
In the subgroup analysis of the FSFI stratified according to the sexually active patients using 
multiple regression model, we found that the self-reported vagina dryness did not play key 
role in compromising the global FSFI score. These results agreed with others who concluded 
that the sexual function and the frequency of intercourse in pSS was not correlated with 
the dry vagina (Skopouli et al., 1994, Marchesoni et al., 1995, Valtysdottir et al., 2003).  
We found that fatigue has interfered with the sexual function and the patients’ senses of 
desire, arousal, orgasm and satisfaction. This finding is compatible with the results of a 
previous large survey (n=615) of the sexual function in women with chronic fatigue 
syndrome, where sexual dysfunction was found greater in patients with intense fatigue 
(p<0.05) including SS (n=510) (Blazquez et al., 2015a). The results of our open-ended 
questions that asked about the main one symptom that the patients think was affecting 
their QoL, have confirmed the above findings.  We found that fatigue was the second most 
frequently reported symptom to compromise patients’ QoL. 
The open-ended questions highlighted aspects that were not covered by the routine clinical 
tests and the questionnaires used in the study. One of our patients was diagnosed with an 
epilepsy alongside pSS, and was prescribed a number of medicines to control both 
conditions. The patient’s main complaint was the failure to pursue a successful sexual 
relationship, referring the reason to the fatigue. The patient believed that fatigue was 
worsened by the variety of medicines taken as she described. Same patient reported that 
due to the fatigue, she had no energy to interact sexually with her partner and therefore 
she constantly tended to avoid having sexual relationship. The patient further reported that 
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the SD was risking her marital life and that she was “not far from getting divorced” because 
of the constant fatigue she suffered from. Two more patients had similar views in that SS 
has affected their sexual life, and that it was one of the reasons that led to the termination 
of their relationships with their partners. We therefore suggest evaluating patients’ sexual 
problems through semi-structured interviews with predetermined topics, to explore in 
greater depth the issues raised which will help develop referral pathway for affected 
patients.  
We report that the sexual performance was painful with increased vaginal dryness, as it 
was shown in the regression analysis. Our findings supported others who referred their 
congruent results to the patient’s fear of pain due to insufficient lubrication during 
intercourse (Blazquez et al., 2015a). The results of our open-ended questions supported 
this finding and showed that one of our patients referred her SD to the lack of desire 
because of the fear of pain during intercourse, in agreement with Blazquez et al. (2015). 
In a large (n=302) Systemic Lupus Erythematosus cohort, 30% (n=85) of the subjects had 
accompanied SS with vaginal dryness, and reported SD. However, their FSFI scores were 
not significantly different from those without SS (Tseng et al., 2011), which indicates that 
vaginal dryness was not the a major factor of the sexual problems.  
Some studies attributed the reason of the SD to the Sjӧgren’s Syndrome-related vasculitis, 
trauma or inflammation, rather than to the commonly encountered vaginal dryness 
(Skopouli et al., 1994, Mulherin et al., 1997, Graziottin A and Giraldi A, 2006, Tseng et al., 
2011). Vaginal lubrication that usually occurs during normal intercourse was referred to a 
form of transudate from the blood vessels due to the increased blood flow on vaginal wall, 
and not because of the vaginal glands secretions. Therefore, the reduction in the vaginal 
glands secretion in pSS group may not contribute to the failure of having a successful 
relationship.  
Interestingly, our open-ended questions revealed that vaginal dryness (1.5%, n = 1/65) was 
not reported as the most one symptom that affected patients’ QoL. In fact only one patient 
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reported dry vagina as the worst symptom of the syndrome. Two more patients reported 
painful intercourse despite of using lubricants. Three other patients thought that their 
vaginal dryness was “not too bad”. All other patients who declared having impaired sexual 
function, did not refer the reason to “vaginal dryness” but described fatigue (30%, n=20/65) 
or non-specified dryness (15.3%, n = 10/65) instead. This may possibly suggest that the SD 
can be referred to the physical pain represented by fatigue and/or joint stiffness rather 
than vaginal dryness. Additionally, due to the sensitivity of the subject, patients could have 
found it hard to describe their vaginal problems as their main complaint of the syndrome, 
and substituted the term with non-specified “dryness”.  
Our study supported others in showing that the SD and vaginal dryness were extremely 
frequent in the SS patients (Marchesoni et al., 1995, Priori et al., 2015). However, in the 
multivariate regression model, we found no association between the self-reported vaginal 
dryness and the sexual activity in pSS patients. Our findings were compatible with others 
where no association was found between decreased vaginal lubrication and dyspareunia in 
a sample of 21 pSS patients diagnosed by the European criteria (Valtysdottir et al., 2003). 
This is not surprising as dyspareunia was also reported in premenopausal pSS patients with 
healthy vaginal mucosa in a study of 51 SS patients. Therefore, we support others in that 
the sexual life of pSS patients is driven by the severity of fatigue rather than vaginal dryness 
(Goodwin, 1997, Frikha et al., 2011, Blazquez et al., 2015a, van Nimwegen et al., 2015). 
Alcohol was found to be associated with the global score of the sexual function, arousal, 
lubrication, satisfaction and pain. This relationship between sexual function and alcohol 
intake may be a cause and effect relationship. It was admitted that the regression analyses 
was unpowered in the study as the power calculation was conducted to detect the mean 
difference between the patients and the healthy volunteers. Therefore, it is anticipated that 
a relationship between the variables may become more obvious when the sample size of 
the sexually active patients is increased. 
 
In the present study, we were unable to match the age between groups, which counts one 
of the limitations of the study. A more detailed matching would have required selection 
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according to several variables including age. However, we adjusted for these variables in 
the multivariate regression model.  
However, despite of the general belief of the decline in the sexual activity with increasing 
age, we found that age was not a strong predictor of the FSFI global in the pSS group. Our 
results showed that age was only associated with the impairment of lubrication and 
worsened the feeling of pain in pSS patients. This correlation can be linked to the hormonal 
changes that affect the mental health status and hence raising the fear from pain that was 
resulted by the increase in vaginal problems. Our findings supported previous studies 
where age was found to have negative correlation with the sexual function in pSS patients 
(van Nimwegen et al., 2015, Isik et al., 2016). However, even if the age was negatively 
correlated with some aspects of the sexual activity in our study, a subgroup analysis of 20-
50 years old pSS patients (n=7/9), scored significantly lower FSFI global, compared with 
age-matched healthy volunteers (n=13/39). Indicating that age was not a major contributor 
for the decline in sexuality, and that the impact of the disease cannot be denied when age 
is adjusted.   
The number of the sexually active patients (n=28) was significantly lower than that of the 
healthy volunteers (n=42) which itself an indication of the impact of the disease on 
sexuality rather than the aging effect. The reasons that the patients were not sexually 
active, may differ from the reasons of the SD, and therefore may not be related to age. Our 
findings supported others who reported that dyspareunia was not limited to the old age 
and it was found in 40% of premenopausal pSS patients (Skopouli et al., 1994). The study 
was focused on finding out how the patients’ group is affected by the syndrome, and it was 
not feasible to run the regression analyses for the control group and compare the results. 
Moreover, if the regression analyses was run for the pooled population of the study, there 
will be high amount of variation in the outcome variable compared to the pSS group 
association alone, and hence, the p-value cannot be relied on in interpreting the results, as 
it violates the assumption of homogenous variance. 
Discussion 
227 
 
The duration of having the syndrome that was reported by pSS group, was found to affect 
lubrication and satisfaction of the sexual performance. This finding contradicted previous 
studies where no association between SD and disease duration was reported (Skopouli et 
al., 1994, Marchesoni et al., 1995, Priori et al., 2015). The difference in the methodology 
and the criteria that was applied in diagnosing pSS patients between these studies and 
ours, can explain the diversity of the results. All p-values were reported for transparency 
regardless of significance. 
When performing logistic regression, a correlation was established between oral dryness 
and vaginal dryness. To find out whether mucosal dryness of one site can be indicative of 
dryness of other mucosal surfaces, we analysed the relationship between the oral and 
vaginal dryness in our study group. The results did not show significant correlation. It is 
acknowledge that one of the measures is an objective assessment tool and the other is 
subjective, which further undermines the reliability of this analysis. However, powered 
regression analysis is needed to confirm these findings. To our knowledge, this is the first 
time that this relationship has been reported. 
10. Quality of life 
Quality of life assessment has received increasing attention in evaluating the impact of 
chronic diseases, in contemporary public health research and practice. In the present study, 
the QoL was drastically affected and that pSS patients were compromised physically, 
psychologically, socially and even environmentally in comparison to healthy volunteers, 
being more affected physically than other domains. Our findings were consistent with 
previous studies which assessed the QoL of pSS patients using WHOQoL-BRÉF (Bowman et 
al., 2004a, Inal et al., 2010), and found that all domains were affected in pSS patients except 
for “Environment” which was comparable between patients and controls. The pilot study 
gave us idea of the feasibility to use questionnaires to avoid data loss in the main study.  
We present interesting evidence that SD has significantly compromised patients’ social life 
quality. This was manifested by self-reporting of dissatisfaction with personal relationships, 
social support and sexual activity. This is a novel finding that highlights the importance of 
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sexual satisfaction for the perception of living a full active social life.  However, the clinical 
management of pSS in most UK clinics at present does not include routine formal 
assessment of the sexual activity. The introduction of an assessment package including 
relevant questionnaire or an appropriate referral pathway for patients with SD would 
improve the quality of the clinical service provision for these patients and may improve 
their QoL.  
There was significant difference in the outcomes between the patients and healthy 
volunteers groups in the t-test analysis, the patients’ group only was approached for 
objective eight. Since that the patients’ group is approached on clinic, we sought to 
investigate the variables that contribute in predicting the affected outcomes. 
The taste impairment was found to compromise the social life quality of pSS patients, 
although the contribution of the taste dysfunction was not as significant as that of the 
sexual impairment. Anecdotally, dry mouth patients often complain that the loss of taste 
has significantly affected their social life, as it interferes with sharing meals with their 
families or friends. To our knowledge, this aspect has not been documented before and 
therefore the availability of studies for comparison was not applicable.  
We found that the SD was a common debilitating factor that interfered with the QoL of 
patients in the four domains despite of the not significant contribution in three domains 
(Physical, psychological and environmental). However, SD had the highest coefficient, which 
indicates that it contributes to the QoL compared to the other variables. Our findings were 
consistent with others who reported that the SD contributed to the impaired QoL of pSS 
patients (Bongi et al., 2013, van Nimwegen et al., 2015, Priori et al., 2015).  
The questions that assessed the environmental domain were asking whether individuals 
feel safe, healthy, having access to health services and the related information, having 
enough money and opportunity for leisure, satisfied with their living conditions and 
transport. However, the fact that the SD in the present study had impaired patients’ 
environmental QoL, indicates that these patients did not get sufficient support to help 
them cope with the sexual impairment they suffer from.  
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We concluded that the smell dysfunction did not compromise the QoL of patients, which 
indicates that smell problems were not identified as a health issue by pSS patients, and it 
is a condition that can be coped with.  Our findings contradicted others who suggested that 
the impairment of smell and taste contributed to the reduced QoL of pSS patients (Kamel 
et al., 2009).  
Alcohol intake was found associated with the environmental domain of the patients’ life 
quality. This association makes sense as patients who were unsatisfied with their 
environment, tended to increase the amount of alcohol intake. 
11. Oral health related quality of life 
The oral health related quality of life is considered as a relevant end-point criterion in 
evaluating the effects of a disease on individual's oral health over time. The oral health 
related QoL was highly compromised in pSS patients compared to the healthy volunteers. 
Our results were consistent with other previous who reported oral distress in pSS patients 
compared to controls (McMillan et al., 2004, Stewart et al., 2008, Enger et al., 2011). The 
minimal important difference (MID) in the OHIP-14 score between the patients and healthy 
volunteers groups (Mean difference=13.7) was higher than the five scale units that was 
estimated by Locker et al. (2004). This shows that patients with pSS demonstrated 
magnificent deterioration in their oral health life quality. The oral health related quality of 
life was not associated with the taste impairment in pSS patients. To our knowledge this is 
the first study to investigate the impact of taste impairment in pSS patients on oral health 
quality of life, and hence, no studies are available for comparison. 
The impact of the oral dryness on the oral health QoL has been well documented and the 
clinically relevant variables to the oral health QoL were included in the regression model. 
Since USFR, SSFR and CODS are different tests for assessing the same outcome (oral 
dryness), they were not included in one regression to avoid the collinearity. Therefore, for 
the oral dryness assessing tests to be included in the regression analysis, the regression has 
to be run three times for each OHIP domain as well as the total OHIP, which will mean an 
additional 24 regression tests (three tests for each of the seven domains and one for the 
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total OHIP). Calculating numerous correlation increases the risk of type 1 error, and 
compromises the clarity of the rationale of the Results and the Discussion. 
The prevalence, extent and severity of oral health problems were significantly higher in the 
pSS group compared to the healthy volunteers. However, patients with increased oral 
health problems did not necessarily equate to the oral dryness, especially that 23% of 
patients had intraoral appliances including night guards, partial or complete dentures, 
which may contribute to their oral health problems.    
We found that the most affected domain of OHIP-14 was the “Functional limitation” in the 
pSS patients compared to the healthy volunteers. In the regression analysis, we found that 
age and the use of mouthwash had contributed significantly to the compromised functional 
aspect of patients’ oral health.  
Age and alcohol intake were common variables associated with oral distress and the 
physical disability of the patients’ oral health. These findings contradicted others who 
found no correlation between ageing and oral health quality (Rodakowska et al., 2014, 
Bortoluzzi et al., 2015). For alcohol, the association with oral health problems may indicate 
that patients with reduced oral health related QoL tend to take more alcohol than healthy 
people. However, the regression analysis does not reveal causality and therefore more 
research is needed with this regards. To our knowledge, there has been no previous 
demonstration that these correlations were reported in this group of pSS patients. 
 
12. Mental health well-being 
It is well documented that pSS is a chronic debilitating condition that affects patients’ 
health physically and mentally (Valtysdottir et al., 2003, Champey et al., 2006). Therefore, 
it was important to assess the mood status of pSS patients, as it can be detrimental to the 
patients’ well-being. We found that the mental health status of pSS patients was 
significantly impaired in comparison to the healthy volunteers, which supported the 
suggestion that pSS was a chronic debilitating condition and affects patients’ health 
physically and mentally (Valtysdottir et al., 2003, Champey et al., 2006). The pSS patients 
were more anxious and four times more depressed than the healthy volunteers. Our 
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results were in line with others who found that the mental health well-being was 
significantly affected in pSS patients (Stevenson et al., 2004, Inal et al., 2010, Bongi et al., 
2013, Lendrem et al., 2014, Ugurlu et al., 2014). The present study showed that anxiety 
symptoms in pSS patients were higher but not significantly different from that of the 
healthy volunteers. Unlike anxiety, depression was significantly higher in our pSS group 
than that in the healthy volunteers. These findings supported others who reported that 
depression symptoms were more pronounced than anxiety in pSS patients when assessed 
by HADS (Stevenson et al., 2004, Lendrem et al., 2014, van Nimwegen et al., 2015, Vita et 
al., 2015). Only one study with relatively small sample size (n=24) reported that anxiety 
symptoms were significantly higher than depression symptoms in pSS patients compared 
to controls (Priori et al., 2015). Whilst other studies that used AECG criteria in diagnosing 
pSS patients reported that anxiety and depression symptoms were equally present in pSS 
patients (Inal et al., 2010, Bongi et al., 2013).  
When performing the multivariate regression analysis to investigate the predictors of the 
mental health status in pSS patients, we found that the sexual function and ageing 
contributed to the anxiety symptoms although not significantly. As for anxiety, depression 
was affected by the impaired sexual function in pSS patients. Our results supported others 
who referred the compromised mental well-being in pSS patients to the impaired sexual 
life in pSS patients (Bongi et al., 2013, Ugurlu et al., 2014, van Nimwegen et al., 2015, Priori 
et al., 2015). The impairment of the smell and taste as well as the disease duration had no 
important contribution to the anxiety or depression symptoms in the pSS patients. 
From the above discussion, our findings of the QoL revealed that neither smell nor taste 
dysfunction had affected the generic QoL or mental health well-being in pSS patients. The 
SD had contributed to the compromised QoL and mental health status in the pSS group, 
however, a study with powered regression analysis is needed to confirm these findings.   
13. Subjective and objective measures   
Patients were aware of the smell change developed in the course of pSS, and that the self-
assessment of the smell function that was rated on VAS, was consistent with the results of 
the clinical assessment tested by UPSIT. Whilst for taste, patients’ self-assessment was not 
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reflective of their taste function that was tested in the clinic, indicating that patients can 
cope with the slow impairment of the taste during the course of the syndrome.  
The self-assessment of oral dryness measured by XI was reflective of the clinical tests of 
oral dryness. Therefore, administering XI may save patients the burden of the clinical tests. 
We found significant correlation between oral dryness that was assessed by the XI and each 
of the USFR and CODS. Therefore, we suggest administering XI for patients who cannot 
afford the clinical oral dryness tests. 
It was beyond the scope of our study to measure the severity of the nasal dryness, however, 
item 11 of the XI assesses the self-perception of the internal nasal dryness. We found no 
correlation between the subjective assessment of the nasal dryness and the smell function 
assessed clinically by UPSIT. With this regard, more studies are needed to investigate the 
influence of the severity of nasal dryness on the acuity of the smell in pSS patients.  
14. Effect of medicines on mucosal dryness 
The impact of medicines was tested against oral dryness that was assessed by the CODS. 
CODS was chosen over the SFR tests in this analysis, as it reflects the severity of oral dryness 
assessed by the clinician rather than being controlled by the patients’ willing to spitting out. 
Oral dryness was found to be strongly predicted by the topical medicines (Eye drops, Eye 
gels, Viscotears, Skin creams, Telmesteine), and that pilocarpin, antidepressants, 
hypothyroidism and inhalers were weaker predictors for oral mucosa dryness. This 
association did not necessarily indicate the impact of the medicine itself on the oral 
dryness. It rather showed that patients with severe oral dryness, suffered from dryness 
elsewhere in the body and they tend to use topical medicines more than other drugs.   
Nasal dryness was strongly affected by hydroxychloroquin and supplements (Ferrous 
fumarate liquid, ferrous sulphate, folic acid, folate, Vitamin B, Vitamin D, Calcichew, 
Buckwheat oil and Omega7). 
To this end, the predictors in the above associations do not necessarily indicate causative 
factors. Therefore, these relationships may suggest indirect association between the 
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mucosal dryness encountered by these patients and the severity of the syndrome. To our 
knowledge, this is the first time that these correlations are reported. 
15. Comparing functions between two age groups 
In the current study, the age group was not specified due to the rarity of the syndrome, 
which is a limitation of the study and may overestimate the results. However, when data 
were subdivided into two age groups based on menstrual age of under and over 50 years 
of age (Dalal and Agarwal, 2015), a significant difference was observed in a number of the 
tested functions between patients and healthy volunteers. Even when the significance level 
was not reached, the patients’ mean score was lower than that of the healthy volunteers, 
which is an indication of the impact of the pSS on these functions. These analyses were 
inserted lately in the thesis in an attempt to control for age, which has been found the main 
confounder in the study. One obvious limitation of obtaining unmatched age of participants 
per group has been observed, which affects the homogeneity of variance assumption and 
hence the validity of the analysis. 
In the first group, aged 20-50 years, functions of the taste (gustatory and neurosensory 
threshold), sexuality, general and oral life quality as well as the mental health status were 
significantly less in pSS patients (n=16) than that of healthy volunteers (n=47). Only the 
smell function did not reach the significance level, although the mean score in the patients’ 
group was less than that in the healthy volunteers. 
In the second age group of 51 years and over, patients also recorded statistical differences 
compared with healthy volunteers in the functions of gustatory, sexuality, general and oral 
life quality (except the social domain of the WHOQoL-BRÉF) and mental health status. The 
smell, neurosensory threshold and the social domain of the WHOQoL-BRÉF were not 
statistically different between patients and healthy volunteers; although patients’ mean 
scores were less than that of the healthy volunteers.   
Anyfanti et al. (2013) evaluated 557 patients with rheumatic diseases, and found that old 
age was a good predictor for SD. They also reported that old age affected the physical and 
psychological status of rheumatic patients. Other studies stated a negative impact of age 
on the smell function but no/or weak association with taste in pSS patients (Kamel et al., 
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2009, Rusthen et al., 2017). However, even if the age has a negative impact on these 
functions, our results showed that pSS patients of pre and postmenstrual age had lower 
scores in all of the tested functions compared to the healthy volunteers group. Our results 
present evidence of a prominent negative impact on pSS patients’ life quality after age has 
been adjusted. As the reviewed studies differ in the methodology and the outcome 
measure they have used, it would be misleading to compare their results directly.  
D. Conclusion 
This study presents evidence of the negative impact of pSS on the patients’ senses of the 
smell, taste and sexuality. The smell and taste were not affected by the dryness of the 
mucosal linings, and they were not correlated with each other in the patients’ group. Our 
study suggests a possible neurological aetiology for the impairment of taste in pSS patients. 
The patients’ OHRQoL was compromised in pSS patients but this was not due to 
compromised smell or taste. Sexual function deterioration was not associated with the 
severity of self-reported vaginal dryness, but rather with fatigue. We present evidence that 
sexual dysfunction significantly compromises patients’ social life quality. This important 
finding highlights the significance of sexual satisfaction for the perception of living a full 
active social life. SD had a negative effect on QoL and the mental health status of pSS 
patients in all aspects, but mostly affected the quality of social life. 
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1. Recommendations for clinical practice 
 Sexual history should be taken from pSS patients as part of the clinical management 
as part of the patients would benefit from appropriate referral.  
 Assessing the smell and taste for pSS patients would inform a referral pathway. 
 CODS or XI can be used as an alternative to the SFR assessment.  
 Tasting the tip of the tongue is adequate for the taste assessment. 
2. Recommendations for research 
 A qualitative and an in-depth investigation of the sexual health problem would 
provide an insight into the patients’ perception and the coping mechanisms with 
the problem and its impact on the QoL. This will contribute to the understanding of 
the possible causes of SD in pSS patients. 
 Study the impact of the neuropathy on the gustatory function in pSS patients. 
 Investigate the severity of nasal dryness and its impact on the smell function in pSS 
patients. 
 Evaluate the severity of vaginal dryness and its impact on the sexual function in pSS 
patients. 
 Compare the sexual function in patients with different autoimmune diseases that 
are complicated by SS to assess the impact of SS on sexual life. 
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Appendix 1 
American-European Consensus Sjögren’s Classification Criteria (Vitali et al., 
2002) 
I. Ocular Symptoms (at least one) 
 Dry eyes >3 months. 
 Foreign body sensation in the eyes. 
 Use of artificial tears >3x per day. 
II. Oral Symptoms (at least one) 
 Dry mouth >3 months. 
 Recurrent or persistently swollen salivary glands. 
 Need liquids to swallow dry foods. 
III. Ocular Signs (at least one) 
 Schirmer's test, (without anaesthesia) ≤5 mm/5 minutes 
 Positive vital dye staining (van Bijsterveld ≥4) 
IV. Histopathology Lip biopsy showing focal lymphocytic sialoadenitis 
     (focus score ≥1 per 4 mm2)2 
 V. Oral Signs (at least one) 
 Unstimulated whole salivary flow (≤1.5 mL in 15 minutes). 
 Abnormal parotid sialography. 
 Abnormal salivary scintigraphy. 
VI. Autoantibodies (at least one) 
 Anti-SSA (Ro) or Anti-SSB (La) 
For a primary Sjögren’s diagnosis: 
a. Any 4 of the 6 criteria, must include either item IV (Histopathology) or VI  
(Autoantibodies). 
b. Any 3 of the 4 objective criteria (III, IV, V, VI). 
For a secondary Sjögren’s diagnosis: 
In patients with another well-defined major connective tissue disease, the presence of one symptom (I or II) plus 2 of the 3 
objective criteria (III, IV and V) is indicative of secondary SS. 
Exclusion Criteria 
 Past head and neck radiation treatment 
 Hepatitis C infection 
 Acquired immunodeficiency syndrome (AIDS) 
 Pre-existing lymphoma 
 Sarcoidosis 
 Graft versus host disease 
 Current use of anticholinergic drugs 
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Appendix 2 
Excluded studies with reasons   
First author Year Title of Study 
Reason for 
exclusion 
Midilli R 2013 
Nasal and paranasal involvement in primary Sjögren's 
syndrome 
European criteria 
Al-Hashimi I 2001 
Frequency and predictive value of the clinical 
manifestations in Sjögren's syndrome 
European criteria 
Weiffenbach JM 1986 Taste and salivary function 
Clinical experience 
in diagnosing pSS 
Weiffenbach JM 1993 
Odor identification ability among patients 
withSjӧgren’s syndrome 
Clinical experience 
in diagnosing pSS 
Weiffenbach JM 1995 Taste performance in Sjögren's syndrome 
Clinical experience 
in diagnosing pSS 
Rasmussen N 1986 
Smell and nasal findings in patients with primary 
Sjögren's syndrome 
No reliable 
diagnostic criteria 
used 
Falkoff RJ 1986 
Nasal manifestations of systemic immunologic 
disorders 
Review 
Su Nan 2015 
Does Sjögren's syndrome affect odor identification 
abilities? 
Letter 
Rohrauer A 2006 
Improvement of a Sjögren-syndrome associated 
anosmia with acupuncture 
Case report 
Cho MA 2010 
Salivary flow rate and clinical characteristics of 
patients with xerostomia according to its aetiology 
No data of taste 
dysfunction 
Negoro A 2004 
Taste function in Sjögren's syndrome patients with 
special reference to clinical tests 
European criteria 
Gomez FE 2004 
Detection and recognition thresholds to the 4 basic 
tastes in Mexican patients with primary Sjögren 's 
syndrome 
European criteria 
Weber JC 1996 
[Changes in taste and smell caused by 
hydroxychloroquine] 
Letter 
Rovni A 1978 
Sialometric and gustometric investigations in some 
parotid gland diseases 
Clinical experience 
in diagnosing pSS 
Henkin RI 1972 Abnormalities of taste and smell in Sjögren's syndrome 
Clinical experience 
in diagnosing pSS 
Aoki H 2007 Effect of oral moisture on taste sensation 
Unreliable 
classification 
criteria 
Carson JA 1976 
Disease-medication relationships in altered taste 
sensitivity 
No data of pSS 
Heckmann JG 2009 
Smell and taste disorders in polyneuropathy: a 
prospective study of chemosensory disorders 
No data of pSS 
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Epstein JB 2015 
Oral symptoms and oral function in people with 
Sjögren's syndrome 
Letter 
Sellier S 2006 Dyspareunia and Sjögren’s Syndrome European criteria 
Haga HJ 2005 
Reproduction and gynaecological manifestations in 
women with primary Sjögren’s Syndrome: a case-
control study. 
Not examined 
sexual dysfunction 
Valtysdottir ST 2003 
Mental wellbeing and quality of sexual life in women 
with primary Sjögren’s Syndrome are related to 
circulating dehydroepiandrosterone sulphate. 
European and 
Copenhagen criteria 
Mulherin DM 1997 
Sjögren’s Syndrome in women presenting with chronic 
dyspareunia. 
European criteria 
Tayal SC 1996 Dyspareunia in undiagnosed Sjögren’s Syndrome. Case report 
Marchesoni D 1995 Gynaecological aspects of primary Sjögren’s Syndrome. European criteria 
Skopouli FN 1994 
Obstetric and gynaecological profile in patients with 
primary Sjögren’s Syndrome. 
Clinical experience 
in diagnosing pSS 
Lehrer S 1994 Gynaecologic manifestations of Sjögren’s Syndrome. 
No data of sexual 
dysfunction 
Capriello P 1988 
Sjögren’s Syndrome: clinical, cytological, histological 
and coloscopic aspects in women. 
Cytological and 
histological 
examination only, 
not about sexual 
dysfunction 
Kageyama K 1981 
Past histories of patients with Sjögren's syndrome the 
high incidence of gynaecological diseases in patients 
with Sjӧgren’s syndrome evaluated from their past 
histories (author's transl). 
Unclear diagnostic 
criteria 
Blazquez A 2015 
The effect of fatigue and fibromyalgia on sexual 
dysfunction in women with chronic fatigue syndrome. 
Unclear whether 
primary or 
secondary SS has 
been diagnosed. No 
clear data. 
Hackett KL 2012 
Impaired functional status in primary Sjögren's 
syndrome. 
No data of sexual 
dysfunction 
Araujo DB 2010 Sexual function in rheumatic diseases Review 
Specker C 2005 
Gynaecological and obstetrical problems in Sjögren’s 
syndrome. 
Review 
Saad SC 1999 
Vaginal lubrication in women with scleroderma and 
Sjӧgren’s syndrome. 
About secondary SS 
Sheeran T 1992 
Chronic dyspareunia Sjögren’s syndrome- another 
clinical presentation. 
Unreliable 
diagnostic criteria 
used 
El Miedany Y 2012 
Sexual dysfunction in rheumatoid arthritis patients: 
Arthritis and beyond. 
No data of pSS 
Tseng JC 2011 
The Impact of Systemic Lupus Erythematosus on 
Women's Sexual Functioning. 
No data of pSS 
Appendences 
 
 
263 
 
 
 
Curry SL 1994 
The impact of systemic lupus erythematosus on 
women's sexual functioning. 
No data of pSS 
Priori R 2013 
Outcome of pregnancy in Italian patients with primary 
Sjögren’s syndrome 
Not examined 
sexual dysfunction 
Anyfanti P 2013 
The impact of frequently encountered cardiovascular 
risk factors on sexual dysfunction in rheumatic 
disorders. 
Unclear diagnostic 
criteria 
Anyfanti P 2014 
Association Between Mental Health Disorders and 
Sexual Dysfunction in Patients Suffering from 
Rheumatic Diseases 
No pSS group 
Ricaud L 1979 Acquired atresia of the vagina (Sjögren's Syndrome). Case report 
Tristano A 2009 The impact of rheumatic diseases on sexual function Review 
Picone O 2006 
Sjögren’s syndrome in obstetrics and gynaecology: 
Literature review 
Review 
Anderson E 2009 
Sexual Dysfunction among Women with Connective 
Tissue Disease 
No data on pSS 
patients 
Mecacci F 2007 
The impact of autoimmune disorders and adverse 
pregnancy outcome. 
Review 
Cirpan T 2007 
Comparison of human papillomavirus testing and 
cervical cytology with coloscopic examination and 
biopsy in cervical cancer screening in a cohort of 
patients withSjӧgren’s syndrome 
Not clear which 
diagnostic criteria 
has been used 
Johnson M 1997 Obstetric complications and rheumatic disease Review 
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Appendix 3 
MODIFIED NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE  
Note: A study can be awarded a maximum of one star for each numbered item within 
the Selection and Exposure categories. A maximum of two stars can be given for 
Comparability. A maximum of three starts can be given for Outcome. 
Selection 
1) Is the case definition adequate? 
a) Yes, with independent validation  
b) Yes, e.g. record linkage or based on self-reports 
c) No description 
2) Representativeness of the cases 
a) Consecutive or obviously representative series of cases  
b) Potential for selection biases or not stated 
3) Selection of Controls 
a) Community controls  
b) Hospital controls 
c) No description 
4) Definition of Controls 
a) No history of disease (endpoint)  
b) No description of source 
5)  Sample size: 
 a) Justified and satisfactory.  
      b) Not justified. 
6) Demonstration that outcome of interest was not present at start of study 
a) Yes  
b) No 
 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) Study controls for _______________ (Select the most important factor)  
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b) Study controls for any additional factor (This criteria could be modified to indicate 
specific __________   control for a second important factor)  
 
Exposure 
1) Ascertainment of exposure 
a) Secure record (e.g. surgical records)  
b) Structured interview where blind to case/control status  
c) Interview not blinded to case/control status 
d) Written self-report or medical record only 
e) No description 
2) Same method of ascertainment for cases and controls 
a) Yes  
b) No 
3) Non-Response rate 
a) Same rate for both groups  
b) Non respondents described 
c) Rate different and no designation 
 
Outcome 
1) Assessment of the outcome: 
  a) Independent blind assessment.  
 b) Record linkage.  
 c) Self report 
      d) No description. 
2) Statistical test: 
a) The statistical test used to analyse the data is clearly described and appropriate, and the 
measurement of the association is presented, including confidence intervals and the 
probability level (p value)  
  b) The statistical test is not appropriate, not described or incomplete. 
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Appendix 4 
 
 
 
 
 
A 
B 
C 
E 
D 
F 
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Forest plots of the sexual function A - G assessed by FSFI (A) Desire, (B) Arousal, (C) Lubrication, (D) 
Orgasm, (E) Satisfaction, (F) Pain, and (G) total FSFI. Quality of life (H and I) assessed by SF-12, SF-36 and 
RAND-36, (H) Physical component, (I) Mental component. Mental health well-being (J and K) assessed by 
HADS and BDI, (J) Anxiety (HADS-A), (K) Depression (HADS-D and BDI). 
  
G 
H 
I 
J 
K 
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Appendix 24 
Impact on vaginal dryness 
Medicines of supplements, anticoagulants, antihistamines and inhalers had an impact 
on vaginal dryness. 
Table 4-68 Variables in the equation of a logistic regression for the prediction of vaginal dryness from 
medicines taken by pSS patients, n = 65. 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Hydroxychloroquine 18.167 6147.873 .000 1 .998 
77573182.91
3 
.000 . 
Pilocarpin .455 32524.427 .000 1 1.000 1.576 .000 . 
Supplements 35.860 9734.967 .000 1 .997 
37481264171
57834.500 
.000 . 
Antidepressant 17.648 11770.197 .000 1 .999 
46179179.64
8 
.000 . 
Immunosuppressant 18.674 19659.278 .000 1 .999 
128829074.3
10 
.000 . 
Anticoagulants 34.045 51329.877 .000 1 .999 
61017274013
0030.500 
.000 . 
Antihistamine -37.236 28161.531 .000 1 .999 .000 .000 . 
Hyperthyroidism 18.994 14805.652 .000 1 .999 
177344084.8
57 
.000 . 
Hypothyroidisms 1.612 19653.962 .000 1 1.000 5.014 .000 . 
Antibiotics 15.090 30681.390 .000 1 1.000 3575114.000 .000 . 
Blood pressure 2.477 18770.153 .000 1 1.000 11.910 .000 . 
Pain relief -1.099 1.633 .453 1 .501 .333 .014 8.182 
Stomach acid 3.221 18827.692 .000 1 1.000 25.041 .000 . 
Hypoglycaemic -19.027 6445.745 .000 1 .998 .000 .000 . 
Inhalers -37.915 26959.320 .000 1 .999 .000 .000 . 
Primary_bil -.329 24535.838 .000 1 1.000 .720 .000 . 
Overactive bladder 15.919 48346.595 .000 1 1.000 8198128.193 .000 . 
Topical -15.010 25913.686 .000 1 1.000 .000 .000 . 
Gabapentin 16.418 21494.346 .000 1 .999 
13495332.96
1 
.000 . 
Other drugs -2.477 18770.153 .000 1 1.000 .084 .000 . 
Constant 1.099 .816 1.810 1 .178 3.000   
. a. Variable(s) entered on step 1: Hydroxychloroquine, Pilocarpin, Supplements, Antidepressant, Immunosuppressant, 
Anticoagulants, Antihistamine, Hyperthyroidism, Hypothyroidism, Antibiotics, Blood pressure, Pain relief, Stomach acid, 
Hypoglycaemic, Inhalers, Primary_bil, Overactive bladder, Topical, Gabapentin, Other drugs 
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Appendix 25 
STROBE Statement—checklist of items that should be included in reports of 
observational studies 
 Item No Recommendation Page 
Title and abstract 1 
(a) Indicate the study’s design with a commonly used 
term in the title or the abstract 
 
1 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what was 
found 
 
5 
Introduction    
Background/rationale 2 
Explain the scientific background and rationale for 
the investigation being reported 
 
27 
Objectives 3 
State specific objectives, including any prespecified 
hypotheses 
29 
Methods    
Study design 4 
Present key elements of study design early in the 
paper 
93 
Setting 5 
Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-
up, and data collection 
 
97 
Participants 6 
(a) Cohort study—Give the eligibility criteria, and the 
sources and methods of selection of participants. 
Describe methods of follow-up 
 
-- 
Case-control study—Give the eligibility criteria, and 
the sources and methods of case ascertainment and 
control selection. Give the rationale for the choice of 
cases and controls 
 
94 
Cross-sectional study—Give the eligibility criteria, 
and the sources and methods of selection of 
participants 
-- 
(b) Cohort study—For matched studies, give 
matching criteria and number of exposed and 
unexposed 
-- 
Case-control study—For matched studies, give 
matching criteria and the number of controls per 
case. 
 
96 
Variables 
7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
100 
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Data sources/ 
measurement 
8* 
For each variable of interest, give sources of data and 
details of methods of assessment (measurement). 
Describe comparability of assessment methods if 
there is more than one group 
 
101 
    
Bias 9 
Describe any efforts to address potential sources of 
bias 
113 
Study size 10 Explain how the study size was arrived at 114 
Quantitative 
variables 
11 
Explain how quantitative variables were handled in 
the analyses. If applicable, describe which groupings 
were chosen and why 
100 
Statistical methods 12 
(a) Describe all statistical methods, including those 
used to control for confounding 
115 
(b) Describe any methods used to examine 
subgroups and interactions 
117 
(c) Explain how missing data were addressed 117 
(d) Cohort study—If applicable, explain how loss to 
follow-up was addressed 
-- 
Case-control study—If applicable, explain how 
matching of cases and controls was addressed 
96 
Cross-sectional study—If applicable, describe 
analytical methods taking account of sampling 
strategy 
 
(e) Describe any sensitivity analyses none 
Results   
Participants 13* 
(a) Report numbers of individuals at each stage of 
study—e.g. numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the 
study, completing follow-up, and analysed 
 
119 
(b) Give reasons for non-participation at each stage 119 
(c) Consider use of a flow diagram 119 
Descriptive data 
14* 
(a) Give characteristics of study participants (e.g. 
demographic, clinical, social) and information on 
exposures and potential confounders 
 
121 
(b) Indicate number of participants with missing data 
for each variable of interest 
119 
(c) Cohort study—Summarise follow-up time (e.g., 
average and total amount) 
 
--- 
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Outcome data 15* 
Cohort study—Report numbers of outcome events or 
summary measures over time 
 
--- 
  
Case-control study—Report numbers in each 
exposure category, or summary measures of 
exposure 
 
121 
Cross-sectional study—Report numbers of outcome 
events or summary measures 
--- 
Main results 16 
(a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision 
(e.g., 95% confidence interval). Make clear which 
confounders were adjusted for and why they were 
included 
123 
(b) Report category boundaries when continuous 
variables were categorized 
140 
(c) If relevant, consider translating estimates of 
relative risk into absolute risk for a meaningful time 
period 
Irrelevant 
Other analyses 17 
Report other analyses done—e.g. analyses of 
subgroups and interactions, and sensitivity analyses 
 
--- 
Discussion    
Key results 18 
Summarise key results with reference to study 
objectives 
194 
Limitations 19 
Discuss limitations of the study, taking into account 
sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias 
 
194 
Interpretation 20 
Give a cautious overall interpretation of results 
considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other 
relevant evidence 
 
195 
Generalisability 21 
Discuss the generalisability (external validity) of the 
study results 
194 
Other information    
Funding 22 
Give the source of funding and the role of the 
funders for the present study and, if applicable, for 
the original study on which the present article is 
based 
26 
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Appendix 26  
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Appendix 27 
 
Table A Coefficients’ table of the impact of the oral dryness assessed by USFR on the 
gustatory function of taste in the total population 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 (Constant) 15.615 1.128  13.837 .000 13.380 17.850 
USSFR 2.589 .886 .241 2.922 .004 .835 4.344 
Age -.101 .018 -.468 -5.686 .000 -.136 .066 
Smoking -1.449 .986 -.103 -1.469 .145 -3.403 505 
Alcohol -.210 .486 -.103 -.432 .666 -3.403 .752 
Mouthwash 
Appliances 
-.945 
-.771 
.480 
.645 
-.137 
-.086 
-1.970 
-1.196 
.051 
.234 
-1.895 
-2.047 
005 
506 
R2=0.45 
Dependent Variable: Gustatory function of taste 
 
 
Table B Coefficients’ table of the impact of the oral dryness assessed by SSFR on the 
gustatory function of taste in the total population 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 (Constant) 16.403 1.182  13.872 .000 14.061 18.746 
SSFR .542 .313 .145 1.733 .086 -.077 1.161 
Age -.112 .018 -.521 -6.291 .000 -.147 -.077 
Smoking -1.276 1.018 -.091 -1.254 .212 -3.292 .740 
Alcohol -.165 .502 -.024 -.328 .744 -1.160 .830 
Mouthwash 
Appliances 
-.899 
-.847 
.495 
.668 
-.130 
-.094 
-1.817 
-1.269 
.072 
.207 
-1.880 
-2.170 
.081 
.476 
R2=0.42 
Dependent Variable: Gustatory function of taste 
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Table C Coefficients’ table of the impact of the oral dryness assessed by CODS on the 
gustatory function of taste in the total population 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
 (Constant) 16.418 .846  19.397 .000 14.742 18.095 
CODS -.470 .094 -.416 -5.020 .000 -.656 -.285 
Age -.076 .018 -.353 -4.319 .000 -.111 -.041 
Smoking -.724 .917 -.052 -.789 .431 -2.541 1.093 
Alcohol -.180 .456 -.026 -.394 .694 -1.083 .724 
Mouthwash 
Appliances 
-.474 
-.525 
.459 
.608 
-.069 
-.058 
-1.033 
-.864 
.304 
.389 
-1.384 
-1.729 
.436 
.679 
R2=0.51 
Dependent Variable: Gustatory function of taste 
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Appendix 28 
 
Beta change when the predictor is USFR and the outcome is the 
gustatory function of taste in pSS patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables 
 
Standardised 
coefficients 
Beta 
 
Beta change 
of USFR 
 
USFR 
 
0.492 
 
---- 
 
USFR, Age 
 
0.240 
 
0.252 
 
USFR, Age, Mouthwash 
 
0.237 
 
0.003 
